Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Aberrant Crypt Foci
B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P.
Acidosis
Hypercapnic acidosis confers antioxidant and anti-apoptosis effects against ventilator-induced lung injury.
Acquired Immunodeficiency Syndrome
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Acute Kidney Injury
Functional role of microRNA-500a-3P-loaded liposomes in the treatment of cisplatin-induced AKI.
Acute Kidney Injury
Important role of apoptosis signal-regulating kinase 1 in ischemic acute kidney injury.
Acute Kidney Injury
MAP3K kinases and kidney injury.
Acute Kidney Injury
Necroptosis in 3-chloro-1, 2-propanediol (3-MCPD)-dipalmitate-induced acute kidney injury in vivo and its repression by miR-223-3p.
Acute Lung Injury
Expression of DUSP12 Reduces Lung Vascular Endothelial Cell Damage in a Murine Model of Lipopolysaccharide-Induced Acute Lung Injury via the Apoptosis Signal-Regulating Kinase 1 (ASK1)-Jun N-Terminal Kinase Activation (JNK) Pathway.
Acute Lung Injury
Mitogen-activated protein kinase kinase kinase 1 protects against nickel-induced acute lung injury.
Acute Lung Injury
SOCS-1 rescues IL-1?-mediated suppression of epithelial sodium channel in mouse lung epithelial cells via ASK-1.
Acute Lung Injury
[Role and mechanisms of MLKL-NLRP3-mediated necroinflammation in mice with sepsis-induced acute lung injury].
Acute-On-Chronic Liver Failure
Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome.
Adenocarcinoma
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Adenocarcinoma
Apoptosis Signal-Regulating Kinase 1 (ASK1) Activation is Involved in Silver Nanoparticles Induced Apoptosis of A549 Lung Cancer Cell Line.
Adenocarcinoma
Association of Breast Cancer Susceptibility Variants with Risk of Pancreatic Cancer.
Adenocarcinoma
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.
Adenocarcinoma
Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1.
Adenocarcinoma
Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas.
Adenocarcinoma
Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008/C13 cells.
Adenocarcinoma
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
Adenocarcinoma
Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.
Adenocarcinoma
Differentially expressed genes associated with mouse lung tumor progression.
Adenocarcinoma
First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion.
Adenocarcinoma
Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients.
Adenocarcinoma
Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G.
Adenocarcinoma
Laricitrin suppresses increased benzo(a)pyrene-induced lung tumor-associated monocyte-derived dendritic cell cancer progression.
Adenocarcinoma
Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Adenocarcinoma
Molecular diagnostic testing as an adjunct to morphologic evaluation of pancreatic ductal system brushings: potential augmentation for diagnostic sensitivity.
Adenocarcinoma
Molecular pathology of lung cancer: current status and perspectives.
Adenocarcinoma
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Adenocarcinoma
Pancoast-Tobias Syndrome: A Unique Presentation of Lung Cancer.
Adenocarcinoma
Permanent conversion of NIH3T3 cells transformed by activated c-Ha-ras, c-Ki-ras, N-ras, or c-raf, and of human pancreatic adenocarcinoma containing activated c-Ki-ras to apparently normal cells by treatment with the antibiotic azatyrosine.
Adenocarcinoma
Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.
Adenocarcinoma
Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.
Adenocarcinoma
Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration.
Adenocarcinoma
Role of the ASK1-SEK1-JNK1-HIPK1 signal in Daxx trafficking and ASK1 oligomerization.
Adenocarcinoma
The role of MEKK1 in hypertrophic cardiomyopathy.
Adenocarcinoma
[Ap1-like cis-elements in 5'-regulatory region of human apolipoprotein A-I gene]
Adenocarcinoma of Lung
A cross-platform comparison of affymetrix and Agilent microarrays reveals discordant miRNA expression in lung tumors of c-Raf transgenic mice.
Adenocarcinoma of Lung
A Cross-Platform Comparison of Genome-Wide Expression Changes of Laser Microdissected Lung Tissue of C-Raf Transgenic Mice Using 3'IVT and Exon Array.
Adenocarcinoma of Lung
Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling.
Adenocarcinoma of Lung
Apoptosis signal-regulating kinase 1 mediates denbinobin-induced apoptosis in human lung adenocarcinoma cells.
Adenocarcinoma of Lung
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.
Adenocarcinoma of Lung
Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population.
Adenocarcinoma of Lung
Molecular alterations in non-small cell lung carcinomas of the young.
Adenocarcinoma of Lung
Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
Adenocarcinoma of Lung
Mutational activation of the MAP3K8 protooncogene in lung cancer.
Adenocarcinoma of Lung
Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma.
Adenocarcinoma of Lung
Serum proteomics of lung adenocarcinomas induced by targeted overexpression of c-raf in alveolar epithelium identifies candidate biomarkers.
Adenoma
B-RAF mutations are a rare event in pituitary adenomas.
Adenoma
BAG-1 haplo-insufficiency impairs lung tumorigenesis.
Adenoma
Detection of up to 65% of Precancerous Lesions of the Human Colon and Rectum by Mutation Analysis of APC, K-Ras, B-Raf and CTNNB1.
Adenoma
Differentially expressed genes associated with mouse lung tumor progression.
Adenoma
Elimination of B-RAF in oncogenic C-RAF-expressing alveolar epithelial type II cells reduces MAPK signal intensity and lung tumor growth.
Adenoma
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Adenoma
No rearrangement of c-mos in salivary gland pleomorphic adenomas with 8q12 aberrations.
Adenoma
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Adenoma
Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice.
Adenoma
Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
Adenoma
Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation.
Adenoma
[The RAS paradoxon of the EGFR-targeted therapy of colorectal cancer]
Adenoma, Bile Duct
Infrequent activation of K-ras, H-ras, and other oncogenes in hepatocellular neoplasms initiated by methyl(acetoxymethyl)nitrosamine, a methylating agent, and promoted by phenobarbital in F344 rats.
Adenoma, Liver Cell
Infrequent activation of K-ras, H-ras, and other oncogenes in hepatocellular neoplasms initiated by methyl(acetoxymethyl)nitrosamine, a methylating agent, and promoted by phenobarbital in F344 rats.
Adenoma, Pleomorphic
No rearrangement of c-mos in salivary gland pleomorphic adenomas with 8q12 aberrations.
Adenoma, Pleomorphic
Structural alterations of the c-mos locus in benign pleomorphic adenomas with chromosome abnormalities of 8q12.
Adenomatous Polyposis Coli
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Adenomatous Polyposis Coli
Colon Cancer: A Clinician's Perspective in 2019.
Adenomatous Polyposis Coli
Differential molecular assemblies underlie the dual function of Axin in modulating the WNT and JNK pathways.
Adenomatous Polyposis Coli
Long-fragment DNA as a potential marker for stool-based detection of colorectal cancer.
Adenoviridae Infections
Adenovirus E1B 19,000-molecular-weight protein activates c-Jun N-terminal kinase and c-Jun-mediated transcription.
Adrenocortical Carcinoma
Regulation of stimulus-induced interleukin-8 gene transcription in human adrenocortical carcinoma cells - Role of AP-1 and NF-?B.
AIDS-Associated Nephropathy
Inhibition of apoptosis signal-regulating kinase 1 mitigates the pathogenesis of human immunodeficiency virus-associated nephropathy.
Alopecia
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Alzheimer Disease
Ameliorative Effect of Necrosulfonamide in a Rat Model of Alzheimer's Disease: Targeting Mixed Lineage Kinase Domain-like Protein-Mediated Necroptosis.
Alzheimer Disease
Human adipose-derived stem cells reduce receptor-interacting protein 1, receptor-interacting protein 3, and mixed lineage kinase domain-like pseudokinase as necroptotic markers in rat model of Alzheimer's disease.
Alzheimer Disease
Necrosome-positive granulovacuolar degeneration is associated with TDP-43 pathological lesions in the hippocampus of ALS/FTLD cases.
Ameloblastoma
Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review.
Amyloidosis
Differential expression of MAP3K7 and TROPONIN C proteins and related perturbations in renal amyloidosis.
Androgen-Insensitivity Syndrome
Novel compound variants of the AR and MAP3K1 genes are related to the clinical heterogeneity of androgen insensitivity syndrome.
Angiomyolipoma
The role of tuberin in cellular differentiation: are B-raf and MAPK involved?
Anthrax
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Anthrax
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
aromatase deficiency
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Arteriovenous Malformations
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Arthralgia
Intermittent B-Raf inhibitor therapy is a feasible option -report of a patient with metastatic melanoma.
Arthritis
c-Jun NH2-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 is a critical regulator for arthritis progression by meditating inflammation in mice model.
Arthritis
Critical role for apoptosis signal-regulating kinase 1 in the development of inflammatory K/BxN serum-induced arthritis.
Arthritis
Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.
Arthritis
The effect of apoptosis signal-regulating kinase 1 gene transfer on rat collagen induced arthritis.
Arthritis, Experimental
Allicin regulates Treg/Th17 balance in mice with collagen-induced arthritis by increasing the expression of MEKK2 protein.
Arthritis, Experimental
c-Jun NH2-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 is a critical regulator for arthritis progression by meditating inflammation in mice model.
Arthritis, Experimental
Necrostatin-1 ameliorates adjuvant arthritis rat articular chondrocyte injury via inhibiting ASIC1a-mediated necroptosis.
Arthritis, Experimental
Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice.
Arthritis, Rheumatoid
Allicin regulates Treg/Th17 balance in mice with collagen-induced arthritis by increasing the expression of MEKK2 protein.
Arthritis, Rheumatoid
Critical role for apoptosis signal-regulating kinase 1 in the development of inflammatory K/BxN serum-induced arthritis.
Arthritis, Rheumatoid
CXCL1 contributes to IL-6 expression in osteoarthritis and rheumatoid arthritis synovial fibroblasts by CXCR2, c-Raf, MAPK, and AP-1 pathway.
Arthritis, Rheumatoid
Development of an HTS-compatible assay for the discovery of ASK1 signalosome inhibitors using alphascreen technology.
Arthritis, Rheumatoid
Gene-gene interaction and RNA splicing profiles of MAP2K4 gene in rheumatoid arthritis.
Arthritis, Rheumatoid
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients.
Arthritis, Rheumatoid
K-RAS GTPase- and B-RAF kinase-mediated T-cell tolerance defects in rheumatoid arthritis.
Arthritis, Rheumatoid
MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes.
Arthritis, Rheumatoid
Regulation and function of apoptosis signal-regulating kinase 1 in rheumatoid arthritis.
Arthritis, Rheumatoid
Regulation and function of TPL-2, an I?B kinase-regulated MAP kinase kinase kinase.
Arthritis, Rheumatoid
Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes.
Astrocytoma
A Multiplex Quantitative Reverse Transcription Polymerase Chain Reaction Assay for the Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pilocytic Astrocytomas.
Astrocytoma
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
Astrocytoma
BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.
Astrocytoma
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.
Astrocytoma
Differential effects of cAMP in neurons and astrocytes. Role of B-raf.
Astrocytoma
Genetic recombination in human melanoma and astrocytoma cell lines involves oncogenes and growth factor genes.
Ataxia Telangiectasia
DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy.
Ataxia Telangiectasia
Racial Disparities in the Molecular Landscape of Cancer.
Atherosclerosis
A new function for MAP4K4 inhibitors during platelet aggregation and platelet-mediated clot retraction.
Atherosclerosis
A Novel ASK Inhibitor AGI-1067 Inhibits TLR-4-Mediated Activation of ASK1 by Preventing Dissociation of Thioredoxin from ASK1.
Atherosclerosis
A20 functions as mediator in TNF?-induced injury of human umbilical vein endothelial cells through TAK1-dependent MAPK/eNOS pathway.
Atherosclerosis
Critical and diverse in vivo roles of apoptosis signal-regulating kinase 1 in animal models of atherosclerosis and cholestatic liver injury.
Atherosclerosis
Endothelial MAP4K4 is critical for lymphatic vascular development and function.
Atherosclerosis
Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques.
Atherosclerosis
Identification of hypo- and hypermethylated genes related to atherosclerosis by a genome-wide analysis of DNA methylation.
Atherosclerosis
Map3k8 Modulates Monocyte State and Atherogenesis in ApoE-/- Mice.
Atherosclerosis
Map4k4 impairs energy metabolism in endothelial cells and promotes insulin resistance in obesity.
Atherosclerosis
Mixed Lineage Kinase Domain-Like Protein Promotes Human Monocyte Cell Adhesion to Human Umbilical Vein Endothelial Cells Via Upregulation of Intercellular Adhesion Molecule-1 Expression.
Atherosclerosis
Mixed Lineage Kinase Domain-Like Pseudokinase (MLKL) Gene Expression in Human Atherosclerosis with and without Type 2 Diabetes Mellitus.
Atherosclerosis
Myeloid-derived growth factor inhibits inflammation and alleviates endothelial injury and atherosclerosis in mice.
Autoimmune Diseases
MAP4K3/GLK in autoimmune disease, cancer and aging.
Bacterial Infections
MEKK3 Regulates IFN-{gamma} Production in T Cells through the Rac1/2-Dependent MAPK Cascades.
Brain Infarction
Regulation of Microglia and Macrophage Polarization via Apoptosis Signal-Regulating Kinase 1 Silencing after Ischemic/Hypoxic Injury.
Brain Injuries
Apoptosis signal-regulating kinase 1 (ASK1) is linked to neural stem cell differentiation after ischemic brain injury.
Brain Injuries
Caspofungin Suppresses Brain Cell Necroptosis in Ischemic Stroke Rats via Up-Regulation of Pellino3.
Brain Injuries
Dual inhibitory roles of geldanamycin on the c-Jun NH(2)-terminal kinase 3 signal pathway through suppressing the expression of mixed-lineage kinase 3 and attenuating the activation of apoptosis signal-regulating kinase 1 via facilitating the activation of Akt in ischemic brain injury.
Brain Injuries
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.
Brain Injuries
Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway.
Brain Injuries
The degradation of mixed lineage kinase domain-like protein promotes neuroprotection after ischemic brain injury.
Brain Injuries
Transforming Growth Factor Beta-Activated Kinase 1-Dependent Microglial and Macrophage Responses Aggravate Long-Term Outcomes After Ischemic Stroke.
Brain Injuries, Traumatic
Inhibition of transforming growth factor beta-activated kinase 1 confers neuroprotection after traumatic brain injury in rats.
Brain Ischemia
Activation and autophosphorylation of apoptosis signal-regulating kinase 1 (ASK1) following cerebral ischemia in rat hippocampus.
Brain Ischemia
Antioxidant N-acetylcysteine inhibits the activation of JNK3 mediated by the GluR6-PSD95-MLK3 signaling module during cerebral ischemia in rat hippocampus.
Brain Ischemia
Biphasic activation of apoptosis signal-regulating kinase 1-stress-activated protein kinase 1-c-Jun N-terminal protein kinase pathway is selectively mediated by Ca2+-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors involving oxidative stress following brain ischemia in rat hippocampus.
Brain Ischemia
Blockade of Apoptosis Signal-Regulating Kinase 1 Attenuates Matrix Metalloproteinase 9 Activity in Brain Endothelial Cells and the Subsequent Apoptosis in Neurons after Ischemic Injury.
Brain Ischemia
Brain-targeting delivery for RNAi neuroprotection against cerebral ischemia reperfusion injury.
Brain Ischemia
Cell Type-Specific Mechanisms in the Pathogenesis of Ischemic Stroke: The Role of Apoptosis Signal-Regulating Kinase 1.
Brain Ischemia
Heat shock proteins in the brain: role of Hsp70, Hsp 27, and HO-1 (Hsp32) and their therapeutic potential.
Brain Ischemia
Post-ischemic salubrinal administration reduces necroptosis in a rat model of global cerebral ischemia.
Brain Ischemia
Regulation of Microglia and Macrophage Polarization via Apoptosis Signal-Regulating Kinase 1 Silencing after Ischemic/Hypoxic Injury.
Brain Ischemia
S-nitrosylation of mixed lineage kinase 3 contributes to its activation after cerebral ischemia.
Brain Neoplasms
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
Brain Neoplasms
JSAP1/JIP3 cooperates with focal adhesion kinase to regulate c-Jun N-terminal kinase and cell migration.
Brain Neoplasms
Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications.
Brain Neoplasms
PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells.
Breast Neoplasms
A cis and trans adenine-dependent hairpin ribozyme against Tpl-2 target.
Breast Neoplasms
A MAP3k1 SNP predicts survival of gastric cancer in a Chinese population.
Breast Neoplasms
A Short Hairpin DNA Analogous to miR-125b Inhibits C-Raf Expression, Proliferation, and Survival of Breast Cancer Cells.
Breast Neoplasms
A single point mutation responsible for c-mos polymorphism in cancer patients.
Breast Neoplasms
Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade.
Breast Neoplasms
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Breast Neoplasms
Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
Breast Neoplasms
Apoptosis signal-regulating kinase 1 is associated with the effect of claudin-6 in breast cancer.
Breast Neoplasms
Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Breast Neoplasms
Association between Mitogen-Activated Protein Kinase Kinase Kinase 1 Polymorphisms and Breast Cancer Susceptibility: A Meta-Analysis of 20 Case-Control Studies.
Breast Neoplasms
Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects.
Breast Neoplasms
Association of single nucleotide polymorphisms in FGF-RAS/MAP signalling cascade with breast cancer susceptibility.
Breast Neoplasms
B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.
Breast Neoplasms
Bag-1 stimulates Bad phosphorylation through activation of Akt and Raf kinases to mediate cell survival in breast cancer.
Breast Neoplasms
BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.
Breast Neoplasms
Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations.
Breast Neoplasms
Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations.
Breast Neoplasms
Breast cancer susceptibility variants alter risks in familial disease.
Breast Neoplasms
Breast cancer susceptibility: current knowledge and implications for genetic counselling.
Breast Neoplasms
c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.
Breast Neoplasms
Calcitonin targets extracellular signal-regulated kinase signaling pathway in human cancers.
Breast Neoplasms
CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.
Breast Neoplasms
Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis.
Breast Neoplasms
Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.
Breast Neoplasms
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
Breast Neoplasms
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Computational algorithms for in silico profiling of activating mutations in cancer.
Breast Neoplasms
Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.
Breast Neoplasms
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Breast Neoplasms
Distribution of FGFR2, TNRC9, MAP3K1, LSP1, and 8q24 alleles in genetically enriched breast cancer patients versus elderly tumor-free women.
Breast Neoplasms
Dominant-negative Jun N-terminal protein kinase (JNK-1) inhibits metabolic oxidative stress during glucose deprivation in a human breast carcinoma cell line.
Breast Neoplasms
Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins.
Breast Neoplasms
Estrogen suppresses MLK3-mediated apoptosis sensitivity in ER+ breast cancer cells.
Breast Neoplasms
Evaluation of drug-targetable genes by defining modes of abnormality in gene expression.
Breast Neoplasms
Expression of apoptosis signal-regulating kinase 1 is associated with tight junction protein claudin-6 in cervical carcinoma.
Breast Neoplasms
Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.
Breast Neoplasms
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Breast Neoplasms
Genetic susceptibility loci for breast cancer by estrogen receptor status.
Breast Neoplasms
Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population.
Breast Neoplasms
Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.
Breast Neoplasms
Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2.
Breast Neoplasms
HER2/HER3 regulates lactate secretion and expression of lactate receptor mRNA through the MAP3K4 associated protein GIT1.
Breast Neoplasms
Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.
Breast Neoplasms
Hormone-related pathways and risk of breast cancer subtypes in African American women.
Breast Neoplasms
Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.
Breast Neoplasms
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Breast Neoplasms
Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk.
Breast Neoplasms
IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.
Breast Neoplasms
Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation.
Breast Neoplasms
Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity.
Breast Neoplasms
Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis.
Breast Neoplasms
Knockdown of apoptosis signal-regulating kinase 1 modulates basal glycogen synthase kinase-3? kinase activity and regulates cell migration.
Breast Neoplasms
Mammary tumor development in dogs is associated with BRCA1 and BRCA2.
Breast Neoplasms
MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitro.
Breast Neoplasms
MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis.
Breast Neoplasms
MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm.
Breast Neoplasms
MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer.
Breast Neoplasms
MEKK1 Regulates Chemokine Expression in Mammary Fibroblasts: Implications for the Breast Tumor Microenvironment.
Breast Neoplasms
MEKK1/JNK signaling stabilizes and activates p53.
Breast Neoplasms
MEKK2 regulates focal adhesion stability and motility in invasive breast cancer cells.
Breast Neoplasms
MEKK2 regulates paxillin ubiquitylation and localization in MDA-MB 231 breast cancer cells.
Breast Neoplasms
Miconazole triggers various forms of cell death in human breast cancer MDA-MB-231 cells.
Breast Neoplasms
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
Breast Neoplasms
MicroRNA-143 inhibits cell growth by targeting ERK5 and MAP3K7 in breast cancer.
Breast Neoplasms
Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer.
Breast Neoplasms
MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1).
Breast Neoplasms
Non-Benzoquinone Geldanamycin Analog, WK-88-1, Induces Apoptosis in Human Breast Cancer Cell Lines.
Breast Neoplasms
Overexpression of the Tpl-2/Cot oncogene in human breast cancer.
Breast Neoplasms
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Breast Neoplasms
Pharmacologic inhibition of MLK3 kinase activity blocks the in vitro migratory capacity of breast cancer cells but has no effect on breast cancer brain metastasis in a mouse xenograft model.
Breast Neoplasms
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Breast Neoplasms
Platycodin d induces reactive oxygen species-mediated apoptosis signal-regulating kinase 1 activation and endoplasmic reticulum stress response in human breast cancer cells.
Breast Neoplasms
Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Breast Neoplasms
Predictive accuracy of the breast cancer genetic risk model based on eight common genetic variants: The BACkSIDE study.
Breast Neoplasms
Presence of an allelic EcoRI restriction fragment of the c-mos locus in leukocyte and tumor cell DNAs of breast cancer patients.
Breast Neoplasms
Replication of breast cancer susceptibility loci in whites and African Americans using a Bayesian approach.
Breast Neoplasms
Replication of five GWAS-identified loci and breast cancer risk among Hispanic and non-Hispanic white women living in the Southwestern United States.
Breast Neoplasms
Risk of genome-wide association study newly identified genetic variants for breast cancer in Chinese women of Heilongjiang Province.
Breast Neoplasms
RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors.
Breast Neoplasms
RNAi silencing of the MEKK3 gene promotes TRAIL-induced apoptosis in MCF-7 cells and suppresses the transcriptional activity of NF-?B.
Breast Neoplasms
Silencing MAP3K1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells.
Breast Neoplasms
Somatic mutation profiling in BRCA-negative breast and ovarian cancer patients by multigene panel sequencing.
Breast Neoplasms
The plasma peptides of breast versus ovarian cancer.
Breast Neoplasms
The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells.
Breast Neoplasms
Topological alternate centrality measure capturing drug targets in the network of MAPK pathways.
Breast Neoplasms
Transcriptional regulation of mixed lineage kinase 3 by estrogen and its implication in ER-positive breast cancer pathogenesis.
Breast Neoplasms
Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant.
Breast Neoplasms
Two-dimensional electrophoretic analysis of human breast carcinoma proteins: mapping of proteins that bind to the SH3 domain of mixed lineage kinase MLK2.
Breast Neoplasms
[Genetic polymorphism and susceptibility to cancer]
Breast Neoplasms
[Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies]
Burkitt Lymphoma
c-Ha-ras1 is not deleted in aniridia-Wilms' tumour association.
Carcinogenesis
A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.
Carcinogenesis
A novel association between core mutations in hepatitis B virus genotype F1b and hepatocellular carcinoma in Alaskan Native People.
Carcinogenesis
A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase alpha in neoplastic cell transformation and tumor development.
Carcinogenesis
A RING to rule them all? Insights into the Map3k1 PHD motif provide a new mechanistic understanding into the diverse roles of Map3k1.
Carcinogenesis
Acacetin and pinostrobin as a promising inhibitor of cancer-associated protein kinases.
Carcinogenesis
Apoptosis signal-regulating kinase 1 and cyclin D1 compose a positive feedback loop contributing to tumor growth in gastric cancer.
Carcinogenesis
Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses.
Carcinogenesis
Association Study of MAP3K1 SNPs and Risk Factors with Susceptibility to Esophageal Squamous Cell Carcinoma in a Chinese Population: A Case-Control Study.
Carcinogenesis
B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
Carcinogenesis
B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells.
Carcinogenesis
B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis.
Carcinogenesis
B-RAF mutations are a rare event in pituitary adenomas.
Carcinogenesis
Baicalein suppresses growth of non-small cell lung carcinoma by targeting MAP4K3.
Carcinogenesis
C-raf expression in early rat liver tumorigenesis after promotion with polychlorinated biphenyls or phenobarbital.
Carcinogenesis
C-Raf is required for the initiation of lung cancer by K-Ras.
Carcinogenesis
Characterization of the aberrant splicing of MAP3K7 induced by cancer-associated SF3B1 mutation.
Carcinogenesis
Conditional expression of oncogenic C-RAF in mouse pulmonary epithelial cells reveals differential tumorigenesis and induction of autophagy leading to tumor regression.
Carcinogenesis
Correction: Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1.
Carcinogenesis
Critical role of miR-10b in B-RafV600E dependent anchorage independent growth and invasion of melanoma cells.
Carcinogenesis
Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Carcinogenesis
Differential roles of ASK1 and TAK1 in Helicobacter pylori-induced cellular responses.
Carcinogenesis
Discovery of driver non-coding splice-site-creating mutations in cancer.
Carcinogenesis
Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling.
Carcinogenesis
Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Carcinogenesis
Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells.
Carcinogenesis
Elimination of B-RAF in oncogenic C-RAF-expressing alveolar epithelial type II cells reduces MAPK signal intensity and lung tumor growth.
Carcinogenesis
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Carcinogenesis
Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development.
Carcinogenesis
Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis.
Carcinogenesis
Expression of B-RAF V600E in type II pneumocytes causes abnormalities in alveolar formation, airspace enlargement and tumor formation in mice.
Carcinogenesis
Expression of c-Ki-ras, c-Ha-ras, and c-myc in specific cell types during hepatocarcinogenesis.
Carcinogenesis
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Carcinogenesis
Functional cooperation between ASK1 and p21Waf1/Cip1 in the balance of cell-cycle arrest, cell death and tumorigenesis of stressed keratinocytes.
Carcinogenesis
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Carcinogenesis
Genomic organization and expression of Tpl-2 in normal cells and Moloney murine leukemia virus-induced rat T-cell lymphomas: activation by provirus insertion.
Carcinogenesis
HCC Specific Protein Network Involving Interactions of EGFR with A-Raf and Transthyretin: Experimental Analysis and Computational Biology Correlates.
Carcinogenesis
Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma.
Carcinogenesis
hKSR-2 inhibits MEKK3-activated MAP kinase and NF-kappaB pathways in inflammation.
Carcinogenesis
Identification, by cDNA microarray, of A-raf and proliferating cell nuclear antigen as genes induced in rat lung by exposure to diesel exhaust.
Carcinogenesis
Induction of squamous cell carcinoma after MAP3K8 overexpression in murine salivry gland epithelial cells.
Carcinogenesis
Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG12D/Pdx-1-Cre Mice.
Carcinogenesis
Inhibition of mutant Kras(G12D)-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Carcinogenesis
Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation.
Carcinogenesis
Lin9, a subunit of the mammalian DREAM complex, is essential for embryonic development, for survival of adult mice and for tumor suppression.
Carcinogenesis
Loss of BRCA1 Spontaneously Induces the Tumorigenesis in Lacrimal Gland.
Carcinogenesis
Mammary cancer promotion and MAPK activation associated with consumption of a corn oil-based high-fat diet.
Carcinogenesis
MAP4K3 modulates cell death via the post-transcriptional regulation of BH3-only proteins.
Carcinogenesis
MAP4K4 promotes pancreatic tumorigenesis via phosphorylation and activation of mixed lineage kinase 3.
Carcinogenesis
Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.
Carcinogenesis
Mitogen-activated protein 3 kinase 6 mediates angiogenic and tumorigenic effects via vascular endothelial growth factor expression.
Carcinogenesis
Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Carcinogenesis
Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1.
Carcinogenesis
Mixed Lineage Kinase MLK4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis.
Carcinogenesis
MLK3 silence induces cervical cancer cell apoptosis via the Notch-1/autophagy network.
Carcinogenesis
MLKL inhibits intestinal tumorigenesis by suppressing STAT3 signaling pathway.
Carcinogenesis
Molecular alterations in non-small cell lung carcinomas of the young.
Carcinogenesis
Mutational activation of the MAP3K8 protooncogene in lung cancer.
Carcinogenesis
Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.
Carcinogenesis
No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Carcinogenesis
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.
Carcinogenesis
Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
Carcinogenesis
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
Carcinogenesis
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Carcinogenesis
p21-activated kinase 1 (PAK1) can promote ERK activation in a kinase-independent manner.
Carcinogenesis
Persistent hepatocyte apoptosis promotes tumorigenesis from diethylnitrosamine-transformed hepatocytes through increased oxidative stress, independent of compensatory liver regeneration.
Carcinogenesis
RAF expression in human astrocytic tumors.
Carcinogenesis
RanBPM is an inhibitor of ERK signaling.
Carcinogenesis
Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas.
Carcinogenesis
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
Carcinogenesis
Revealing A-Raf functions through its interactome.
Carcinogenesis
Skin tumorigenesis stimulated by Raf inhibitors relies upon Raf functions that are dependent and independent of ERK.
Carcinogenesis
Structural investigation of B-raf paradox breaker and inducer inhibitors.
Carcinogenesis
TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis.
Carcinogenesis
Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.
Carcinogenesis
TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases.
Carcinogenesis
The BRAF mutation is associated with the prognosis in colorectal cancer.
Carcinogenesis
The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines.
Carcinogenesis
Tpl-2 kinase downregulates the activity of p53 and enhances signaling pathways leading to activation of activator protein 1 induced by EGF.
Carcinogenesis
Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL-10 secretion and regulatory T-cell generation.
Carcinogenesis
Tumorigenesis suppressor pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion.
Carcinogenesis
[CNC proteins in physiology and pathology].
Carcinogenesis
[Serous genital carcinoma : Molecular pathogenesis and the role of tubal fimbria.]
Carcinogenesis
[The RAS paradoxon of the EGFR-targeted therapy of colorectal cancer]
Carcinoid Tumor
Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
Carcinoma
A single point mutation responsible for c-mos polymorphism in cancer patients.
Carcinoma
Abrogation of c-Raf expression induces apoptosis in tumor cells.
Carcinoma
Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations.
Carcinoma
Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab.
Carcinoma
Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
Carcinoma
Apoptosis signal-regulating kinase 1 is involved in WISP-1-promoted cell motility in human oral squamous cell carcinoma cells.
Carcinoma
ASK1 mediates apoptotic cell death induced by genotoxic stress.
Carcinoma
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Carcinoma
Association Study of MAP3K1 SNPs and Risk Factors with Susceptibility to Esophageal Squamous Cell Carcinoma in a Chinese Population: A Case-Control Study.
Carcinoma
B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
Carcinoma
B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis.
Carcinoma
B-Raf Mutations, Microsatellite Instability and p53 Protein Expression in Sporadic Basal Cell Carcinomas.
Carcinoma
Baicalein suppresses growth of non-small cell lung carcinoma by targeting MAP4K3.
Carcinoma
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Carcinoma
c-mos immunoreactivity is an indicator of good prognosis in lung cancer.
Carcinoma
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.
Carcinoma
Cancer emerging from the recurrence of sessile serrated adenoma/polyp resected endoscopically 5 years ago.
Carcinoma
Complete Regression of Carcinoma via Combined C-RAF and EGFR Targeted Therapy.
Carcinoma
Computational study on the unbinding pathways of B-RAF inhibitors and its implication for the difference of residence time: insight from random acceleration and steered molecular dynamics simulations.
Carcinoma
Conditional expression of oncogenic C-RAF in mouse pulmonary epithelial cells reveals differential tumorigenesis and induction of autophagy leading to tumor regression.
Carcinoma
Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
Carcinoma
Cooperation of c-raf-1 and c-myc protooncogenes in the neoplastic transformation of simian virus 40 large tumor antigen-immortalized human bronchial epithelial cells.
Carcinoma
Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
Carcinoma
Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance.
Carcinoma
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.
Carcinoma
Downregulation of long non-coding RNA B-Raf proto-oncogene-activated non-coding RNA reverses cisplatin resistance in laryngeal squamous cell carcinoma.
Carcinoma
Downregulation of survivin and aurora a by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy.
Carcinoma
Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK(1,2)) activity in SW-13 human adrenal carcinoma cells.
Carcinoma
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Carcinoma
Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.
Carcinoma
Expression and prognostic role of MEKK3 and pERK in patients with renal clear cell carcinoma.
Carcinoma
Expression of apoptosis signal-regulating kinase 1 is associated with tight junction protein claudin-6 in cervical carcinoma.
Carcinoma
Expression of polysialic acid in primary laryngeal squamous cell carcinoma.
Carcinoma
Expression of ssDNA in mammalian cells.
Carcinoma
Expression of TAK1/TAB1 expression in non-small cell lung carcinoma and adjacent normal tissues and their clinical significance.
Carcinoma
Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation.
Carcinoma
Gene expression in poorly differentiated papillary thyroid carcinomas.
Carcinoma
H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma.
Carcinoma
Identification of a negative regulatory element that inhibits c-mos transcription in somatic cells.
Carcinoma
Immunohistochemical localization of c-mos at the light and electron microscope level in non-small cell lung carcinomas.
Carcinoma
Induction of squamous cell carcinoma after MAP3K8 overexpression in murine salivary gland epithelial cells.
Carcinoma
Induction of squamous cell carcinoma after MAP3K8 overexpression in murine salivry gland epithelial cells.
Carcinoma
Inhibition of mutant Kras(G12D)-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Carcinoma
Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G.
Carcinoma
K-ras Mutation, HPV Infection and Smoking or Alcohol Abuse Positively Correlate with Esophageal Squamous Carcinoma.
Carcinoma
Lack of B-RAF mutations in head and neck squamous cell carcinoma.
Carcinoma
Long non-coding RNA-OIS1 inhibits HPV-positive, but not HPV-negative cervical squamous cell carcinoma by upregulating MTK-1.
Carcinoma
Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).
Carcinoma
Loss of heterozygosity at the c-raf locus in small cell lung carcinoma.
Carcinoma
MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas.
Carcinoma
MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis.
Carcinoma
MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
Carcinoma
microRNA-375 inhibits colorectal cancer cells proliferation by downregulating JAK2/STAT3 and MAP3K8/ERK signaling pathways.
Carcinoma
MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma.
Carcinoma
miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8.
Carcinoma
MiR-451 inhibits proliferation of esophageal carcinoma cell line EC9706 by targeting CDKN2D and MAP3K1.
Carcinoma
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
Carcinoma
Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.
Carcinoma
No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Carcinoma
Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma.
Carcinoma
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Carcinoma
Overexpression of the Tpl-2/Cot oncogene in human breast cancer.
Carcinoma
Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells.
Carcinoma
pERK activation in esophageal carcinomas: clinicopathological associations.
Carcinoma
Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers.
Carcinoma
Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumors.
Carcinoma
Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Carcinoma
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
Carcinoma
Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.
Carcinoma
Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx.
Carcinoma
Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus.
Carcinoma
Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas.
Carcinoma
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Carcinoma
The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
Carcinoma
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Carcinoma
The Expression and Role of MEKK3 in Renal Clear Cell Carcinoma.
Carcinoma
The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Carcinoma
Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma.
Carcinoma
Tumorigenesis suppressor pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion.
Carcinoma
[Genetic polymorphism and susceptibility to cancer]
Carcinoma
[Serous genital carcinoma : Molecular pathogenesis and the role of tubal fimbria.]
Carcinoma in Situ
[Serous genital carcinoma : Molecular pathogenesis and the role of tubal fimbria.]
Carcinoma, Basal Cell
B-Raf Mutations, Microsatellite Instability and p53 Protein Expression in Sporadic Basal Cell Carcinomas.
Carcinoma, Ehrlich Tumor
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Carcinoma, Embryonal
Differential expression of protooncogenes in human germ cell tumors of the testis.
Carcinoma, Embryonal
Expression of JNK cascade scaffold protein JSAP1 in the mouse nervous system.
Carcinoma, Embryonal
MEKK4 mediates differentiation in response to retinoic acid via activation of c-Jun N-terminal kinase in rat embryonal carcinoma P19 cells.
Carcinoma, Endometrioid
Differential gene expression profile reveals overexpression of MAP3K8 in invasive endometrioid carcinoma.
Carcinoma, Hepatocellular
A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
Carcinoma, Hepatocellular
A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma.
Carcinoma, Hepatocellular
Activated c-raf gene in a rat hepatocellular carcinoma induced by 2-amino-3-methylimidazo[4,5-f]quinoline.
Carcinoma, Hepatocellular
Activation of rat c-raf during transfection of hepatocellular carcinoma DNA.
Carcinoma, Hepatocellular
Apoptosis signal-regulating kinase 1 inhibits hepatocarcinogenesis by controlling the tumor-suppressing function of stress-activated mitogen-activated protein kinase.
Carcinoma, Hepatocellular
Apoptosis signal-regulating kinase 1 mediates the inhibitory effect of hepatocyte nuclear factor-4? on hepatocellular carcinoma.
Carcinoma, Hepatocellular
B-Raf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Cross-talk between aryl hydrocarbon receptor and mitogen-activated protein kinase signaling pathway in liver cancer through c-raf transcriptional regulation.
Carcinoma, Hepatocellular
Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Carcinoma, Hepatocellular
Elevated expression of A-Raf and FA2H in hepatocellular carcinoma is associated with lipid metabolism dysregulation and cancer progression.
Carcinoma, Hepatocellular
Expression of the c-raf protooncogene, gamma-glutamyltranspeptidase, and gap junction protein in rat liver neoplasms.
Carcinoma, Hepatocellular
Glycogen synthase kinase-3? antagonizes ROS-induced hepatocellular carcinoma cell death through suppression of the apoptosis signal-regulating kinase 1.
Carcinoma, Hepatocellular
Hepatitis B virus X protein promotes hepatoma cell proliferation via upregulation of MEKK2.
Carcinoma, Hepatocellular
High Expression of LINC01268 is Positively Associated with Hepatocellular Carcinoma Progression via Regulating MAP3K7.
Carcinoma, Hepatocellular
Hypomethylation of c-myc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver.
Carcinoma, Hepatocellular
Increased expression of c-jun gene during spontaneous hepatocarcinogenesis in LEC rats.
Carcinoma, Hepatocellular
Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.
Carcinoma, Hepatocellular
Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf.
Carcinoma, Hepatocellular
MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1.
Carcinoma, Hepatocellular
MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells.
Carcinoma, Hepatocellular
Molecular mechanisms governing microRNA-125a expression in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Mouse hepatomas with Ha-ras and B-raf mutations differ in mitogen-activated protein kinase signaling and response to constitutive androstane receptor activation.
Carcinoma, Hepatocellular
Mutual suppression of miR-125a and Lin28b in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumors.
Carcinoma, Hepatocellular
Rat c-raf oncogene is located on chromosome 4 and may be activated by sequences from chromosome 13.
Carcinoma, Hepatocellular
RNA interference may be more potent than antisense RNA in human cancer cell lines.
Carcinoma, Hepatocellular
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Carcinoma, Hepatocellular
Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.
Carcinoma, Hepatocellular
Studying the Role and Molecular Mechanisms of MAP4K3 in Sorafenib Resistance of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Synergistic activity of magnolin combined with B-RAF inhibitor SB590885 in hepatocellular carcinoma cells via targeting PI3K-AKT/mTOR and ERK MAPK pathway.
Carcinoma, Hepatocellular
The ménage à trois of autophagy, lipid droplets and liver disease.
Carcinoma, Hepatocellular
[A study on expression of various oncogenes and tumor-associated genes in LEC rats spontaneously developing hepatitis and hepatoma]
Carcinoma, Large Cell
Cooperation of c-raf-1 and c-myc protooncogenes in the neoplastic transformation of simian virus 40 large tumor antigen-immortalized human bronchial epithelial cells.
Carcinoma, Medullary
Targeted therapy: A new hope for thyroid carcinomas.
Carcinoma, Non-Small-Cell Lung
B-RAF mutation in non-small cell lung cancer: the sleeping beauty is waking up.
Carcinoma, Non-Small-Cell Lung
Baicalein suppresses growth of non-small cell lung carcinoma by targeting MAP4K3.
Carcinoma, Non-Small-Cell Lung
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Conditional expression of oncogenic C-RAF in mouse pulmonary epithelial cells reveals differential tumorigenesis and induction of autophagy leading to tumor regression.
Carcinoma, Non-Small-Cell Lung
Expression of TAK1/TAB1 expression in non-small cell lung carcinoma and adjacent normal tissues and their clinical significance.
Carcinoma, Non-Small-Cell Lung
MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3.
Carcinoma, Non-Small-Cell Lung
miR-145-5p inhibits epithelial-mesenchymal transition via the JNK signaling pathway by targeting MAP3K1 in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Multiple primary malignant neoplasms: A case report and literature review.
Carcinoma, Non-Small-Cell Lung
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
Carcinoma, Non-Small-Cell Lung
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Carcinoma, Non-Small-Cell Lung
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Carcinoma, Non-Small-Cell Lung
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Carcinoma, Non-Small-Cell Lung
Tumor Cell-Derived Exosomal miR-770 Inhibits M2 Macrophage Polarization via Targeting MAP3K1 to Inhibit the Invasion of Non-small Cell Lung Cancer Cells.
Carcinoma, Papillary
B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules.
Carcinoma, Papillary
BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.
Carcinoma, Papillary
High prevalence of B-RAF mutation in papillary carcinoma of the thyroid in north-east Italy.
Carcinoma, Papillary
New molecular targeted therapies in thyroid cancer.
Carcinoma, Papillary
Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule.
Carcinoma, Renal Cell
Computational study on the unbinding pathways of B-RAF inhibitors and its implication for the difference of residence time: insight from random acceleration and steered molecular dynamics simulations.
Carcinoma, Renal Cell
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
Carcinoma, Renal Cell
Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.
Carcinoma, Renal Cell
Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation.
Carcinoma, Renal Cell
Genome-Wide Association Studies of Autoimmune Thyroid Diseases, Thyroid Function, and Thyroid Cancer.
Carcinoma, Renal Cell
MEK and PI3K inhibition in solid tumors: rationale and evidence to date.
Carcinoma, Renal Cell
MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma.
Carcinoma, Renal Cell
miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8.
Carcinoma, Renal Cell
Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumors.
Carcinoma, Renal Cell
Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus.
Carcinoma, Renal Cell
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Carcinoma, Renal Cell
The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
Carcinoma, Renal Cell
Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma.
Carcinoma, Squamous Cell
Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance.
Carcinoma, Squamous Cell
Induction of squamous cell carcinoma after MAP3K8 overexpression in murine salivary gland epithelial cells.
Carcinoma, Squamous Cell
Induction of squamous cell carcinoma after MAP3K8 overexpression in murine salivry gland epithelial cells.
Carcinoma, Squamous Cell
Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G.
Carcinoma, Squamous Cell
Lack of B-RAF mutations in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Long non-coding RNA-OIS1 inhibits HPV-positive, but not HPV-negative cervical squamous cell carcinoma by upregulating MTK-1.
Carcinoma, Squamous Cell
pERK activation in esophageal carcinomas: clinicopathological associations.
Carcinoma, Squamous Cell
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Carcinoma, Transitional Cell
Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).
Cardio-Renal Syndrome
Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome.
Cardio-Renal Syndrome
Blockade of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction in cardiorenal syndrome via enhancing angiogenesis.
Cardio-Renal Syndrome
Inhibition of apoptosis signal-regulating kinase 1 ameliorates left ventricular dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome.
Cardio-Renal Syndrome
Inhibition of apoptosis signal-regulating kinase 1 might be a novel therapeutic target in the treatment of cardiorenal syndrome.
Cardio-Renal Syndrome
RE: Blockade of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction in cardiorenal syndrome via enhancing angiogenesis.
Cardio-Renal Syndrome
RE: Inhibition of apoptosis signal-regulating kinase 1 might be a novel therapeutic target in the treatment of cardiorenal syndrome.
Cardiomegaly
A direct interaction between TGFbeta activated kinase 1 and the TGFbeta type II receptor: implications for TGFbeta signalling and cardiac hypertrophy.
Cardiomegaly
Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome.
Cardiomegaly
Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling.
Cardiomegaly
Heat-shock protein 90 modulates cardiac ventricular hypertrophy via activation of MAPK pathway.
Cardiomegaly
Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy.
Cardiomegaly
MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq.
Cardiomegaly
Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: the critical role of ASK1 and VEGF.
Cardiomegaly
Oligomerized grape seed proanthocyanidins ameliorates isoproterenol-induced cardiac remodeling in rats: role of oxidative stress.
Cardiomegaly
Regulator of G Protein Signaling 6 Facilities Cardiac Hypertrophy by Activating Apoptosis Signal-Regulating Kinase 1-P38/c-JUN N-Terminal Kinase 1/2 Signaling.
Cardiomegaly
The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy.
Cardiomegaly
The role of MEKK1 in hypertrophic cardiomyopathy.
Cardiomegaly
Tissue distribution and functional expression of a cDNA encoding a novel mixed lineage kinase.
Cardiomegaly
Ubiquitin-specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1-dependent pathway.
Cardiomegaly
[The regulatory mechanism of Raf/MEK/ERK pathway on the rat cardiac hypertrophy induced by transverse aortic constriction].
Cardiomyopathy, Dilated
Progression of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via transcoronary gene transfer.
Cardiomyopathy, Hypertrophic
The role of MEKK1 in hypertrophic cardiomyopathy.
Cardiovascular Diseases
Crystal structures of ASK1-inhibtor complexes provide a platform for structure-based drug design.
Cardiovascular Diseases
Identification of novel ASK1 inhibitors using virtual screening.
Catalepsy
Map3k1, Il6st, Gzmk, and Hspb3 gene coexpression network in the mechanism of freezing reaction in mice.
Cell Transformation, Neoplastic
A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase alpha in neoplastic cell transformation and tumor development.
Cerebral Hemorrhage
MEKK1 Associated with Neuronal Apoptosis Following Intracerebral Hemorrhage.
Cerebral Infarction
Long noncoding RNA CDKN2B-AS1 interacts with transcription factor BCL11A to regulate progression of cerebral infarction through mediating MAP4K1 transcription.
Cerebrovascular Disorders
MAP3K6 Mutations in a Neurovascular Disease Causing Stroke, Cognitive Impairment, and Tremor.
Cholangiocarcinoma
Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes.
Cholangiocarcinoma
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Cholangiocarcinoma
Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities.
Cholangiocarcinoma
The MAPK Kinase Kinase 4 Deficiency in Intrahepatic Cholangiocarcinoma Leads to Invasive Growth and Epithelial-Mesenchymal Transition.
Cholangiocarcinoma
[Molecular genetic approaches in parasitology (in case of opisthorchiasis)]
Chondrosarcoma
Apoptosis signal-regulating kinase 1 is involved in brain-derived neurotrophic factor (BDNF)-enhanced cell motility and matrix metalloproteinase 1 expression in human chondrosarcoma cells.
Chondrosarcoma
Epigallocatechin-3-gallate induces cell apoptosis of human chondrosarcoma cells through apoptosis signal-regulating kinase 1 pathway.
Chondrosarcoma
FPipTB, a benzimidazole derivative, induces chondrosarcoma cell apoptosis via endoplasmic reticulum stress and apoptosis signal-regulating kinase 1.
Choriocarcinoma
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Choriocarcinoma
miR-196b inhibits cell migration and invasion through targeting MAP3K1 in hydatidiform mole.
Choriocarcinoma
Next-Generation Sequencing Panel Analysis of Clinically Relevant Mutations in Circulating Cell-Free DNA from Patients with Gestational Trophoblastic Neoplasia: A Pilot Study.
Chronic Periodontitis
Loss of periodontal ligament fibroblasts by RIPK3-MLKL-mediated necroptosis in the progress of chronic periodontitis.
Colitis
ABIN-2, of the TPL-2 Signaling Complex, Modulates Mammalian Inflammation.
Colitis
Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses.
Colitis
Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?
Colitis
Inhibition of RIPK3 Pathway Attenuates Intestinal Inflammation and Cell Death of Inflammatory Bowel Disease and Suppresses Necroptosis in Peripheral Mononuclear Cells of Ulcerative Colitis Patients.
Colitis, Ulcerative
Expression of receptor interacting protein 3 and mixed lineage kinase domain-like protein-key proteins in necroptosis is upregulated in ulcerative colitis.
Colitis, Ulcerative
Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages.
Colitis, Ulcerative
Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?
Colitis, Ulcerative
How autophagy controls the intestinal epithelial barrier.
Colonic Diseases
Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses.
Colonic Neoplasms
A LIN28B polymorphism predicts for colon cancer survival.
Colonic Neoplasms
Activation of the apoptosis signal-regulating kinase 1/c-Jun N-terminal kinase pathway is involved in the casticin-induced apoptosis of colon cancer cells.
Colonic Neoplasms
Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction.
Colonic Neoplasms
Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer.
Colonic Neoplasms
Association of Mixed Lineage Kinase Domain-Like Protein Expression With Prognosis in Patients With Colon Cancer.
Colonic Neoplasms
Cationic liposome co-encapsulation of SMAC mimetic and zVAD using a novel lipid bilayer fusion loaded with MLKL-pDNA for tumour inhibition in vivo.
Colonic Neoplasms
Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability.
Colonic Neoplasms
Cholecystokinin 1 receptor modulates the MEKK1-induced c-Jun trans-activation: structural requirements of the receptor.
Colonic Neoplasms
Colon Cancer: A Clinician's Perspective in 2019.
Colonic Neoplasms
Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells.
Colonic Neoplasms
Comparative mutational analysis of distal colon cancer with rectal cancer.
Colonic Neoplasms
ERK/pERK expression, B-raf and K-ras mutations in colon adenocarcinomas: correlation with clinicopathological characteristics and expression of hMLH1 and hMSH2.
Colonic Neoplasms
NF?B-Associated Pathways in Progression of Chemoresistance to 5-Fluorouracil in an In Vitro Model of Colonic Carcinoma.
Colonic Neoplasms
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.
Colonic Neoplasms
Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells.
Colonic Neoplasms
RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors.
Colonic Neoplasms
Suppression of serum-induced c-jun expression by activated Ki-ras in human colon cancer cells.
Colonic Neoplasms
Tumor necrosis factor-related genes and colon and rectal cancer.
Colorectal Neoplasms
5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma.
Colorectal Neoplasms
A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers.
Colorectal Neoplasms
Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.
Colorectal Neoplasms
Alternative splicing of BRAF transcripts and characterization of C-terminally truncated B-Raf isoforms in colorectal cancer.
Colorectal Neoplasms
Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab.
Colorectal Neoplasms
Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
Colorectal Neoplasms
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Colorectal Neoplasms
B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
Colorectal Neoplasms
B-Raf mutation: a key player in molecular biology of cancer.
Colorectal Neoplasms
BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.
Colorectal Neoplasms
BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
Colorectal Neoplasms
Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
Colorectal Neoplasms
Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
Colorectal Neoplasms
Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
Colorectal Neoplasms
Data on tumor progression of c-mos deficiency in murine models of Kras
G12D
lung and Apc
Min
colorectal cancer.
Colorectal Neoplasms
Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy.
Colorectal Neoplasms
Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Colorectal Neoplasms
Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.
Colorectal Neoplasms
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Colorectal Neoplasms
Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.
Colorectal Neoplasms
Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines.
Colorectal Neoplasms
How autophagy controls the intestinal epithelial barrier.
Colorectal Neoplasms
Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
Colorectal Neoplasms
Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
Colorectal Neoplasms
Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis.
Colorectal Neoplasms
Involvement of Kruppel-like factor 6 (KLF6) mutation in the development of nonpolypoid colorectal carcinoma.
Colorectal Neoplasms
K-ras and B-raf gene mutations are not associated with gastrin- and CCK2-receptor mRNA expression in human colorectal tumour tissues.
Colorectal Neoplasms
KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population.
Colorectal Neoplasms
MAP3K1 functionally interacts with Axin1 in the canonical Wnt signalling pathway.
Colorectal Neoplasms
MiR-142-5p act as an oncogenic microRNA in colorectal cancer: Clinicopathological and functional insights.
Colorectal Neoplasms
Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Colorectal Neoplasms
Mixed Lineage Kinase MLK4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis.
Colorectal Neoplasms
MLK3 phosphorylation by ERK1/2 is required for oxidative stress-induced invasion of colorectal cancer cells.
Colorectal Neoplasms
Mps1 is associated with the BRAFV600E mutation and predicts poor outcome in patients with colorectal cancer.
Colorectal Neoplasms
MTDH and MAP3K1 are direct targets of apoptosis-regulating miRNAs in colorectal carcinoma.
Colorectal Neoplasms
mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.
Colorectal Neoplasms
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Colorectal Neoplasms
Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients.
Colorectal Neoplasms
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Colorectal Neoplasms
OVOL2 attenuates the expression of MAP3K8 to suppress epithelial mesenchymal transition in colorectal cancer.
Colorectal Neoplasms
PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation.
Colorectal Neoplasms
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.
Colorectal Neoplasms
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
Colorectal Neoplasms
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation.
Colorectal Neoplasms
Prognostic value of BRAF/MIR-17 signature and B-Raf protein expression in patients with colorectal cancer: A pilot study.
Colorectal Neoplasms
Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx.
Colorectal Neoplasms
RAF protein-serine/threonine kinases: structure and regulation.
Colorectal Neoplasms
RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA.
Colorectal Neoplasms
Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf.
Colorectal Neoplasms
Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis.
Colorectal Neoplasms
TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status.
Colorectal Neoplasms
Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer.
Colorectal Neoplasms
The BRAF mutation is associated with the prognosis in colorectal cancer.
Colorectal Neoplasms
The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer.
Colorectal Neoplasms
The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Colorectal Neoplasms
Therapeutic implications of B-RAF mutations in colorectal cancer.
Colorectal Neoplasms
Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
Colorectal Neoplasms
[Biomarkers and anti-EGFR therapies for KRAS wild-type tumors in metastatic colorectal cancer patients]
Colorectal Neoplasms
[Correlation of K-ras Gene Mutations with the Protein Expressions of TAK1 and MAP4K2 in Colorectal Cancer].
Colorectal Neoplasms
[The RAS paradoxon of the EGFR-targeted therapy of colorectal cancer]
Confusion
Isoforms of JSAP1 scaffold protein generated through alternative splicing.
Congenital Disorders of Glycosylation
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Coronary Artery Disease
Effects of miR-124-3p regulation of the p38MAPK signaling pathway via MEKK3 on apoptosis and proliferation of macrophages in mice with coronary atherosclerosis.
Crohn Disease
Defective IL-1A expression in patients with Crohn's disease is related to attenuated MAP3K4 signaling.
Crohn Disease
Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?
Crohn Disease
How autophagy controls the intestinal epithelial barrier.
Crohn Disease
MEKK4 sequesters RIP2 to dictate NOD2 signal specificity.
Crohn Disease
Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease.
Cutis Laxa
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Cystadenoma
[Serous genital carcinoma : Molecular pathogenesis and the role of tubal fimbria.]
Cystic Fibrosis
How autophagy controls the intestinal epithelial barrier.
Cysts
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
Cysts
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.
Cysts
Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice.
Cysts
Glycomolecules in Echinococcus granulosus cyst fluid inhibit TLR4-mediated inflammatory responses via c-Raf.
Cysts
Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach.
Cysts
Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
Cysts
Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
Deafness
C-Raf deficiency leads to hearing loss and increased noise susceptibility.
Dehydration
A gene encoding a mitogen-activated protein kinase kinase kinase is induced simultaneously with genes for a mitogen-activated protein kinase and an S6 ribosomal protein kinase by touch, cold, and water stress in Arabidopsis thaliana.
Dehydration
Arabidopsis MKKK20 is involved in osmotic stress response via regulation of MPK6 activity.
Demyelinating Diseases
RIP1 kinase inhibitor halts the progression of an immune-induced demyelination disease at the stage of monocyte elevation.
Dendritic Cell Sarcoma, Interdigitating
Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature.
Dermatitis, Phototoxic
Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
Diabetes Mellitus
A new function for MAP4K4 inhibitors during platelet aggregation and platelet-mediated clot retraction.
Diabetes Mellitus
Association of Common Genetic Variants in Mitogen-activated Protein Kinase Kinase Kinase Kinase 4 with Type 2 Diabetes Mellitus in a Chinese Han Population.
Diabetes Mellitus
Inhibition of MafA transcriptional activity and human insulin gene transcription by interleukin-1beta and mitogen-activated protein kinase kinase kinase in pancreatic islet beta cells.
Diabetes Mellitus
MAP3K1 May be a Promising Susceptibility Gene for Type 2 Diabetes Mellitus in an Iranian Population.
Diabetes Mellitus
Mixed Lineage Kinase Domain-Like Pseudokinase (MLKL) Gene Expression in Human Atherosclerosis with and without Type 2 Diabetes Mellitus.
Diabetes Mellitus
The Rap-B-Raf signalling pathway is activated by glucose and glucagon-like peptide-1 in human islet cells.
Diabetes Mellitus, Type 2
A new function for MAP4K4 inhibitors during platelet aggregation and platelet-mediated clot retraction.
Diabetes Mellitus, Type 2
Association of Common Genetic Variants in Mitogen-activated Protein Kinase Kinase Kinase Kinase 4 with Type 2 Diabetes Mellitus in a Chinese Han Population.
Diabetes Mellitus, Type 2
Identification of apoptosis signal-regulating kinase 1 (ASK1) inhibitors among the derivatives of benzothiazol-2-yl-3-hydroxy-5-phenyl-1,5-dihydro-pyrrol-2-one.
Diabetes Mellitus, Type 2
MAP3K1 May be a Promising Susceptibility Gene for Type 2 Diabetes Mellitus in an Iranian Population.
Diabetes Mellitus, Type 2
Mixed Lineage Kinase Domain-Like Pseudokinase (MLKL) Gene Expression in Human Atherosclerosis with and without Type 2 Diabetes Mellitus.
Diabetic Cardiomyopathies
14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy.
Diabetic Nephropathies
ASK1 Inhibitor Halts Progression of Diabetic Nephropathy in Nos3-Deficient Mice.
Diabetic Nephropathies
Cyclin-dependent kinase 5 contributes to endoplasmic reticulum stress induced podocyte apoptosis via promoting MEKK1 phosphorylation at Ser280 in diabetic nephropathy.
Diabetic Nephropathies
High glucose stimulates synthesis of fibronectin via a novel protein kinase C, Rap1b, and B-Raf signaling pathway.
Diabetic Nephropathies
Ras-Related C3 Botulinum Toxin Substrate 1 Combining With the Mixed Lineage Kinase 3- Mitogen-Activated Protein Kinase 7- c-Jun N-Terminal Kinase Signaling Module Accelerates Diabetic Nephropathy.
Diabetic Retinopathy
MicroRNA-337 participates in the progression of early-stage diabetic retinopathy by upregulating MAP3K12.
Diastema
A new species of the genus Rhabdophis Fitzinger, 1843 (Squamata: Colubridae) from Guangdong Province, southern China.
dihydropyrimidinase deficiency
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation.
Dihydropyrimidine Dehydrogenase Deficiency
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation.
Disorders of Sex Development
Minor abnormalities of testis development in mice lacking the gene encoding the MAPK signalling component, MAP3K1.
Disorders of Sex Development
Mutation analysis of mitogen activated protein kinase 1 gene in Indian cases of 46,XY disorder of sex development.
Disorders of Sex Development
Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination.
Disorders of Sex Development
Mutations in MAP3K1 that cause 46,XY disorders of sex development disrupt distinct structural domains in the protein.
Disorders of Sex Development
Nonsense-associated altered splicing of MAP3K1 in two siblings with 46,XY disorders of sex development.
Encephalitis
Mechanisms of minocycline-induced suppression of simian immunodeficiency virus encephalitis: inhibition of apoptosis signal-regulating kinase 1.
Encephalitis, Japanese
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalomyelitis
Regulation of Experimental Autoimmune Encephalomyelitis by TPL-2 Kinase.
Encephalomyelitis, Autoimmune, Experimental
Regulation of Experimental Autoimmune Encephalomyelitis by TPL-2 Kinase.
Endocrine Gland Neoplasms
Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
Endometrial Neoplasms
Differential gene expression profile reveals overexpression of MAP3K8 in invasive endometrioid carcinoma.
Endometrial Neoplasms
RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
Endometriosis
Analysis of the oncogene BRAF mutation and the correlation of the expression of wild-type BRAF and CREB1 in endometriosis.
Endometriosis
Genome-wide genetic analyses highlight mitogen-activated protein kinase (MAPK) signaling in the pathogenesis of endometriosis.
Endotoxemia
GSK-3?-induced ASK1 stabilization is crucial in LPS-induced endotoxin shock.
Enterocolitis, Necrotizing
Tumor necrosis factor-alpha and apoptosis signal-regulating kinase 1 control reactive oxygen species release, mitochondrial autophagy, and c-Jun N-terminal kinase/p38 phosphorylation during necrotizing enterocolitis.
Eosinophilia
Tumor progression locus 2 reduces severe allergic airway inflammation by inhibiting Ccl24 production in dendritic cells.
Epilepsy
The inhibition of transforming growth factor beta-activated kinase 1 contributed to neuroprotection via inflammatory reaction in pilocarpine-induced rats with epilepsy.
Esophageal Neoplasms
Griffipavixanthone, a dimeric xanthone extracted from edible plants, inhibits tumor metastasis and proliferation via downregulation of the RAF pathway in esophageal cancer.
Esophageal Neoplasms
miR-203 affects esophageal cancer cell proliferation, apoptosis and invasion by targeting MAP3K1.
Esophageal Neoplasms
Presence of an EcoRI RFLP of the c-mos locus in normal and tumor tissue of esophageal cancer patients.
Esophageal Squamous Cell Carcinoma
Association Study of MAP3K1 SNPs and Risk Factors with Susceptibility to Esophageal Squamous Cell Carcinoma in a Chinese Population: A Case-Control Study.
Esophageal Squamous Cell Carcinoma
K-ras Mutation, HPV Infection and Smoking or Alcohol Abuse Positively Correlate with Esophageal Squamous Carcinoma.
Exanthema
Intermittent B-Raf inhibitor therapy is a feasible option -report of a patient with metastatic melanoma.
Eye Manifestations
MEK kinase 1 regulates c-Jun phosphorylation in the control of corneal morphogenesis.
Fanconi Anemia
Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1.
Fatty Liver
Chronic-plus-binge alcohol intake induces production of proinflammatory mtDNA-enriched extracellular vesicles and steatohepatitis via ASK1/p38MAPK?-dependent mechanisms.
Fatty Liver
Decrease in fat de novo synthesis and chemokine ligand expression in non-alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain-like pseudokinase.
Fatty Liver
Discovery of potent apoptosis signal-regulating kinase 1 inhibitors via integrated computational strategy and biological evaluation.
Fatty Liver
Mixed lineage kinase 3 deficient mice are protected against the high fat high carbohydrate diet-induced steatohepatitis.
Fatty Liver
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Fatty Liver
The ménage à trois of autophagy, lipid droplets and liver disease.
Fibrosarcoma
Depletion of RIPK3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis.
Fibrosarcoma
Inhibition of apoptosis signal-regulating kinase 1 by nitric oxide through a thiol redox mechanism.
Fibrosarcoma
Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1.
Ganglioglioma
BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.
Ganglion Cysts
Up-regulation of Ras/Raf/ERK1/2 signaling in the spinal cord impairs neural cell migration, neurogenesis, synapse formation, and dendritic spine development.
Gastrointestinal Stromal Tumors
Multiple primary malignant neoplasms: A case report and literature review.
Genetic Diseases, Inborn
Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development.
Genetic Diseases, Inborn
[Gonadal dysgenesis 46,XY DSD associated with variants in the MAP3K1 gene].
Gestational Trophoblastic Disease
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Glaucoma
Dock3-NMDA receptor interaction as a target for glaucoma therapy.
Glaucoma
Targeting Oxidative Stress for Treatment of Glaucoma and Optic Neuritis.
Glioblastoma
A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma.
Glioblastoma
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
Glioblastoma
Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Glioblastoma
Correction to: Synergism between the phosphatidylinositol 3-kinase p110? isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
Glioblastoma
Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase- and B-Raf Proto-Oncogene-Wildtype Epithelioid Glioblastoma.
Glioblastoma
MiR-338-3p inhibits growth of glioblastoma through targeting MAP4K3.
Glioblastoma
Multiple forms of protein kinase from normal human brain and glioblastoma.
Glioblastoma
Mutation analysis of B-RAF gene in human gliomas.
Glioblastoma
Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications.
Glioblastoma
RAF expression in human astrocytic tumors.
Glioblastoma
Regulation of the uPA gene in various grades of human glioma cells.
Glioblastoma
Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines.
Glioblastoma
Synergism between the phosphatidylinositol 3-kinase p110? isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
Glioma
AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma.
Glioma
BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.
Glioma
Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Glioma
LRRC4 inhibits glioblastoma cell proliferation, migration, and angiogenesis by downregulating pleiotropic cytokine expression and responses.
Glioma
Mutation analysis of B-RAF gene in human gliomas.
Glioma
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Glioma
Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells.
Glioma
Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.
Glioma
Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models.
Glioma
Protein kinase translocation following beta-adrenergic receptor activation in C6 glioma cells.
Glioma
Radiomics of Pediatric Low-Grade Gliomas: Toward a Pretherapeutic Differentiation of BRAF-Mutated and BRAF-Fused Tumors.
Glioma
RAF expression in human astrocytic tumors.
Glioma
To BRAF or not to BRAF: is that even a question anymore?
Gliosarcoma
Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas.
Glomerulonephritis
Inactivation of MAP3K7 in FOXD1-expressing cells results in loss of mesangial PDGFR? and juvenile kidney scarring.
Glomerulonephritis
Proto-oncogene expression in human glomerular diseases.
Glomerulonephritis
[Proto-oncogene, proliferating cell nuclear antigen, perforin and growth factor gene expression in peripheral blood mononuclear cells from patients with IgA nephropathy]
Glomerulonephritis, IGA
Proto-oncogene expression in peripheral blood mononuclear cells in IgA nephropathy.
Glomerulonephritis, IGA
[Proto-oncogene, proliferating cell nuclear antigen, perforin and growth factor gene expression in peripheral blood mononuclear cells from patients with IgA nephropathy]
glutamate-5-semialdehyde dehydrogenase deficiency
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Gonadal Dysgenesis
A novel missense heterozygous mutation in MAP3K1 gene causes 46, XY disorder of sex development: case report and literature review.
Gonadal Dysgenesis
A practical guide for evaluating gonadal germ cell tumor predisposition in differences of sex development.
Gonadal Dysgenesis
Human sex-determination and disorders of sex-development (DSD).
Gonadal Dysgenesis
MAP3K1-related gonadal dysgenesis: Six new cases and review of the literature.
Gonadal Dysgenesis
Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination.
Gonadal Dysgenesis
Mutations in MAP3K1 that cause 46,XY disorders of sex development disrupt distinct structural domains in the protein.
Gonadal Dysgenesis
Rapidly screening variants of uncertain significance in the MAP3K1 gene for phenotypic effects.
Gout
Xanthine Oxidase and Transforming Growth Factor Beta-activated Kinase 1: Potential Targets for Gout Intervention.
Head and Neck Neoplasms
c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway.
Hearing Loss
Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure.
Hearing Loss
C-Raf deficiency leads to hearing loss and increased noise susceptibility.
Hearing Loss
MEKK4 Signaling Regulates Sensory Cell Development and Function in the Mouse Inner Ear.
Hearing Loss
The goya mouse mutant reveals distinct newly identified roles for MAP3K1 in the development and survival of cochlear sensory hair cells.
Hearing Loss, Noise-Induced
Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure.
Hearing Loss, Sensorineural
The goya mouse mutant reveals distinct newly identified roles for MAP3K1 in the development and survival of cochlear sensory hair cells.
Heart Defects, Congenital
The phenotypic spectrum of proximal 6q deletions based on a large cohort derived from social media and literature reports.
Heart Diseases
Development of an HTS-compatible assay for the discovery of ASK1 signalosome inhibitors using alphascreen technology.
Heart Diseases
MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq.
Heart Diseases
Silencing MEKK3 attenuates cardiomyocyte injury caused by hypoxia/reoxygenation via the sonic hedgehog pathway.
Heart Failure
A direct interaction between TGFbeta activated kinase 1 and the TGFbeta type II receptor: implications for TGFbeta signalling and cardiac hypertrophy.
Heart Failure
Apoptosis signal-regulating kinase 1 attenuates atrial natriuretic peptide secretion.
Heart Failure
Progression of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via transcoronary gene transfer.
Heart Failure
The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy.
Heart Failure
Tissue distribution and functional expression of a cDNA encoding a novel mixed lineage kinase.
Heart Failure
Transforming growth factor ?-activated kinase 1 signaling pathway critically regulates myocardial survival and remodeling.
Heart Septal Defects
Insights into the molecular pathogenesis of cardiospondylocarpofacial syndrome: MAP3K7 c.737-7A > G variant alters the TGF?-mediated ?-SMA cytoskeleton assembly and autophagy.
Hemangioma, Cavernous, Central Nervous System
Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican.
Hemangioma, Cavernous, Central Nervous System
Laser-scanning velocimetry: a confocal microscopy method for quantitative measurement of cardiovascular performance in zebrafish embryos and larvae.
Hemangioma, Cavernous, Central Nervous System
Micro-CT Imaging Reveals Mekk3 Heterozygosity Prevents Cerebral Cavernous Malformations in Ccm2-Deficient Mice.
Hemangioma, Cavernous, Central Nervous System
Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.
Hemangioma, Cavernous, Central Nervous System
Structural Insights into the Molecular Recognition between Cerebral Cavernous Malformation 2 and Mitogen-Activated Protein Kinase Kinase Kinase 3.
Hemangioma, Cavernous, Central Nervous System
The Cerebral Cavernous Malformation Pathway Controls Cardiac Development via Regulation of Endocardial MEKK3 Signaling and KLF Expression.
Hemangioma, Cavernous, Central Nervous System
The cerebral cavernous malformation proteins CCM2L and CCM2 prevent the activation of the MAP kinase MEKK3.
Hepatitis
The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.
Hepatitis B
Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome.
Hepatitis B
Hepatitis B virus X protein promotes hepatoma cell proliferation via upregulation of MEKK2.
Hepatitis C
Hepatitis C Virus NS5A Inhibits Mixed Lineage Kinase 3 to Block Apoptosis.
Hepatitis C, Chronic
Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C.
Hepatitis, Autoimmune
The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.
Herpes Simplex
Herpes simplex virus type 1 ICP27 induces p38 mitogen-activated protein kinase signaling and apoptosis in HeLa cells.
Herpes Zoster
Characterization of Porcine Multipotent Stem/Stromal Cells Derived from Skin, Adipose, and Ovarian Tissues and Their Differentiation In Vitro into Putative Oocyte-Like Cells.
Herpes Zoster
Functional analysis of oocyte-expressed genes using transgenic models.
Herpes Zoster
Oocyte-specific gene signaling and its regulation of mammalian reproductive potential.
Herpes Zoster
Ovary-selective genes I: the generation and characterization of an ovary-selective complementary deoxyribonucleic acid library.
Histiocytic Sarcoma
Histiocytic neoplasms in the era of personalized genomic medicine.
Histiocytosis
B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.
Histiocytosis
Histiocytic neoplasms in the era of personalized genomic medicine.
Histiocytosis
MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
Histiocytosis
The diagnostic pathology of the nuclear envelope in human cancers.
Histiocytosis, Langerhans-Cell
B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.
Histiocytosis, Langerhans-Cell
MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
Histiocytosis, Langerhans-Cell
The diagnostic pathology of the nuclear envelope in human cancers.
Hodgkin Disease
Heterogeneous expression of proto-oncogenes in Hodgkin's disease derived cell lines.
Hodgkin Disease
The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2.
Hodgkin Disease
[Genetic polymorphism and susceptibility to cancer]
Huntington Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Huntington Disease
Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
Hydatidiform Mole
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Hydatidiform Mole
miR-196b inhibits cell migration and invasion through targeting MAP3K1 in hydatidiform mole.
Hyperalgesia
The role of P2X7R/ERK signaling in dorsal root ganglia satellite glial cells in the development of chronic postsurgical pain induced by skin/muscle incision and retraction (SMIR).
Hyperglycemia
Apoptosis Signal-Regulating Kinase 1 Mediates Cellular Senescence Induced by High Glucose in Endothelial Cells.
Hyperglycemia
Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications.
Hyperglycemia
Maternal Hyperglycemia Activates an ASK1-FoxO3a-Caspase 8 Pathway That Leads to Embryonic Neural Tube Defects.
Hyperinsulinism
Protein Kinase Mitogen-activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Promotes Obesity-induced Hyperinsulinemia.
Hypersensitivity
TPL-2 restricts Ccl24-dependent immunity to Heligmosomoides polygyrus.
Hypersensitivity
Tumor progression locus 2 reduces severe allergic airway inflammation by inhibiting Ccl24 production in dendritic cells.
Hypertension
Apoptosis signal-regulating kinase 1 inhibition in in vivo and in vitro models of pulmonary hypertension.
Hypertension
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.
Hypertension, Pulmonary
Apoptosis signal-regulating kinase 1 inhibition in in vivo and in vitro models of pulmonary hypertension.
Hypertension, Pulmonary
Apoptosis Signal-regulating Kinase 1 Inhibition in Pulmonary Hypertension: Too Much to ASK?
Hypertension, Pulmonary
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Hypospadias
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Infections
Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells.
Infections
ALV-J inhibits autophagy through the GADD45?/MEKK4/P38MAPK signaling pathway and mediates apoptosis following autophagy.
Infections
An expanded subfamily of G-protein-coupled receptor genes in Fusarium graminearum required for wheat infection.
Infections
Analysis of erythrocyte signalling pathways during Plasmodium falciparum infection identifies targets for host-directed antimalarial intervention.
Infections
Apigenin inhibits cell migration through MAPK pathways in human bladder smooth muscle cells.
Infections
B-Raf/Rap1 signaling, but not c-Raf-1/Ras, induces the histidine decarboxylase promoter in Helicobacter pylori infection.
Infections
Ce-Duox1/BLI-3 generated reactive oxygen species trigger protective SKN-1 activity via p38 MAPK signaling during infection in C. elegans.
Infections
Cell Signaling of Caenorhabditis elegans in Response to Enterotoxigenic Escherichia coli Infection and Lactobacillus zeae Protection.
Infections
Comparative transcriptional analysis of human macrophages exposed to animal and human isolates of Mycobacterium avium subspecies paratuberculosis with diverse genotypes.
Infections
Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni.
Infections
Down-regulation apoptosis signal-regulating kinase 1 gene reduced the Litopenaeus vannamei hemocyte apoptosis in WSSV infection.
Infections
Early-life long-term exposure to ZnO nanoparticles suppresses innate immunity regulated by SKN-1/Nrf and the p38 MAPK signaling pathway in Caenorhabditis elegans.
Infections
EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation.
Infections
gga-miR-21 modulates Mycoplasma gallisepticum (HS strain)-Induced inflammation via targeting MAP3K1 and activating MAPKs and NF-?B pathways.
Infections
GhMAP3K65, a Cotton Raf-Like MAP3K Gene, Enhances Susceptibility to Pathogen Infection and Heat Stress by Negatively Modulating Growth and Development in Transgenic Nicotiana benthamiana.
Infections
H7N9 influenza A virus activation of necroptosis in human monocytes links innate and adaptive immune responses.
Infections
Identification and characterization of c-raf from orange-spotted grouper (Epinephelus coioides).
Infections
Identification of novel therapeutic targets for HIV infection through functional genomic cDNA screening.
Infections
In vivo and in vitro phosphorylation of DNA-dependent RNA polymerase of Escherichia coli by bacteriophage-T7-induced protein kinase.
Infections
Influenza Virus Infection Induces ZBP1 Expression and Necroptosis in Mouse Lungs.
Infections
Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells.
Infections
Interferon gamma induces cellular protein alteration and increases replication of porcine circovirus type 2 in PK-15 cells.
Infections
Kinome-Wide RNA Interference Screening Identifies Mitogen-Activated Protein Kinases and Phosphatidylinositol Metabolism as Key Factors for Rabies Virus Infection.
Infections
Lactobacillus Regulates Caenorhabditis elegans Cell Signaling to Combat Salmonella Infection.
Infections
Listeria monocytogenes infection of HeLa cells results in listeriolysin O-mediated transient activation of the Raf-MEK-MAP kinase pathway.
Infections
Macrophages inhibit Salmonella typhimurium replication through MEK/ERK kinase and phagocyte NADPH oxidase activities.
Infections
Map3k8 controls granulocyte colony-stimulating factor production and neutrophil precursor proliferation in lipopolysaccharide-induced emergency granulopoiesis.
Infections
mcr-1 Gene Expression Modulates the Inflammatory Response of Human Macrophages to Escherichia coli.
Infections
MEKK1 is required for MPK4 activation and regulates tissue-specific and temperature-dependent cell death in Arabidopsis.
Infections
MEKK3 activates IRF7 to trigger a potent type I interferon induction in response to TLR7/9 signaling.
Infections
MEKK3 and TAK1 synergize to activate IKK complex in Helicobacter pylori infection.
Infections
MEKK3 in hybrid snakehead (Channa maculate ? ×Channa argus ?): Molecular characterization and immune response to infection with Nocardia seriolae and Aeromonas schubertii.
Infections
MLKL Requires the Inositol Phosphate Code to Execute Necroptosis.
Infections
Mouse cytomegalovirus M36 and M45 death suppressors cooperate to prevent inflammation resulting from antiviral programmed cell death pathways.
Infections
Mycobacteria induce TPL-2 mediated IL-10 in IL-4-generated alternatively activated macrophages.
Infections
Physiological roles of ASK family members in innate immunity and their involvement in pathogenesis of immune diseases.
Infections
Protein kinase of bacteriophage T7. 1. Purification.
Infections
Raf/MEK/ERK signalling triggers reactivation of Kaposi's sarcoma-associated herpesvirus latency.
Infections
Regulation of mTOR and S6K1 activation by the nPKC isoforms, PKCepsilon and PKCdelta, in adult cardiac muscle cells.
Infections
Roquin-2 promotes ubiquitin-mediated degradation of ASK1 to regulate stress responses.
Infections
Suppression of extracellular signal-regulated kinase activity in herpes simplex virus 1-infected cells by the Us3 protein kinase.
Infections
Sustained activation of Akt and Erk1/2 is required for Coxiella burnetii antiapoptotic activity.
Infections
The Ectopic Expression of CaRop1 Modulates the Response of Tobacco Plants to Ralstonia solanacearum and Aphids.
Infections
The MAPKKK Mekk1 regulates the expression of Turandot stress genes in response to septic injury in Drosophila.
Infections
The Pathogenic Effects of Fusobacterium nucleatum on the Proliferation, Osteogenic Differentiation, and Transcriptome of Osteoblasts.
Infections
TPL-2 Regulates Macrophage Lipid Metabolism and M2 Differentiation to Control TH2-Mediated Immunopathology.
Infections
TPL-2 restricts Ccl24-dependent immunity to Heligmosomoides polygyrus.
Infections
Transcriptome analysis of liver elucidates key immune-related pathways in Nile tilapia Oreochromis niloticus following infection with tilapia lake virus.
Infections
Transcriptome-based analysis of mitogen-activated protein kinase cascades in the rice response to Xanthomonas oryzae infection.
Infections
Transcriptomic Response to Nitric Oxide Treatment in Larix olgensis Henry.
Infections
Varicella-zoster virus influences the activities of components and targets of the ERK signalling pathway.
Infections
Viral-induced systemic necrosis in plants involves both programmed cell death and the inhibition of viral multiplication, which are regulated by independent pathways.
Infertility
A dominant truncation allele identifies a gene, STE20, that encodes a putative protein kinase necessary for mating in Saccharomyces cerevisiae.
Infertility
A gene-specific requirement of RNA polymerase II CTD phosphorylation for sexual differentiation in S. pombe.
Infertility
A zinc-finger protein, Rst2p, regulates transcription of the fission yeast ste11(+) gene, which encodes a pivotal transcription factor for sexual development.
Infertility
Interactions among the subunits of the G protein involved in Saccharomyces cerevisiae mating.
Infertility
Role of STE genes in the mating factor signaling pathway mediated by GPA1 in Saccharomyces cerevisiae.
Infertility
The RNA binding protein Csx1 promotes sexual differentiation in Schizosaccharomyces pombe.
Inflammatory Bowel Diseases
How autophagy controls the intestinal epithelial barrier.
Inflammatory Bowel Diseases
Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis.
Inflammatory Bowel Diseases
Regulation and function of TPL-2, an I?B kinase-regulated MAP kinase kinase kinase.
Influenza, Human
Differential Responses to Rhinovirus and Influenza-associated Pulmonary Exacerbations in Patients with Cystic Fibrosis.
Influenza, Human
Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs.
Influenza, Human
Influenza Virus Z-RNAs Induce ZBP1-Mediated Necroptosis.
Influenza, Human
Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice.
Influenza, Human
Mixed Lineage Kinase 3 deficiency delays viral clearance in the lung and is associated with diminished influenza-induced cytopathic effect in infected cells.
Insulin Resistance
Association of common genetic variants in the MAP4K4 locus with prediabetic traits in humans.
Insulin Resistance
Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications.
Insulin Resistance
MAP3K8 (TPL2/COT) affects obesity-induced adipose tissue inflammation without systemic effects in humans and in mice.
Insulin Resistance
Protein Kinase Mitogen-activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Promotes Obesity-induced Hyperinsulinemia.
Insulin Resistance
Resistin promotes cardiac hypertrophy via AMPK/mTOR and JNK/IRS1 pathways.
Insulin Resistance
The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance.
Insulinoma
Pyruvate kinase M1 interacts with A-Raf and inhibits endoplasmic reticulum stress-induced apoptosis by activating MEK1/ERK pathway in mouse insulinoma cells.
Insulinoma
Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
Insulinoma
Stimulation of B-Raf increases c-Jun and c-Fos expression and upregulates AP-1-regulated gene transcription in insulinoma cells.
Intestinal Neoplasms
Data on tumor progression of c-mos deficiency in murine models of Kras
G12D
lung and Apc
Min
colorectal cancer.
Intracranial Aneurysm
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Ischemic Stroke
Apoptosis Signal-regulating Kinase 1 Silencing on Astroglial Inflammasomes in an Experimental Model of Ischemic Stroke.
Ischemic Stroke
Cell Type-Specific Mechanisms in the Pathogenesis of Ischemic Stroke: The Role of Apoptosis Signal-Regulating Kinase 1.
Ischemic Stroke
Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway.
Ischemic Stroke
microRNA-381-3p Confers Protection Against Ischemic Stroke Through Promoting Angiogenesis and Inhibiting Inflammation by Suppressing Cebpb and Map3k8.
Ischemic Stroke
Silencing of Long Non-coding RNA GAS5 Suppresses Neuron Cell Apoptosis and Nerve Injury in Ischemic Stroke Through Inhibiting DNMT3B-Dependent MAP4K4 Methylation.
Ischemic Stroke
Thousand and one kinase 1 protects MCAO-induced cerebral ischemic stroke in rats by decreasing apoptosis and pro-inflammatory factors.
Keratoacanthoma
Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?
Kidney Diseases
ASK1: a new therapeutic target for kidney disease.
Kidney Diseases
Effects of Selonsertib in Patients with Diabetic Kidney Disease.
Kidney Diseases
Inhibition of apoptosis signal-regulating kinase 1 mitigates the pathogenesis of human immunodeficiency virus-associated nephropathy.
Kidney Diseases
MAP3K kinases and kidney injury.
Kidney Diseases
TGF-{beta}1 activated kinase-1 (TAK1) regulates inflammation and fibrosis in the obstructed kidney.
Kidney Neoplasms
Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.
Kidney Neoplasms
Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus.
Kidney Neoplasms
The Expression and Role of MEKK3 in Renal Clear Cell Carcinoma.
LEOPARD Syndrome
C-Raf deficiency leads to hearing loss and increased noise susceptibility.
Leukemia
A generalized method of subcloning DNA fragments by restriction site reconstruction: application to sequencing the amino-terminal coding region of the transforming gene of Gazdar murine sarcoma virus.
Leukemia
A single point mutation responsible for c-mos polymorphism in cancer patients.
Leukemia
Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase.
Leukemia
B-Raf Inhibition in the Clinic: Present and Future.
Leukemia
Chromosomal locations of human tissue plasminogen activator and urokinase genes.
Leukemia
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Leukemia
Cot kinase regulation of IL-2 production in Jurkat T cells.
Leukemia
Dissecting the novel partners of nuclear c-Raf and its role in all-trans retinoic acid (ATRA)-induced myeloblastic leukemia cells differentiation.
Leukemia
DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
Leukemia
Essential role of the 58-kDa microspherule protein in the modulation of Daxx-dependent transcriptional repression as revealed by nucleolar sequestration.
Leukemia
Expression and activation of B-Raf kinase isoforms in human and murine leukemia cell lines.
Leukemia
Genomic organization and expression of Tpl-2 in normal cells and Moloney murine leukemia virus-induced rat T-cell lymphomas: activation by provirus insertion.
Leukemia
GW5074 and PP2 kinase inhibitors implicate nontraditional c-Raf and Lyn function as drivers of retinoic acid-induced maturation.
Leukemia
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Leukemia
Integration of transfected LTR sequences into the c-raf proto-oncogene: activation by promoter insertion.
Leukemia
LncRNA KCNQ1OT1 activated by c-Myc promotes cell proliferation via interacting with FUS to stabilize MAP3K1 in acute promyelocytic leukemia.
Leukemia
Localization of the human c-mos gene by in situ hybridization in two cases of acute nonlymphocytic leukemia type M2.
Leukemia
MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-?B.
Leukemia
Molecular cloning and characterization of a leukemia-inducing myeloproliferative sarcoma virus and two of its temperature-sensitive mutants.
Leukemia
Necroptosis Interfaces with MOMP and the MPTP in Mediating Cell Death.
Leukemia
Proto-oncogene expression in human normal bone marrow.
Leukemia
Raf-1 is a necessary component of the mitogenic response of the human megakaryoblastic leukemia cell line MO7 to human stem cell factor, granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 9.
Leukemia
Raf-1 protein is required for growth factor-induced proliferation of hematopoietic cells.
Leukemia
Rates of evolution of the retroviral oncogene of Moloney murine sarcoma virus and of its cellular homologues.
Leukemia
RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines.
Leukemia
Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells.
Leukemia
Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1).
Leukemia
The c-Raf modulator RRD-251 enhances nuclear c-Raf/GSK-3/VDR axis signaling and augments 1,25-dihydroxyvitamin D3-induced differentiation of HL-60 myeloblastic leukemia cells.
Leukemia
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.
Leukemia
The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells.
Leukemia
The role of the c-mos gene in the 8;21 translocation in human acute myeloblastic leukemia.
Leukemia
Trisomy 8 in human hematologic neoplasia and the c-myc and c-mos oncogenes.
Leukemia
Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation.
Leukemia
[Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
Leukemia
[Expression and kinase activity of B-Raf and Raf-1 in leukemia cell lines]
Leukemia, Erythroblastic, Acute
Protooncogene expression in normal, preleukemic, and leukemic murine erythroid cells and its relationship to differentiation and proliferation.
Leukemia, Hairy Cell
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.
Leukemia, Hairy Cell
[Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation.
Leukemia, Myeloid
Identification in several human myeloid leukemias or cell lines of a DNA rearrangement next to the c-mos 3'-end.
Leukemia, Myeloid
RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines.
Leukemia, Myeloid
Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
Leukemia, Myeloid
TPL-2 MEK kinase is not targeted by mutation in diffuse large B cell lymphoma and myeloid leukemia.
Leukemia, Myeloid, Acute
Hu-ets-2 is translocated to chromosome 8 in the t(8;21) in acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Isolation and analysis of the 21q+ chromosome in the acute myelogenous leukemia 8;21 translocation: evidence that c-mos is not translocated.
Leukemia, Myeloid, Acute
Localization of human c-mos to chromosome band 8q11 in leukemic cells with the t(8;21) (q22;q22).
Leukemia, Myeloid, Acute
Localization of the human c-mos gene by in situ hybridization in two cases of acute nonlymphocytic leukemia type M2.
Leukemia, Myeloid, Acute
Long non-coding RNA LRRC75A-AS1 facilitates triple negative breast cancer cell proliferation and invasion via functioning as a ceRNA to modulate BAALC.
Leukemia, Myeloid, Acute
Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.
Leukemia, Myeloid, Acute
Prognostic Value of mRNA Expression of MAP4K Family in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
The role of the c-mos gene in the 8;21 translocation in human acute myeloblastic leukemia.
Leukemia, Myeloid, Acute
Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
Leukemia, Promyelocytic, Acute
LncRNA KCNQ1OT1 activated by c-Myc promotes cell proliferation via interacting with FUS to stabilize MAP3K1 in acute promyelocytic leukemia.
Leukemia, T-Cell
Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions.
Leukoplakia, Oral
Peroxiredoxin 1 suppresses apoptosis via regulation of the apoptosis signal-regulating kinase 1 signaling pathway in human oral leukoplakia.
Liposarcoma
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Liver Diseases
Decrease in fat de novo synthesis and chemokine ligand expression in non-alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain-like pseudokinase.
Liver Diseases
Nodular Regenerative Hyperplasia Associated with Immune Checkpoint Blockade.
Liver Diseases
The ménage à trois of autophagy, lipid droplets and liver disease.
Liver Diseases
Tumor Necrosis Factor ?-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.
Liver Neoplasms
B-raf and Ha-ras mutations in chemically induced mouse liver tumors.
Liver Neoplasms
Cross-talk between aryl hydrocarbon receptor and mitogen-activated protein kinase signaling pathway in liver cancer through c-raf transcriptional regulation.
Liver Neoplasms
Expression of the c-raf protooncogene, gamma-glutamyltranspeptidase, and gap junction protein in rat liver neoplasms.
Liver Neoplasms
miR24-2 accelerates progression of liver cancer cells by activating Pim1 through tri-methylation of Histone H3 on the ninth lysine.
Liver Neoplasms
The MAP3K TAK1: a chock block to liver cancer formation.
Lung Injury
Deletion of Apoptosis Signal Regulating Kinase-1 Prevents Ventilator-induced Lung Injury In Mice.
Lung Neoplasms
A cross-platform comparison of affymetrix and Agilent microarrays reveals discordant miRNA expression in lung tumors of c-Raf transgenic mice.
Lung Neoplasms
Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.
Lung Neoplasms
Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation: A case report and literature review.
Lung Neoplasms
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Lung Neoplasms
Apoptosis Signal-Regulating Kinase 1 (ASK1) Activation is Involved in Silver Nanoparticles Induced Apoptosis of A549 Lung Cancer Cell Line.
Lung Neoplasms
B-RAF mutation in non-small cell lung cancer: the sleeping beauty is waking up.
Lung Neoplasms
Baicalein suppresses growth of non-small cell lung carcinoma by targeting MAP4K3.
Lung Neoplasms
Biomarkers in non-small cell lung cancer prevention.
Lung Neoplasms
Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide.
Lung Neoplasms
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Lung Neoplasms
c-mos immunoreactivity is an indicator of good prognosis in lung cancer.
Lung Neoplasms
C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A.
Lung Neoplasms
C-Raf is required for the initiation of lung cancer by K-Ras.
Lung Neoplasms
Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
Lung Neoplasms
Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology.
Lung Neoplasms
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Lung Neoplasms
Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF).
Lung Neoplasms
Data on tumor progression of c-mos deficiency in murine models of Kras
G12D
lung and Apc
Min
colorectal cancer.
Lung Neoplasms
Downregulation of PKC?/Pard3/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion.
Lung Neoplasms
Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors.
Lung Neoplasms
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2.
Lung Neoplasms
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Lung Neoplasms
Heat shock protein 90 inhibition in lung cancer.
Lung Neoplasms
Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation.
Lung Neoplasms
MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3.
Lung Neoplasms
MIG-7 and phosphorylated prohibitin coordinately regulate lung cancer invasion/metastasis.
Lung Neoplasms
miR-145-5p inhibits epithelial-mesenchymal transition via the JNK signaling pathway by targeting MAP3K1 in non-small cell lung cancer cells.
Lung Neoplasms
miRNAs deregulation in serum of mice is associated with lung cancer related pathway deregulation induced by PM2.5.
Lung Neoplasms
Mitogenic effect of orphan receptor TR3 and its regulation by MEKK1 in lung cancer cells.
Lung Neoplasms
Multiple primary malignant neoplasms: A case report and literature review.
Lung Neoplasms
Mutational activation of the MAP3K8 protooncogene in lung cancer.
Lung Neoplasms
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
Lung Neoplasms
Polyelectrolyte complex micelles composed of c-raf antisense oligodeoxynucleotide-poly(ethylene glycol) conjugate and poly(ethylenimine): effect of systemic administration on tumor growth.
Lung Neoplasms
Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
Lung Neoplasms
RAF expression in human astrocytic tumors.
Lung Neoplasms
Ras-mutant Cancer Cells Display B-Raf Binding to Ras That Activates Extracellular Signal-regulated Kinase and Is Inhibited by Protein Kinase A Phosphorylation.
Lung Neoplasms
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Lung Neoplasms
RUVBL1, a novel C-RAF-binding protein, activates the RAF/MEK/ERK pathway to promote lung cancer tumorigenesis.
Lung Neoplasms
Safety and proof-of-concept efficacy of inhaled drug loaded nano- and immunonanoparticles in a c-Raf transgenic lung cancer model.
Lung Neoplasms
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Lung Neoplasms
Targeted Lung Cancer Treatments and Eye Metastasis.
Lung Neoplasms
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Lung Neoplasms
The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy.
Lung Neoplasms
Tumor Cell-Derived Exosomal miR-770 Inhibits M2 Macrophage Polarization via Targeting MAP3K1 to Inhibit the Invasion of Non-small Cell Lung Cancer Cells.
Lung Neoplasms
Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
Lung Neoplasms
[Effect of celastrol in inhibiting metastasis of lung cancer cells by influencing Akt signaling pathway and expressing integrins].
Lupus Erythematosus, Systemic
AhR-ROR-?t complex is a therapeutic target for MAP4K3/GLKhighIL-17Ahigh subpopulation of systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Increased MLKL mRNA level in the PBMCs is correlated with autoantibody production, renal involvement, and SLE disease activity.
Lupus Nephritis
Proto-oncogene expression in human glomerular diseases.
Lymphatic Metastasis
Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.
Lymphatic Metastasis
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
Lymphatic Metastasis
Hematopoietic progenitor kinase 1, mitogen-activated protein/extracellular signal-related protein kinase kinase kinase 1, and phosphomitogen-activated protein kinase kinase 4 are overexpressed in extramammary Paget disease.
Lymphatic Metastasis
MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis.
Lymphatic Metastasis
Multifocal gastric gastrointestinal stromal tumors (GISTs) with lymph node metastases in children and young adults: a comparative clinical and histomorphological study of three cases including a new case of Carney triad.
Lymphatic Metastasis
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphatic Metastasis
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Lymphatic Metastasis
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
Lymphatic Metastasis
Squamous Cell Differentiation in Metastatic Papillary Thyroid Carcinoma: Metaplastic Reversion or Progression?
Lymphatic Metastasis
The MAPK Kinase Kinase 4 Deficiency in Intrahepatic Cholangiocarcinoma Leads to Invasive Growth and Epithelial-Mesenchymal Transition.
Lymphoma
Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.
Lymphoma
Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase.
Lymphoma
Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation: A case report and literature review.
Lymphoma
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Lymphoma
Altered regulation of cyclic AMP-dependent protein kinase in a mouse lymphoma cell line.
Lymphoma
Chromosomal locations of human tissue plasminogen activator and urokinase genes.
Lymphoma
Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis.
Lymphoma
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: A highly active combination against human mantle cell lymphoma (MCL) cells.
Lymphoma
Computational algorithms for in silico profiling of activating mutations in cancer.
Lymphoma
Continuous overexpression of thioredoxin 1 enhances cancer development and does not extend maximum lifespan in male C57BL/6 mice.
Lymphoma
Cot kinase regulation of IL-2 production in Jurkat T cells.
Lymphoma
Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Lymphoma
EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer.
Lymphoma
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.
Lymphoma
Histiocytic neoplasms in the era of personalized genomic medicine.
Lymphoma
Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G.
Lymphoma
Kinase group protooncogenes in non-hodgkins-lymphomas and nonmalignant lymphoid-tissues - analysis of their expression by insitu hybridization assays.
Lymphoma
Molecular alterations in non-small cell lung carcinomas of the young.
Lymphoma
Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
Lymphoma
Novel Therapeutic Targets in Non-small Cell Lung Cancer.
Lymphoma
Pancoast-Tobias Syndrome: A Unique Presentation of Lung Cancer.
Lymphoma
Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.
Lymphoma
Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
Lymphoma
Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration.
Lymphoma
Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.
Lymphoma
Signalling pathways identified in salivary glands from primary Sjögren's syndrome patients reveal enhanced adipose tissue development.
Lymphoma
Subunit interaction in cyclic AMP-dependent protein kinase of mutant lymphoma cells.
Lymphoma
Targeted Lung Cancer Treatments and Eye Metastasis.
Lymphoma
The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.
Lymphoma
Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation.
Lymphoma
TPL-2 MEK kinase is not targeted by mutation in diffuse large B cell lymphoma and myeloid leukemia.
Lymphoma
TRAIL activates JNK and NF-?B through RIP1-dependent and -independent pathways.
Lymphoma
Understanding and targeting resistance mechanisms in NSCLC.
Lymphoma
[Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
Lymphoma, B-Cell
Activation of the apoptosis signal-regulating kinase 1/c-Jun N-terminal kinase pathway is involved in the casticin-induced apoptosis of colon cancer cells.
Lymphoma, B-Cell
Docking-based inverse virtual screening strategy for identification of novel protein targets for triclosan.
Lymphoma, B-Cell
Effects of prostaglandin F2? (PGF2?) on cell-death pathways in the bovine corpus luteum (CL).
Lymphoma, B-Cell
Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.
Lymphoma, B-Cell
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Lymphoma, B-Cell
The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.
Lymphoma, B-Cell
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.
Lymphoma, B-Cell
TPL-2 MEK kinase is not targeted by mutation in diffuse large B cell lymphoma and myeloid leukemia.
Lymphoma, Large B-Cell, Diffuse
The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.
Lymphoma, Large B-Cell, Diffuse
TPL-2 MEK kinase is not targeted by mutation in diffuse large B cell lymphoma and myeloid leukemia.
Lymphoma, Non-Hodgkin
The EcoRI RFLP of c-mos in patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia, compared to geriatric and non-geriatric controls.
Lymphoma, Non-Hodgkin
Trisomy 8 in human hematologic neoplasia and the c-myc and c-mos oncogenes.
Lymphoma, T-Cell
Genomic organization and expression of Tpl-2 in normal cells and Moloney murine leukemia virus-induced rat T-cell lymphomas: activation by provirus insertion.
Lymphoma, T-Cell
Structure of a Moloney murine leukemia virus-virus-like 30 recombinant: implications for transduction of the c-Ha-ras proto-oncogene.
Lymphoma, T-Cell
Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation.
Lymphoma, T-Cell
[Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
Lymphoma, T-Cell, Cutaneous
The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma.
Lymphoproliferative Disorders
Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx.
Malaria
Analysis of erythrocyte signalling pathways during Plasmodium falciparum infection identifies targets for host-directed antimalarial intervention.
Measles
The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity.
Medulloblastoma
MEKK2 and MEKK3 suppress Hedgehog pathway-dependent medulloblastoma by inhibiting GLI1 function.
Medulloblastoma
Mitogen-activated kinase kinase kinase 1 inhibits hedgehog signaling and medulloblastoma growth through GLI1 phosphorylation.
Megalencephaly
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Melanoma
1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.
Melanoma
17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Melanoma
5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma.
Melanoma
7-dehydrocholesterol suppresses melanoma cell proliferation and invasion via Akt1/NF-?B signaling.
Melanoma
A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations.
Melanoma
A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity in Melanoma.
Melanoma
A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma.
Melanoma
A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells.
Melanoma
A new B-Raf inhibitor combo for advanced melanoma.
Melanoma
A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker.
Melanoma
A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.
Melanoma
A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth.
Melanoma
A Novel Polyamine-Targeted Therapy for BRAF Mutant Melanoma Tumors.
Melanoma
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Melanoma
A prognostic signature of G 2 checkpoint function in melanoma cell lines.
Melanoma
A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
Melanoma
A(nother) RAF mutation in LCH.
Melanoma
Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.
Melanoma
Acquisition of resistance to vemurafenib leads to interleukin-10 production through an aberrant activation of Akt in a melanoma cell line.
Melanoma
Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System.
Melanoma
Activating the Wnt/?-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
Melanoma
Activation of B-raf in non-malignant nevi predicts a novel tumor suppressor gene in melanoma (MAP kinase phosphatase).
Melanoma
Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells.
Melanoma
Active Notch1 confers a transformed phenotype to primary human melanocytes.
Melanoma
Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.
Melanoma
Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.
Melanoma
Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction.
Melanoma
Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells.
Melanoma
Advanced Melanoma: A Progressive Review of V600E-B-RAF Kinase And Drugs Inhibiting It.
Melanoma
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.
Melanoma
Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.
Melanoma
alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells.
Melanoma
An Integrative Analysis of The Micro-RNAs Contributing in Stemness, Metastasis and B-Raf Pathways in Malignant Melanoma and Melanoma Stem Cell.
Melanoma
Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
Melanoma
Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure.
Melanoma
Anti-inflammatory effects of dabrafenib in vitro and in vivo.
Melanoma
Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption.
Melanoma
Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses.
Melanoma
Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E.
Melanoma
Anticancer potential of benzothiazolic derivative (E)-2-((2-(benzo[d]thiazol-2-yl)hydrazono)methyl)-4-nitrophenol against melanoma cells.
Melanoma
Antiseptic effects of dabrafenib on TGFBIp-induced septic responses.
Melanoma
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS.
Melanoma
Are all melanomas the same?: spitzoid melanoma is a distinct subtype of melanoma.
Melanoma
Aryl Hydrocarbon Receptor Modulates Carcinogenesis and Maintenance of Skin Cancers.
Melanoma
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.
Melanoma
Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib.
Melanoma
Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf.
Melanoma
B-Raf and C-Raf are required for melanocyte stem cell self-maintenance.
Melanoma
B-raf and Ha-ras mutations in chemically induced mouse liver tumors.
Melanoma
B-RAF and melanocytic neoplasia.
Melanoma
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
Melanoma
B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis.
Melanoma
B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms.
Melanoma
B-Raf Associates with and Activates the NHE1 Isoform of the Na+/H+ Exchanger.
Melanoma
B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
Melanoma
B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720.
Melanoma
B-Raf Inhibition in the Clinic: Present and Future.
Melanoma
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Melanoma
B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.
Melanoma
B-RAF is a therapeutic target in melanoma.
Melanoma
B-Raf kinase inhibitors for cancer treatment.
Melanoma
B-Raf mutation: a key player in molecular biology of cancer.
Melanoma
B-RAF mutations are a rare event in pituitary adenomas.
Melanoma
B-Raf Mutations, Microsatellite Instability and p53 Protein Expression in Sporadic Basal Cell Carcinomas.
Melanoma
B-RAF Regulation of Rnd3 Participates in Actin Cytoskeletal and Focal Adhesion Organization.
Melanoma
B-Raf specific antibody responses in melanoma patients.
Melanoma
B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
Melanoma
B-RAF, naevi and melanoma: a complex relationship.
Melanoma
B-RAF: A contributor to the melanoma phenotype.
Melanoma
Baicalein and Baicalin Promote Melanoma Apoptosis and Senescence via Metabolic Inhibition.
Melanoma
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.
Melanoma
Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf.
Melanoma
BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
Melanoma
BRAF mutational epidemiology in dysplastic nevi: Does different solar UV radiation exposure matter?
Melanoma
BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
Melanoma
c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C activities and melanoma tumorigenesis.
Melanoma
c-Myc modulation: a key role in melanoma drug response.
Melanoma
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Melanoma
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Melanoma
CD133? melanoma subpopulation acquired resistance to caffeic acid phenethyl ester-induced apoptosis is attributed to the elevated expression of ABCB5: significance for melanoma treatment.
Melanoma
CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation.
Melanoma
Characterization of vemurafenib phototoxicity in a mouse model.
Melanoma
Chemoprevention of melanoma.
Melanoma
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Melanoma
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
Melanoma
Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas.
Melanoma
Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.
Melanoma
Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.
Melanoma
Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas.
Melanoma
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Melanoma
Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts.
Melanoma
Combined Toxicity of Gas Plasma Treatment and Nanoparticles Exposure in Melanoma Cells In Vitro.
Melanoma
Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma.
Melanoma
Computational algorithms for in silico profiling of activating mutations in cancer.
Melanoma
Computational study on the unbinding pathways of B-RAF inhibitors and its implication for the difference of residence time: insight from random acceleration and steered molecular dynamics simulations.
Melanoma
Concomitant Inhibition of PI3K? and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K?-Selective Inhibitor.
Melanoma
Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome.
Melanoma
Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.
Melanoma
Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
Melanoma
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Melanoma
Critical role of miR-10b in B-RafV600E dependent anchorage independent growth and invasion of melanoma cells.
Melanoma
Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma.
Melanoma
Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Melanoma
Cures with B-Raf inhibitors as single agents in metastatic B-Raf mutated melanoma: Curb your enthusiasm?
Melanoma
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Melanoma
Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression.
Melanoma
Cytotoxicity of amide-linked local anesthetics on melanoma cells via inhibition of Ras and RhoA signaling independent of sodium channel blockade.
Melanoma
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Melanoma
Dabrafenib in the treatment of advanced melanoma.
Melanoma
Dabrafenib, an inhibitor of RIP3 kinase-dependent necroptosis, reduces ischemic brain injury.
Melanoma
Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression.
Melanoma
Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors.
Melanoma
Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines.
Melanoma
Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells.
Melanoma
Detection of B-RAF and N-RAS mutations in human melanoma.
Melanoma
Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.
Melanoma
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma.
Melanoma
Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization.
Melanoma
Development of novel 3D-QSAR combination approach for screening and optimizing B-Raf inhibitors in silico.
Melanoma
Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
Melanoma
Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Melanoma
Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
Melanoma
Discovery and Optimization of a Novel Series of Potent Mutant B-Raf(V600E) Selective Kinase Inhibitors.
Melanoma
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors.
Melanoma
Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells.
Melanoma
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Melanoma
Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Melanoma
Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment.
Melanoma
Energetics and structural characterization of the "DFG-flip" conformational transition of B-RAF kinase: a SITS molecular dynamics study.
Melanoma
ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis.
Melanoma
Evaluation of (fli:GFP) Casper Zebrafish Embryos as a Model for Human Conjunctival Melanoma.
Melanoma
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Melanoma
Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts.
Melanoma
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Melanoma
Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells.
Melanoma
Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy.
Melanoma
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.
Melanoma
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
Melanoma
Fisetin: a natural fist against melanoma?
Melanoma
FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.
Melanoma
FOXD3 regulates migratory properties and Rnd3 expression in melanoma cells.
Melanoma
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Melanoma
Function and evolution of B-Raf loop dynamics relevant to cancer recurrence under drug inhibition.
Melanoma
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Melanoma
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma.
Melanoma
Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.
Melanoma
Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
Melanoma
Genotype-Dependent Sensitivity Of Uveal Melanoma Cell Lines To Inhibition of B-Raf, MEK And Akt Kinases: Rationale For Personalized Therapy.
Melanoma
GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax.
Melanoma
Glutamatergic Pathway Targeting in Melanoma; Single Agent and Combinatorial Therapies.
Melanoma
Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
Melanoma
GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells.
Melanoma
Heme oxygenase 1 facilitates cell proliferation via the B-Raf-ERK signaling pathway in melanoma.
Melanoma
HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma.
Melanoma
Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma.
Melanoma
Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
Melanoma
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.
Melanoma
Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Melanoma
Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.
Melanoma
Identification and Characterization of a B-Raf Kinase ?-Helix Critical for the Activity of MEK Kinase in MAPK Signaling.
Melanoma
Identification of novel B-Raf(V600E) inhibitors employing FBDD strategy.
Melanoma
Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
Melanoma
Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations.
Melanoma
Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
Melanoma
IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin.
Melanoma
IGFBP7 is not required for B-RAF-induced melanocyte senescence.
Melanoma
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Melanoma
Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
Melanoma
In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease.
Melanoma
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas.
Melanoma
Induction of apoptosis signal-regulating Kinase 1 by E2F-1 may not be essential for E2F-1-mediated apoptosis in melanoma cells.
Melanoma
Induction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulation.
Melanoma
Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
Melanoma
Inhibition of mutated, activated BRAF in metastatic melanoma.
Melanoma
Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation.
Melanoma
Insight into the Binding of DFG-out Allosteric Inhibitors to B-Raf Kinase Using Molecular Dynamics and Free Energy Calculations.
Melanoma
Intermittent B-Raf inhibitor therapy is a feasible option -report of a patient with metastatic melanoma.
Melanoma
Involvement of human beta-defensin-2 in regulation of malignant potential of cultured human melanoma cells.
Melanoma
Is B-Raf a good therapeutic target for melanoma and other malignancies?
Melanoma
Is Mcl-1L the new anti-apoptotic effector of B-RAFV(600E) in melanoma?
Melanoma
Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review.
Melanoma
Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.
Melanoma
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
Melanoma
Latest approved therapies for metastatic melanoma: what comes next?
Melanoma
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.
Melanoma
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
Melanoma
Low Incidence of Minor BRAF V600 Mutation-Positive Subclones in Primary and Metastatic Melanoma Determined by Sensitive and Quantitative Real-Time qPCR.
Melanoma
Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma.
Melanoma
Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Melanoma
MageC2 protein is upregulated by oncogenic activation of MAPK pathway and causes impairment of the p53 transactivation function.
Melanoma
Malignant melanoma--a genetic overview.
Melanoma
Mcl-1 is required for melanoma cell resistance to anoikis.
Melanoma
Mechanisms of apoptosis induced by anticancer compounds in melanoma cells.
Melanoma
Mechanisms of regulating the Raf kinase family.
Melanoma
Mechanisms of Resistance to RAF Inhibitors in Melanoma.
Melanoma
MEK and PI3K inhibition in solid tumors: rationale and evidence to date.
Melanoma
MEK targeting in N-RAS mutated metastatic melanoma.
Melanoma
MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Melanoma
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
Melanoma
MELANOMA ADJUVANT TREATMENT: current insight and clinical features.
Melanoma
Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.
Melanoma
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.
Melanoma
Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy.
Melanoma
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
Melanoma
Metabolic imaging using hyperpolarized 13 C-pyruvate to assess sensitivity to the B-Raf inhibitor vemurafenib in melanoma cells and xenografts.
Melanoma
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges.
Melanoma
Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Melanoma
MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies.
Melanoma
MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma.
Melanoma
MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma.
Melanoma
Missense mutations of the BRAF gene in human lung adenocarcinoma.
Melanoma
Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma.
Melanoma
Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Melanoma
MLK3 Is Associated With Poor Prognosis in Patients With Glioblastomas and Actin Cytoskeleton Remodeling in Glioblastoma Cells.
Melanoma
Modulation of plasma metabolite biomarkers of MAPK pathway with the MEK inhibitor RO4987655: pharmacodynamic and predictive potential in metastatic melanoma.
Melanoma
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Melanoma
Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells.
Melanoma
Monitoring oncogenic B-RAF-induced senescence in melanocytes.
Melanoma
Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-RafV600E melanoma cells.
Melanoma
Mouse model for pre-clinical study of human cancer immunotherapy.
Melanoma
Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases.
Melanoma
Mutant B-RAF mediates resistance to anoikis via Bad and Bim.
Melanoma
Mutant B-RAF regulates a Rac-dependent cadherin switch in melanoma.
Melanoma
Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.
Melanoma
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.
Melanoma
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Melanoma
Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.
Melanoma
Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients.
Melanoma
Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
Melanoma
Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma.
Melanoma
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma.
Melanoma
Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.
Melanoma
Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
Melanoma
New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.
Melanoma
NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.
Melanoma
No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Melanoma
Nodular Regenerative Hyperplasia Associated with Immune Checkpoint Blockade.
Melanoma
Non-melanoma skin cancer in mouse and man.
Melanoma
Novel biomarkers in malignant melanoma.
Melanoma
Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.
Melanoma
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.
Melanoma
Novel mechanisms of resistance to vemurafenib in melanoma - V600E B-Raf reversion and switching VEGF-A splice isoform expression.
Melanoma
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.
Melanoma
Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions.
Melanoma
Oncogenic B-RAF signalling in melanoma impairs the therapeutic advantage of autophagy inhibition.
Melanoma
Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
Melanoma
Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion.
Melanoma
Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim.
Melanoma
Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability.
Melanoma
Optical control of MAP kinase kinase 6 (MKK6) reveals that it has divergent roles in pro-apoptotic and anti-proliferative signaling.
Melanoma
Overcoming Drug Resistance to BRAF Inhibitor.
Melanoma
p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.
Melanoma
Pathologic Characteristics of Spitz Melanoma With MAP3K8 Fusion or Truncation in a Pediatric Cohort.
Melanoma
Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Melanoma
Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors.
Melanoma
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Melanoma
Phenotype characterization of human melanoma cells resistant to dabrafenib.
Melanoma
Phosphoethanolamine induces caspase-independent cell death by reducing the expression of C-RAF and inhibits tumor growth in human melanoma model.
Melanoma
Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
Melanoma
Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells.
Melanoma
PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
Melanoma
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.
Melanoma
Polymorphisms at site 469 of B-RAF protein associated with skin melanoma may be correlated with dabrafenib resistance: An in silico study.
Melanoma
Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties.
Melanoma
Potentially Actionable MAP3K8 Alterations Are Common in Spitzoid Melanoma.
Melanoma
Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Melanoma
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
Melanoma
Primary pineal malignant melanoma with B-Raf V600E mutation: a case report and brief review of the literature.
Melanoma
Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study.
Melanoma
Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy.
Melanoma
Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
Melanoma
Protein expression of KIT, BRAF, GNA11, GNAQ and RASSF1 in feline diffuse iris melanomas.
Melanoma
Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
Melanoma
Quaternized chitosan promotes the antiproliferative effect of vemurafenib in melanoma cells by increasing cell permeability.
Melanoma
Raf kinases: Oncogenesis and drug discovery.
Melanoma
RAF protein-serine/threonine kinases: structure and regulation.
Melanoma
Raf proteins and cancer: B-Raf is identified as a mutational target.
Melanoma
Ras-mutant Cancer Cells Display B-Raf Binding to Ras That Activates Extracellular Signal-regulated Kinase and Is Inhibited by Protein Kinase A Phosphorylation.
Melanoma
RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.
Melanoma
Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine.
Melanoma
Rb/E2F: a two-edged sword in the melanocytic system.
Melanoma
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma.
Melanoma
Recent Advances in the Research and Development of B-Raf Inhibitors.
Melanoma
Recent advances of MEK inhibitors and their clinical progress.
Melanoma
Regulation of Raf through phosphorylation and N terminus-C terminus interaction.
Melanoma
Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review.
Melanoma
Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Melanoma
RKIP downregulates B-Raf kinase activity in melanoma cancer cells.
Melanoma
RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
Melanoma
Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions.
Melanoma
Role of Melanoma Inhibitor of Apoptosis (ML-IAP) Protein, a Member of the Baculoviral IAP Repeat (BIR) Domain Family, in the Regulation of C-RAF Kinase and Cell Migration.
Melanoma
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Melanoma
Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma.
Melanoma
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.
Melanoma
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib.
Melanoma
Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.
Melanoma
Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside.
Melanoma
Similar nucleotide excision repair capacity in melanocytes and melanoma cells.
Melanoma
Skp2 regulates G2/M progression in a p53-dependent manner.
Melanoma
So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020.
Melanoma
Somatic p16(INK4a) loss accelerates melanomagenesis.
Melanoma
Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth.
Melanoma
Specialty pharmacy services for patients receiving oral medications for solid tumors.
Melanoma
Spitz melanoma is a distinct subset of spitzoid melanoma.
Melanoma
Structural Optimization and Biological Screening of a Steroidal Scaffold Possessing Cucurbitacin-Like Functionalities as B-Raf Inhibitors.
Melanoma
Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
Melanoma
Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision.
Melanoma
Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy.
Melanoma
Suppression of B-Raf(V600E) melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone.
Melanoma
Suppression of microphthalmia-associated transcription factor, but not NF-kappa B sensitizes melanoma specific cell death.
Melanoma
Suppressive effects of dabrafenib on endothelial protein C receptor shedding.
Melanoma
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Melanoma
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin.
Melanoma
Synthesis of a 11C-Isotopologue of the B-Raf-Selective Inhibitor Encorafenib Using In-Loop [11C]CO2 Fixation.
Melanoma
Synthesis, antitumor activity and molecular docking study of some novel 3-benzyl-4(3H)quinazolinone analogues.
Melanoma
Synthesis, characterization, molecular docking and anticancer studies of fluoroaniline derivatives of hydroxybenzoquinone and hydroxynaphthoquinone.
Melanoma
Systemic Therapy of Metastatic Melanoma: On the Road to Cure.
Melanoma
TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma.
Melanoma
Targeted therapies in brain metastases.
Melanoma
Targeted Therapy in Melanoma and Mechanisms of Resistance.
Melanoma
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
Melanoma
Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
Melanoma
Targeting growth factors and angiogenesis; using small molecules in malignancy.
Melanoma
Targeting mitochondria in melanoma: Interplay between MAPK signaling pathway and mitochondrial dynamics.
Melanoma
Targeting Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases.
Melanoma
Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation.
Melanoma
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Melanoma
Targeting oxidative phosphorylation: why, when, and how.
Melanoma
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.
Melanoma
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
Melanoma
Targeting the Raf kinases in human cancer: the Raf dimer dilemma.
Melanoma
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
Melanoma
Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.
Melanoma
Targets of Raf in tumorigenesis.
Melanoma
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Melanoma
The diagnostic pathology of the nuclear envelope in human cancers.
Melanoma
The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death.
Melanoma
The effect of a widespread cancer-causing mutation on the inactive to active dynamics of the B-Raf kinase.
Melanoma
The genesis of Zelboraf: targeting mutant B-Raf in melanoma.
Melanoma
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Melanoma
The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma-Association with Clinical Outcome and Tumor Phenotypes.
Melanoma
The In Vitro and In Vivo Anticancer Properties of Chalcone Flavokawain B through Induction of ROS-Mediated Apoptotic and Autophagic Cell Death in Human Melanoma Cells.
Melanoma
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Melanoma
The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Melanoma
The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Melanoma
The role of B-RAF in melanoma.
Melanoma
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-?B/Snail/RKIP/PTEN Circuit.
Melanoma
The role of gene fusions in melanocytic neoplasms.
Melanoma
The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment.
Melanoma
The use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.
Melanoma
The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice.
Melanoma
Towards new therapeutic approaches for malignant melanoma.
Melanoma
Tracking of Glycans Structure and Metallomics Profiles in BRAF Mutated Melanoma Cells Treated with Vemurafenib.
Melanoma
Trametinib for the treatment of melanoma.
Melanoma
Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe.
Melanoma
Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model.
Melanoma
Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
Melanoma
Two distinct steps of Bak regulation during apoptotic stress signaling: different roles of MEKK1 and JNK1.
Melanoma
U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo.
Melanoma
Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.
Melanoma
Understanding signaling cascades in melanoma.
Melanoma
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Melanoma
Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.
Melanoma
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
Melanoma
UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma.
Melanoma
V599EB-RAF is an oncogene in melanocytes.
Melanoma
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.
Melanoma
Vemurafenib-Associated Keratoses With Genetic Heterogeneity of RAS.
Melanoma
Vemurafenib: the road to personalized medicine in melanoma.
Melanoma
Violacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process.
Melanoma
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment.
Melanoma
Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Melanoma
Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
Melanoma
[Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition].
Melanoma
[Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
Melanoma
[Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Melanoma
[Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
Melanoma
[MAP-Kinase pathway abnormalities in melanoma: B-RAF is not the sole cause].
Melanoma
[MEK inhibitor-associated retinopathy under binimetinib treatment for cutaneous malignant melanoma].
Melanoma
[Treatment of patients with brain metastases from a melanoma].
Melanoma
[Whats new in dermato-oncology?].
Melanoma, Experimental
Mouse model for pre-clinical study of human cancer immunotherapy.
Menkes Kinky Hair Syndrome
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Metabolic Syndrome
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth.
mitogen-activated protein kinase kinase kinase deficiency
Apoptosis signal-regulating kinase 1 deficiency accelerates hyperlipidemia-induced atheromatous plaques via suppression of macrophage apoptosis.
mitogen-activated protein kinase kinase kinase deficiency
Apoptosis signal-regulating kinase 1 deficiency attenuates vascular injury-induced neointimal hyperplasia by suppressing apoptosis in smooth muscle cells.
mitogen-activated protein kinase kinase kinase deficiency
Apoptosis signal-regulating kinase 1 deficiency eliminates cardiovascular injuries induced by high-salt diet.
mitogen-activated protein kinase kinase kinase deficiency
B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.
mitogen-activated protein kinase kinase kinase deficiency
B-Raf is required for positive selection and survival of DP cells, but not for negative selection of SP cells.
mitogen-activated protein kinase kinase kinase deficiency
C-Raf deficiency leads to hearing loss and increased noise susceptibility.
mitogen-activated protein kinase kinase kinase deficiency
Data on tumor progression of c-mos deficiency in murine models of Kras
G12D
lung and Apc
Min
colorectal cancer.
mitogen-activated protein kinase kinase kinase deficiency
Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?
mitogen-activated protein kinase kinase kinase deficiency
Impairment of cardiomyogenesis in embryonic stem cells lacking scaffold protein JSAP1.
mitogen-activated protein kinase kinase kinase deficiency
Map3k8 controls granulocyte colony-stimulating factor production and neutrophil precursor proliferation in lipopolysaccharide-induced emergency granulopoiesis.
mitogen-activated protein kinase kinase kinase deficiency
Map3k8 Modulates Monocyte State and Atherogenesis in ApoE-/- Mice.
mitogen-activated protein kinase kinase kinase deficiency
MAP3K8 Regulates Cox-2-Mediated Prostaglandin E2 Production in the Lung and Suppresses Pulmonary Inflammation and Fibrosis.
mitogen-activated protein kinase kinase kinase deficiency
MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer.
mitogen-activated protein kinase kinase kinase deficiency
MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts.
mitogen-activated protein kinase kinase kinase deficiency
MEKK3 Regulates IFN-{gamma} Production in T Cells through the Rac1/2-Dependent MAPK Cascades.
mitogen-activated protein kinase kinase kinase deficiency
Platelet MEKK3 regulates arterial thrombosis and myocardial infarct expansion in mice.
mitogen-activated protein kinase kinase kinase deficiency
Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes.
mitogen-activated protein kinase kinase kinase deficiency
Silencing MEKK3 attenuates cardiomyocyte injury caused by hypoxia/reoxygenation via the sonic hedgehog pathway.
mitogen-activated protein kinase kinase kinase deficiency
Structure and vascular function of MEKK3-cerebral cavernous malformations 2 complex.
mitogen-activated protein kinase kinase kinase deficiency
The role of MAP4K3 in lifespan regulation of Caenorhabditiselegans.
mitogen-activated protein kinase kinase kinase deficiency
TPL-2 restricts Ccl24-dependent immunity to Heligmosomoides polygyrus.
mitogen-activated protein kinase kinase kinase deficiency
Tumor progression locus 2 reduces severe allergic airway inflammation by inhibiting Ccl24 production in dendritic cells.
Motor Neuron Disease
ZPK/DLK, a mitogen-activated protein kinase kinase kinase, is a critical mediator of programmed cell death of motoneurons.
Mouth Neoplasms
Aliphatic acetogenin constituents of avocado fruits inhibit human oral cancer cell proliferation by targeting the EGFR/RAS/RAF/MEK/ERK1/2 pathway.
Multiple Endocrine Neoplasia
Patterns of neoplasia in c-mos transgenic mice and their relevance to multiple endocrine neoplasia.
Multiple Endocrine Neoplasia
Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 syndrome.
Multiple Endocrine Neoplasia Type 2a
Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 syndrome.
Multiple Myeloma
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Multiple Myeloma
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Multiple Sclerosis
Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1).
Multiple Sclerosis
Regulation of Experimental Autoimmune Encephalomyelitis by TPL-2 Kinase.
Multiple Sclerosis
Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy.
Muscular Atrophy
Gadd45a Protein Promotes Skeletal Muscle Atrophy by Forming a Complex with the Protein Kinase MEKK4.
Muscular Atrophy, Spinal
Impairment of the neurotrophic signaling hub B-Raf contributes to motoneuron degeneration in spinal muscular atrophy.
Mycoses
The Arabidopsis MAPKKK ?-1 is required for full immunity against bacterial and fungal infection.
Myocardial Infarction
An Apoptosis Signal-regulating Kinase 1 Inhibitor Reduces Cardiomyocyte Apoptosis and Infarct Size in a Rat Ischemia-reperfusion Model.
Myocardial Infarction
Exploration of the effect of salvianolate on myocardial infarction in rats based on tandem mass tags.
Myocardial Infarction
Heat-shock protein 90 modulates cardiac ventricular hypertrophy via activation of MAPK pathway.
Myocardial Infarction
Platelet MEKK3 regulates arterial thrombosis and myocardial infarct expansion in mice.
Myocardial Infarction
Possible mechanisms behind cardiac troponin elevations.
Narcolepsy
Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy.
Nasopharyngeal Carcinoma
The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2.
Neoplasm Metastasis
An Integrative Analysis of The Micro-RNAs Contributing in Stemness, Metastasis and B-Raf Pathways in Malignant Melanoma and Melanoma Stem Cell.
Neoplasm Metastasis
Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
Neoplasm Metastasis
ASK1 facilitates tumor metastasis through phosphorylation of an ADP receptor P2Y12 in platelets.
Neoplasm Metastasis
ASK1 suppresses NK cell-mediated intravascular tumor cell clearance in lung metastasis.
Neoplasm Metastasis
Association of Mixed Lineage Kinase Domain-Like Protein Expression With Prognosis in Patients With Colon Cancer.
Neoplasm Metastasis
B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.
Neoplasm Metastasis
B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
Neoplasm Metastasis
Chemotherapy-induced miR-141/MAP4K4 signaling suppresses progression of colorectal cancer.
Neoplasm Metastasis
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Neoplasm Metastasis
Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis.
Neoplasm Metastasis
Demethylation-induced overexpression of Shc3 drives c-Raf-independent activation of MEK/ERK in HCC.
Neoplasm Metastasis
Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.
Neoplasm Metastasis
Detection of B-RAF and N-RAS mutations in human melanoma.
Neoplasm Metastasis
Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.
Neoplasm Metastasis
Development and Validation of a High-Throughput Intrinsic ATPase Activity Assay for the Discovery of MEKK2 Inhibitors.
Neoplasm Metastasis
Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2).
Neoplasm Metastasis
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Neoplasm Metastasis
Expression of Raf kinase inhibitor protein is downregulated in response to Newcastle disease virus infection to promote viral replication.
Neoplasm Metastasis
Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells.
Neoplasm Metastasis
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Neoplasm Metastasis
Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer.
Neoplasm Metastasis
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
Neoplasm Metastasis
Hematopoietic progenitor kinase 1, mitogen-activated protein/extracellular signal-related protein kinase kinase kinase 1, and phosphomitogen-activated protein kinase kinase 4 are overexpressed in extramammary Paget disease.
Neoplasm Metastasis
Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.
Neoplasm Metastasis
Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis.
Neoplasm Metastasis
Isolation and molecular characterization of circulating melanoma cells.
Neoplasm Metastasis
Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets.
Neoplasm Metastasis
Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.
Neoplasm Metastasis
MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitro.
Neoplasm Metastasis
MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer.
Neoplasm Metastasis
MEKK1 Regulates Chemokine Expression in Mammary Fibroblasts: Implications for the Breast Tumor Microenvironment.
Neoplasm Metastasis
MEKK2 regulates focal adhesion stability and motility in invasive breast cancer cells.
Neoplasm Metastasis
MEKK2 regulates paxillin ubiquitylation and localization in MDA-MB 231 breast cancer cells.
Neoplasm Metastasis
MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis.
Neoplasm Metastasis
Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.
Neoplasm Metastasis
MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3.
Neoplasm Metastasis
miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8.
Neoplasm Metastasis
MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma.
Neoplasm Metastasis
MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells.
Neoplasm Metastasis
Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer.
Neoplasm Metastasis
Mouse model for pre-clinical study of human cancer immunotherapy.
Neoplasm Metastasis
Multifocal gastric gastrointestinal stromal tumors (GISTs) with lymph node metastases in children and young adults: a comparative clinical and histomorphological study of three cases including a new case of Carney triad.
Neoplasm Metastasis
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.
Neoplasm Metastasis
New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer.
Neoplasm Metastasis
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Neoplasm Metastasis
Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion.
Neoplasm Metastasis
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Neoplasm Metastasis
Overview of MDM2 and B-RAF Expression in Gastric Lesions.
Neoplasm Metastasis
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Neoplasm Metastasis
Pharmacologic inhibition of MLK3 kinase activity blocks the in vitro migratory capacity of breast cancer cells but has no effect on breast cancer brain metastasis in a mouse xenograft model.
Neoplasm Metastasis
Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Neoplasm Metastasis
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
Neoplasm Metastasis
Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.
Neoplasm Metastasis
Radiomics in Differentiated Thyroid Cancer and Nodules: Explorations, Application, and Limitations.
Neoplasm Metastasis
Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3?.
Neoplasm Metastasis
Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review.
Neoplasm Metastasis
RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA.
Neoplasm Metastasis
Role of miR-148a in cutaneous squamous cell carcinoma by repression of MAPK pathway.
Neoplasm Metastasis
Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.
Neoplasm Metastasis
Silencing TAK1 alters gene expression signatures in bladder cancer cells.
Neoplasm Metastasis
Squamous Cell Differentiation in Metastatic Papillary Thyroid Carcinoma: Metaplastic Reversion or Progression?
Neoplasm Metastasis
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
Neoplasm Metastasis
Targeting Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases.
Neoplasm Metastasis
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.
Neoplasm Metastasis
The MAPK Kinase Kinase 4 Deficiency in Intrahepatic Cholangiocarcinoma Leads to Invasive Growth and Epithelial-Mesenchymal Transition.
Neoplasm Metastasis
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-?B/Snail/RKIP/PTEN Circuit.
Neoplasm Metastasis
Therapeutic implications of B-RAF mutations in colorectal cancer.
Neoplasm Metastasis
[Metastatic ability and type IV collagenase expression of oncogene-transformed human bronchial epithelial cells]
Neoplasm, Residual
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.
Neoplasms
17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Neoplasms
2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes.
Neoplasms
A 2-DE MALDI-TOF study to identify disease regulated serum proteins in lung cancer of c-myc transgenic mice.
Neoplasms
A Case of Paratubal Serous Borderline Tumor Driven by a Somatic BRAF Mutation in an Adolescent Patient.
Neoplasms
A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway.
Neoplasms
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
Neoplasms
A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors.
Neoplasms
A cross-platform comparison of affymetrix and Agilent microarrays reveals discordant miRNA expression in lung tumors of c-Raf transgenic mice.
Neoplasms
A cryptic tubulin-binding domain links MEKK1 to curved tubulin protomers.
Neoplasms
A MAP3k1 SNP predicts survival of gastric cancer in a Chinese population.
Neoplasms
A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers.
Neoplasms
A method for screening and validation of resistant mutations against kinase inhibitors.
Neoplasms
A Multivariate Computational Method to Analyze High-Content RNAi Screening Data.
Neoplasms
A mutation and expression analysis of the oncogene BRAF in pituitary adenomas.
Neoplasms
A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation.
Neoplasms
A new function for MAP4K4 inhibitors during platelet aggregation and platelet-mediated clot retraction.
Neoplasms
A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.
Neoplasms
A new model to evaluate Raf signaling in hematopoietic cells.
Neoplasms
A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker.
Neoplasms
A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.
Neoplasms
A Novel Polyamine-Targeted Therapy for BRAF Mutant Melanoma Tumors.
Neoplasms
A novel role for mixed lineage kinase 3 (MLK3) in B-Raf activation and cell proliferation.
Neoplasms
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Neoplasms
A rare c-mos RFLP in normal (noncancerous) fibroblasts from two related cancer patients.
Neoplasms
A RING to rule them all? Insights into the Map3k1 PHD motif provide a new mechanistic understanding into the diverse roles of Map3k1.
Neoplasms
A single point mutation responsible for c-mos polymorphism in cancer patients.
Neoplasms
A-Raf: A new star of the family of raf kinases.
Neoplasms
Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.
Neoplasms
Aberrant Expression of COT Is Related to Recurrence of Papillary Thyroid Cancer.
Neoplasms
ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses.
Neoplasms
Abrogation of c-Raf expression induces apoptosis in tumor cells.
Neoplasms
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
Neoplasms
Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants.
Neoplasms
Activation of a cellular oncogene by DNA rearrangement: possible involvement of an IS-like element.
Neoplasms
Activation of AKT of signaling pathway and the level of mTOR substrates in tumor of patients with kidney cancer, connection with prevalence of malignancy.
Neoplasms
Activation of ALDH2 attenuates high glucose induced rat cardiomyocyte fibrosis and necroptosis.
Neoplasms
Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin.
Neoplasms
Activation of B-raf in non-malignant nevi predicts a novel tumor suppressor gene in melanoma (MAP kinase phosphatase).
Neoplasms
Activation of c-mos oncogene by integration of an endogenous long terminal repeat element during transfection of genomic DNA from mouse skin tumor cells.
Neoplasms
Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations.
Neoplasms
Activation of the c-Raf protein kinase by protein kinase C phosphorylation.
Neoplasms
Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions.
Neoplasms
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Neoplasms
Adenocarcinoma in Crohn's disease: the pathologist's experience in a tertiary referral centre of inflammatory bowel disease.
Neoplasms
Advancement in TPL2-regulated innate immune response.
Neoplasms
Advances in revealing the molecular targets downstream of oxidative stress-induced proapoptotic kinase signaling in diabetic embryopathy.
Neoplasms
Aggressiveness of the tall cell variant of papillary thyroid carcinoma is independent of the tumor size and patient age.
Neoplasms
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.
Neoplasms
Aliphatic acetogenin constituents of avocado fruits inhibit human oral cancer cell proliferation by targeting the EGFR/RAS/RAF/MEK/ERK1/2 pathway.
Neoplasms
Allele-specific, non-extendable primer blocker PCR (AS-NEPB-PCR) for DNA mutation detection in cancer.
Neoplasms
Alterations in oncogene expression and radiosensitivity in the most frequently used SV40-transformed human skin fibroblasts.
Neoplasms
Altered gene expression profiles of NIH3T3 cells regulated by human lung cancer associated gene CT120.
Neoplasms
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth.
Neoplasms
An in silico study of the molecular basis of B-RAF activation and conformational stability.
Neoplasms
An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.
Neoplasms
An Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase Inhibitors.
Neoplasms
Analysis of c-raf oncogene expression in gastrointestinal tumor cells.
Neoplasms
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
Neoplasms
Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
Neoplasms
Anti-inflammatory effects of ginsenoside Rg1 and its metabolites ginsenoside Rh1 and 20(S)-protopanaxatriol in mice with TNBS-induced colitis.
Neoplasms
Anticancer therapy: boosting the bang of Bim.
Neoplasms
Antisense oligonucleotide therapy in urology.
Neoplasms
Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Neoplasms
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.
Neoplasms
Apoptosis signal-regulating kinase (ASK1) and transcription factor tumor suppressor protein TP53 suppress rabbit ovarian granulosa cell functions.
Neoplasms
Apoptosis signal-regulating kinase 1 and cyclin D1 compose a positive feedback loop contributing to tumor growth in gastric cancer.
Neoplasms
Apoptosis signal-regulating kinase 1 inhibition attenuates human airway smooth muscle growth and migration in chronic obstructive pulmonary disease.
Neoplasms
Apoptosis signal-regulating kinase 1 mediates the inhibitory effect of hepatocyte nuclear factor-4? on hepatocellular carcinoma.
Neoplasms
Apoptosis signal-regulating kinase 1-thioredoxin complex dissociation by capsaicin causes pancreatic tumor growth suppression by inducing apoptosis.
Neoplasms
Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.
Neoplasms
Are all melanomas the same?: spitzoid melanoma is a distinct subtype of melanoma.
Neoplasms
ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications.
Neoplasms
ASK1 associates with troponin T and induces troponin T phosphorylation and contractile dysfunction in cardiomyocytes.
Neoplasms
ASK1 facilitates tumor metastasis through phosphorylation of an ADP receptor P2Y12 in platelets.
Neoplasms
ASK1 suppresses NK cell-mediated intravascular tumor cell clearance in lung metastasis.
Neoplasms
Assaying kinase activity of the TPL-2/NF-?B1 p105/ABIN-2 complex using an optimal peptide substrate.
Neoplasms
Assessing the Utility of a Mutational Assay for B-RAF as an Adjunct to Conventional Fine Needle Aspiration of the Thyroid Gland.
Neoplasms
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Neoplasms
Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer.
Neoplasms
Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes.
Neoplasms
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Neoplasms
Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.
Neoplasms
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Neoplasms
Association of Mixed Lineage Kinase Domain-Like Protein Expression With Prognosis in Patients With Colon Cancer.
Neoplasms
Associations between single-nucleotide polymorphisms and epidural ropivacaine consumption in patients undergoing breast cancer surgery.
Neoplasms
ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.
Neoplasms
Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib.
Neoplasms
B-raf and Ha-ras mutations in chemically induced mouse liver tumors.
Neoplasms
B-RAF and melanocytic neoplasia.
Neoplasms
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
Neoplasms
B-Raf and the inhibitors: from bench to bedside.
Neoplasms
B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.
Neoplasms
B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720.
Neoplasms
B-Raf Inhibition in the Clinic: Present and Future.
Neoplasms
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Neoplasms
B-RAF is a therapeutic target in melanoma.
Neoplasms
B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells.
Neoplasms
B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis.
Neoplasms
B-Raf kinase inhibitors for cancer treatment.
Neoplasms
B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P.
Neoplasms
B-Raf mutation: a key player in molecular biology of cancer.
Neoplasms
B-RAF mutations are a rare event in pituitary adenomas.
Neoplasms
B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas.
Neoplasms
B-RAF mutations in tumors from melanoma-breast cancer families.
Neoplasms
B-Raf Mutations, Microsatellite Instability and p53 Protein Expression in Sporadic Basal Cell Carcinomas.
Neoplasms
B-RAF Regulation of Rnd3 Participates in Actin Cytoskeletal and Focal Adhesion Organization.
Neoplasms
B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival.
Neoplasms
Back to the roots: the remarkable RAF oncogene story.
Neoplasms
BAG-1 haplo-insufficiency impairs lung tumorigenesis.
Neoplasms
Baicalein suppresses growth of non-small cell lung carcinoma by targeting MAP4K3.
Neoplasms
Beclin 2 negatively regulates innate immune signaling and tumor development.
Neoplasms
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Neoplasms
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.
Neoplasms
Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome.
Neoplasms
Bleomycin-induced lung injury in mice investigated by MRI: Model assessment for target analysis.
Neoplasms
BRAF mutation status in gastrointestinal stromal tumors.
Neoplasms
BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.
Neoplasms
BRAF V600E Mutation: A Significant Biomarker for Prediction of Disease Relapse in Pediatric Langerhans Cell Histiocytosis.
Neoplasms
BRAFV600E-induced KRT19 expression in thyroid cancer promotes lymph node metastasis via EMT.
Neoplasms
Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations.
Neoplasms
Breast cancer susceptibility variants alter risks in familial disease.
Neoplasms
BuCy RAFs drive cells into MEK addiction.
Neoplasms
c-Ha-ras1 is not deleted in aniridia-Wilms' tumour association.
Neoplasms
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Neoplasms
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.
Neoplasms
C-Raf controlled pathways in the protection of tumor cells from apoptosis.
Neoplasms
c-Raf in KRas Mutant Cancers: A Moving Target.
Neoplasms
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Neoplasms
C-Raf is required for the initiation of lung cancer by K-Ras.
Neoplasms
C-RAF mutations confer resistance to RAF inhibitors.
Neoplasms
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.
Neoplasms
Cancer cells regulate biomechanical properties of human microvascular endothelial cells.
Neoplasms
Cancer Osaka thyroid (Cot) phosphorylates Polo-like kinase (PLK1) at Ser137 but not at Thr210.
Neoplasms
Cardioprotective Role of Tumor Necrosis Factor Receptor-Associated Factor 2 by Suppressing Apoptosis and Necroptosis.
Neoplasms
Cellular Intrinsic Factors Involved in the Resistance of Squamous Cell Carcinoma to Photodynamic Therapy.
Neoplasms
CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-alpha release from lipopolysaccharide-treated cells and mice.
Neoplasms
Characterization of protein tyrosine kinase activity in murine Leydig tumor cells.
Neoplasms
Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.
Neoplasms
Chronic Resistance Exercise Improves Functioning and Reduces Toll-Like Receptor Signaling in Elderly Patients With Postoperative Deconditioning.
Neoplasms
CLDN6-induced apoptosis via regulating ASK1-p38/JNK signaling in breast cancer MCF-7 cells.
Neoplasms
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Neoplasms
Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas.
Neoplasms
Clinical studies of antisense therapy in cancer.
Neoplasms
CMV promoter is repressed by p53 and activated by JNK pathway.
Neoplasms
Combination of Biological Screening in a Cellular Model of Viral Latency and Virtual Screening Identifies Novel Compounds That Reactivate HIV-1.
Neoplasms
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Neoplasms
Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.
Neoplasms
Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells.
Neoplasms
Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Neoplasms
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Comparative analysis of various in vitro COT kinase assay formats and their applications in inhibitor identification and characterization.
Neoplasms
Comparative kinome analysis to identify putative colon tumor biomarkers.
Neoplasms
Comparative transcriptome and proteome analysis of Ha-ras and B-raf mutated mouse liver tumors.
Neoplasms
Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology.
Neoplasms
Comparison of the effects of 40% oxygen and two atmospheric absolute air pressure conditions on stress-induced premature senescence of normal human diploid fibroblasts.
Neoplasms
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
Neoplasms
Comprehensive molecular portraits of human breast tumours.
Neoplasms
Conditional expression of oncogenic C-RAF in mouse pulmonary epithelial cells reveals differential tumorigenesis and induction of autophagy leading to tumor regression.
Neoplasms
Conformation-specific inhibitors of Raf kinases.
Neoplasms
Conserved residues at the MAPKs binding interfaces that regulate transcriptional machinery.
Neoplasms
Continuous overexpression of thioredoxin 1 enhances cancer development and does not extend maximum lifespan in male C57BL/6 mice.
Neoplasms
Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy.
Neoplasms
Coordinate Loss of MAP3K7 and CHD1 Promotes Aggressive Prostate Cancer.
Neoplasms
Coordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinase.
Neoplasms
Coordinate Regulation of TPL-2 and NF-?B Signaling in Macrophages by NF-?B1 p105.
Neoplasms
Correction: Restoration of miR17/20a in Solid Tumor Cells Enhances the Natural Killer Cell Antitumor Activity by Targeting Mekk2.
Neoplasms
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Neoplasms
Corticosteroids inhibit Mycobacterium tuberculosis-induced necrotic host cell death by abrogating mitochondrial membrane permeability transition.
Neoplasms
Cot kinase plays a critical role in Helicobacter pylori-induced IL-8 expression.
Neoplasms
Critical role of miR-10b in B-RafV600E dependent anchorage independent growth and invasion of melanoma cells.
Neoplasms
Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2.
Neoplasms
Crystal structures of ASK1-inhibtor complexes provide a platform for structure-based drug design.
Neoplasms
Curcumin ameliorates streptozotocin-induced liver damage through modulation of endoplasmic reticulum stress-mediated apoptosis in diabetic rats.
Neoplasms
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Neoplasms
Cystatin cures visceral leishmaniasis by NF-?B-mediated proinflammatory response through co-ordination of TLR/MyD88 signaling with p105-Tpl2-ERK pathway.
Neoplasms
Cytokine-induced activation of mixed lineage kinase 3 requires TRAF2 and TRAF6.
Neoplasms
Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
Neoplasms
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Neoplasms
Data on tumor progression of c-mos deficiency in murine models of Kras
G12D
lung and Apc
Min
colorectal cancer.
Neoplasms
Deciphering signaling pathways in vivo: the Ras/Raf/MEK/ERK cascade.
Neoplasms
Deficiency in fibroblast PPAR?/? reduces nonmelanoma skin cancers in mice.
Neoplasms
Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis.
Neoplasms
Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers.
Neoplasms
Deletion of ASK1 Protects against Hyperoxia-Induced Acute Lung Injury.
Neoplasms
Deletion of tumor progression locus 2 attenuates alcohol-induced hepatic inflammation.
Neoplasms
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
Neoplasms
Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery.
Neoplasms
Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.
Neoplasms
Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
Neoplasms
Deregulation of PPAR?/? target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment.
Neoplasms
Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors.
Neoplasms
Detection of activated proto-oncogenes in N-nitrosodiethylamine-induced liver tumors: a comparison between B6C3F1 mice and Fischer 344 rats.
Neoplasms
Development and Validation of a High-Throughput Intrinsic ATPase Activity Assay for the Discovery of MEKK2 Inhibitors.
Neoplasms
Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization.
Neoplasms
Development of an enzyme-linked immunosorbent assay (ELISA) for the specific detection of MEKK1 expression in cells.
Neoplasms
Development of novel 3D-QSAR combination approach for screening and optimizing B-Raf inhibitors in silico.
Neoplasms
Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy.
Neoplasms
Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Neoplasms
Differential activation of stress-activated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogen-activated protein kinase kinase (MKK) kinase-1.
Neoplasms
Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance.
Neoplasms
Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors.
Neoplasms
Differential gene expression profile reveals overexpression of MAP3K8 in invasive endometrioid carcinoma.
Neoplasms
Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
Neoplasms
Differential localization of A-Raf regulates MST2-mediated apoptosis during epithelial differentiation.
Neoplasms
Differential radio-adaptive responses in BALB/c and C57BL/6 mice: pivotal role of calcium and nitric oxide signalling.
Neoplasms
Differential selection for B-raf and Ha-ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis.
Neoplasms
Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
Neoplasms
Differential spheroid formation by oral cancer cells.
Neoplasms
Direct activation of mitogen-activated protein kinase kinase kinase MEKK1 by the Ste20p homologue GCK and the adapter protein TRAF2.
Neoplasms
Direct relationship between the expression of tumor suppressor H19 mRNA and c-mos proto-oncogene during myogenesis.
Neoplasms
Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2).
Neoplasms
Discovery and development of pyrazole-scaffold Hsp90 inhibitors.
Neoplasms
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
Neoplasms
Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.
Neoplasms
Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma.
Neoplasms
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
Neoplasms
Dissecting the novel partners of nuclear c-Raf and its role in all-trans retinoic acid (ATRA)-induced myeloblastic leukemia cells differentiation.
Neoplasms
Distinct functions of the dual leucine zipper kinase depending on its subcellular localization.
Neoplasms
DNA amplification of the c-myc and c-erbB-1 genes in a human stomach cancer.
Neoplasms
DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
Neoplasms
DNA fingerprinting of glioma cell lines and considerations on similarity measurements.
Neoplasms
DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy.
Neoplasms
Dominant negative MEKK1 inhibits survival of pancreatic cancer cells.
Neoplasms
Downregulation of survivin and aurora a by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy.
Neoplasms
Drosophila happyhour modulates JNK-dependent apoptosis.
Neoplasms
Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Neoplasms
Dsi-1, a region with frequent proviral insertions in Moloney murine leukemia virus-induced rat thymomas.
Neoplasms
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
Neoplasms
Early-onset colorectal cancer: A distinct entity with unique genetic features.
Neoplasms
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Neoplasms
Effect of inositol hexakisphosphate kinase 2 on transforming growth factor beta-activated kinase 1 and NF-kappaB activation.
Neoplasms
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Neoplasms
Effect of selenite on T-cell mitogenesis: contribution of ROS production and apoptosis signal-regulating kinase 1.
Neoplasms
Elastin peptides activate extracellular signal-regulated kinase 1/2 via a Ras-independent mechanism requiring both p110gamma/Raf-1 and protein kinase A/B-Raf signaling in human skin fibroblasts.
Neoplasms
Elevated expression of A-Raf and FA2H in hepatocellular carcinoma is associated with lipid metabolism dysregulation and cancer progression.
Neoplasms
Elimination of B-RAF in oncogenic C-RAF-expressing alveolar epithelial type II cells reduces MAPK signal intensity and lung tumor growth.
Neoplasms
Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks.
Neoplasms
Endogenous nitric oxide induces activation of apoptosis signal-regulating kinase 1 via S-nitrosylation in rat hippocampus during cerebral ischemia-reperfusion.
Neoplasms
Endothelial Tpl2 regulates vascular barrier function via JNK-mediated degradation of claudin-5 promoting neuroinflammation or tumor metastasis.
Neoplasms
Enhanced expression of the proto-oncogenes fos and raf in the rhabdomyosarcoma cell line BA-HAN-1C after differentiation induction with retinoic acid and N-methylformamide.
Neoplasms
Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors.
Neoplasms
Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes.
Neoplasms
Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors.
Neoplasms
eQTL analysis from co-localization of 2739 GWAS loci detects associated genes across 14 human cancers.
Neoplasms
ERK Crosstalks with 4EBP1 to Activate Cyclin D1 Translation During Quinol-Thioether Induced Tuberous Sclerosis Renal Cell Carcinoma.
Neoplasms
ERK-dependent downregulation of the atypical chemokine receptor D6 drives tumor aggressiveness in Kaposi sarcoma.
Neoplasms
ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity.
Neoplasms
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex.
Neoplasms
Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis.
Neoplasms
Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.
Neoplasms
Evaluation of Ki-67 as prognostic factor for pediatric neuroblastoma and the possibility of molecular-targeted drugs with vascular endothelial growth factor and platelet-derived growth factor receptor.
Neoplasms
Evidence against a tumour-specific EcoRI RFLP of the c-mos locus.
Neoplasms
Expression analysis of B-Raf oncogene in V600E-negative benign and malignant tumors of the thyroid gland: correlation with late disease onset.
Neoplasms
Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines.
Neoplasms
Expression and prognostic role of MEKK3 and pERK in patients with renal clear cell carcinoma.
Neoplasms
Expression of B-RAF V600E in type II pneumocytes causes abnormalities in alveolar formation, airspace enlargement and tumor formation in mice.
Neoplasms
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Neoplasms
Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts.
Neoplasms
Expression of polysialic acid in primary laryngeal squamous cell carcinoma.
Neoplasms
Expression of Raf kinase inhibitor protein is downregulated in response to Newcastle disease virus infection to promote viral replication.
Neoplasms
Expression of the c-raf protooncogene, gamma-glutamyltranspeptidase, and gap junction protein in rat liver neoplasms.
Neoplasms
Expression of the oncogenes mil and ras abolishes the in vivo differentiation of mammary epithelial cells.
Neoplasms
Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Neoplasms
Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.
Neoplasms
Formation of a tumour necrosis factor receptor 1 molecular scaffolding complex and activation of apoptosis signal-regulating kinase 1 during seizure-induced neuronal death.
Neoplasms
Function and evolution of B-Raf loop dynamics relevant to cancer recurrence under drug inhibition.
Neoplasms
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Neoplasms
Functional analysis of sperm from c-mos(-/-) mice.
Neoplasms
Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
Neoplasms
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Neoplasms
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma.
Neoplasms
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Neoplasms
G1 to S phase transition protein 1 induces apoptosis signal-regulating kinase 1 activation by dissociating 14-3-3 from ASK1.
Neoplasms
Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker.
Neoplasms
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Neoplasms
Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer.
Neoplasms
Genetic approaches for the identification of apoptotic components.
Neoplasms
Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
Neoplasms
Genetic susceptibility loci for breast cancer by estrogen receptor status.
Neoplasms
Genetic variability of proto-oncogenes for breast cancer risk and prognosis.
Neoplasms
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
Neoplasms
Genomic organization and expression of Tpl-2 in normal cells and Moloney murine leukemia virus-induced rat T-cell lymphomas: activation by provirus insertion.
Neoplasms
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.
Neoplasms
Germline mutations in MAP3K6 are associated with familial gastric cancer.
Neoplasms
Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
Neoplasms
Global gene expression in Ha-ras and B-raf mutated mouse liver tumors.
Neoplasms
Glutamatergic Pathway Targeting in Melanoma; Single Agent and Combinatorial Therapies.
Neoplasms
Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1).
Neoplasms
GOPC-ROS1 mosaicism in agminated Spitz naevi: report of two cases.
Neoplasms
Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
Neoplasms
Guilty as charged: B-RAF is a human oncogene.
Neoplasms
Heme oxygenase 1 facilitates cell proliferation via the B-Raf-ERK signaling pathway in melanoma.
Neoplasms
Hepatitis C virus nonstructural 5B protein regulates tumor necrosis factor alpha signaling through effects on cellular IkappaB kinase.
Neoplasms
Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits.
Neoplasms
Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription.
Neoplasms
Heterozygous Mutations in MAP3K7, Encoding TGF-?-Activated Kinase 1, Cause Cardiospondylocarpofacial Syndrome.
Neoplasms
High prevalence of B-RAF mutation in papillary carcinoma of the thyroid in north-east Italy.
Neoplasms
Histiocytic neoplasms in the era of personalized genomic medicine.
Neoplasms
Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.
Neoplasms
How autophagy controls the intestinal epithelial barrier.
Neoplasms
HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma?not otherwise specified.
Neoplasms
Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
Neoplasms
Hsp90 modulates the stability of MLKL and is required for TNF-induced necroptosis.
Neoplasms
Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.
Neoplasms
Human mitogen-activated protein kinase kinase kinase mediates the stress-induced activation of mitogen-activated protein kinase cascades.
Neoplasms
Human papillomavirus and gene mutations in head and neck squamous carcinomas.
Neoplasms
Hypoxia potentiates monocyte-derived dendritic cells for release of tumor necrosis factor ? via MAP3K8.
Neoplasms
I?B kinase regulation of the TPL-2/ERK MAPK pathway.
Neoplasms
I?B kinase-induced interaction of TPL-2 kinase with 14-3-3 is essential for Toll-like receptor activation of ERK-1 and -2 MAP kinases.
Neoplasms
Identification and Characterization of a B-Raf Kinase ?-Helix Critical for the Activity of MEK Kinase in MAPK Signaling.
Neoplasms
Identification of apoptosis signal-regulating kinase 1 (ASK1) inhibitors among the derivatives of benzothiazol-2-yl-3-hydroxy-5-phenyl-1,5-dihydro-pyrrol-2-one.
Neoplasms
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Neoplasms
Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.
Neoplasms
Identification of guanine nucleotide exchange factors (GEFs) for the Rap1 GTPase. Regulation of MR-GEF by M-Ras-GTP interaction.
Neoplasms
Identification of novel ASK1 inhibitors using virtual screening.
Neoplasms
Identification of novel B-Raf(V600E) inhibitors employing FBDD strategy.
Neoplasms
Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.
Neoplasms
Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
Neoplasms
Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations.
Neoplasms
Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder, prostate, kidney cancers.
Neoplasms
IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin.
Neoplasms
IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.
Neoplasms
Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue.
Neoplasms
Immune Homeostatic Macrophages Programmed by the Bacterial Surface Protein NhhA Potentiate Nasopharyngeal Carriage of Neisseria meningitidis.
Neoplasms
Immunohistochemical localization of c-mos at the light and electron microscope level in non-small cell lung carcinomas.
Neoplasms
Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling.
Neoplasms
Implication of RAF and RKIP Genes in Urinary Bladder Cancer.
Neoplasms
Implication of the Tpl2 kinase in inflammatory changes and insulin resistance induced by the interaction between adipocytes and macrophages.
Neoplasms
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.
Neoplasms
In vivo pro-apoptotic and antitumor efficacy of a c-Raf antisense phosphorothioate oligonucleotide: relationship to tumor size.
Neoplasms
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas.
Neoplasms
Induction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulation.
Neoplasms
Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3? and NF-?B to suppress tumor cell growth.
Neoplasms
Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
Neoplasms
Inhibition of Cdc42-mediated activation of mixed lineage kinase 3 by the tumor suppressor protein merlin.
Neoplasms
Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG12D/Pdx-1-Cre Mice.
Neoplasms
Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.
Neoplasms
Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis.
Neoplasms
Inhibition of HGF/MET signaling decreases overall tumor burden and blocks malignant conversion in Tpl2-related skin cancer.
Neoplasms
Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation.
Neoplasms
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Neoplasms
Inhibitors of the HSP90 molecular chaperone: current status.
Neoplasms
Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.
Neoplasms
Integrated Omics Reveals Tollip as an Regulator and Therapeutic Target for Hepatic Ischemia-Reperfusion Injury in Mice.
Neoplasms
Integrative identification of Epstein-Barr virus-associated mutations and epigenetic alterations in gastric cancer.
Neoplasms
Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV-positive tumor cells.
Neoplasms
Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation.
Neoplasms
Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity.
Neoplasms
Intermittent B-Raf inhibitor therapy is a feasible option -report of a patient with metastatic melanoma.
Neoplasms
Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis.
Neoplasms
Involvement of IRE1? signaling in the hippocampus in patients with mesial temporal lobe epilepsy.
Neoplasms
Involvement of Kruppel-like factor 6 (KLF6) mutation in the development of nonpolypoid colorectal carcinoma.
Neoplasms
Involvement of mixed lineage kinase 3 in cancer.
Neoplasms
Is B-Raf a good therapeutic target for melanoma and other malignancies?
Neoplasms
Isoform-specific interaction of C-RAF with mitochondria.
Neoplasms
Isolation and analysis of the 21q+ chromosome in the acute myelogenous leukemia 8;21 translocation: evidence that c-mos is not translocated.
Neoplasms
Isolation and molecular characterization of circulating melanoma cells.
Neoplasms
JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension.
Neoplasms
JSAP1/JIP3 cooperates with focal adhesion kinase to regulate c-Jun N-terminal kinase and cell migration.
Neoplasms
JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Neoplasms
K-ras and B-raf gene mutations are not associated with gastrin- and CCK2-receptor mRNA expression in human colorectal tumour tissues.
Neoplasms
K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.
Neoplasms
K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy.
Neoplasms
K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.
Neoplasms
Keratinocyte autophagy enables the activation of keratinocytes and fibroblasts and facilitates wound healing.
Neoplasms
Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-? and chemotherapeutic gemcitabine-induced necroptosis.
Neoplasms
Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets.
Neoplasms
Knockdown of apoptosis signal-regulating kinase 1 modulates basal glycogen synthase kinase-3? kinase activity and regulates cell migration.
Neoplasms
KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population.
Neoplasms
Lack of B-RAF mutations in head and neck squamous cell carcinoma.
Neoplasms
Latest approved therapies for metastatic melanoma: what comes next?
Neoplasms
Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
Neoplasms
Long-Term Inhibition of Notch in A-375 Melanoma Cells Enhances Tumor Growth Through the Enhancement of AXIN1, CSNK2A3, and CEBPA2 as Intermediate Genes in Wnt and Notch Pathways.
Neoplasms
Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).
Neoplasms
Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma.
Neoplasms
Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous Recombination.
Neoplasms
Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.
Neoplasms
Low Intensity Pulsed Ultrasound (LIPUS) Influences the Multilineage Differentiation of Mesenchymal Stem and Progenitor Cell Lines through ROCK-Cot/Tpl2-MEK-ERK Signaling Pathway.
Neoplasms
Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf.
Neoplasms
Malignant melanoma--a genetic overview.
Neoplasms
Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1.
Neoplasms
MAP/ERK kinase kinase 1 (Mekk1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.
Neoplasms
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.
Neoplasms
MAP3K1 rs889312 genotypes influence survival outcomes of Chinese gastric cancer patients who received adjuvant chemotherapy based on platinum and fluorouracil regimes.
Neoplasms
MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitro.
Neoplasms
MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis.
Neoplasms
MAP3K7 and CHD1 Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells.
Neoplasms
MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-?B.
Neoplasms
MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages.
Neoplasms
Map3k8 Modulates Monocyte State and Atherogenesis in ApoE-/- Mice.
Neoplasms
MAP3K8 Regulates Cox-2-Mediated Prostaglandin E2 Production in the Lung and Suppresses Pulmonary Inflammation and Fibrosis.
Neoplasms
MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas.
Neoplasms
MAP4K3 modulates cell death via the post-transcriptional regulation of BH3-only proteins.
Neoplasms
MAP4K3/GLK in autoimmune disease, cancer and aging.
Neoplasms
mcr-1 Gene Expression Modulates the Inflammatory Response of Human Macrophages to Escherichia coli.
Neoplasms
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Neoplasms
Mechanisms of regulating the Raf kinase family.
Neoplasms
Mechanisms of Resistance to RAF Inhibitors in Melanoma.
Neoplasms
Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress.
Neoplasms
MEK and PI3K inhibition in solid tumors: rationale and evidence to date.
Neoplasms
MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration.
Neoplasms
MEK kinase is involved in tumor necrosis factor alpha-induced NF-kappaB activation and degradation of IkappaB-alpha.
Neoplasms
MEK targeting in N-RAS mutated metastatic melanoma.
Neoplasms
MEK-1 activates C-Raf through a Ras-independent mechanism.
Neoplasms
MEK1 activation by PAK: a novel mechanism.
Neoplasms
MEK1/2 dual-specificity protein kinases: structure and regulation.
Neoplasms
MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer.
Neoplasms
MEKK1 Regulates Chemokine Expression in Mammary Fibroblasts: Implications for the Breast Tumor Microenvironment.
Neoplasms
MEKK1-dependent activation of the CRL4 complex is important for DNA damage-induced degradation of p21 and DDB2 and cell survival.
Neoplasms
MEKK2 regulates focal adhesion stability and motility in invasive breast cancer cells.
Neoplasms
MEKK2 regulates paxillin ubiquitylation and localization in MDA-MB 231 breast cancer cells.
Neoplasms
MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
Neoplasms
MEKK3 is essential for lipopolysaccharide-induced interleukin-6 and granulocyte-macrophage colony-stimulating factor production in macrophages.
Neoplasms
MEKK3 is required for endothelium function but is not essential for tumor growth and angiogenesis.
Neoplasms
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity.
Neoplasms
Melanocytic tumors with MAP3K8 fusions: report of 33 cases with morphological-genetic correlations.
Neoplasms
Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation.
Neoplasms
Metastasizing Maxillary Ameloblastoma: Report of a Case with Molecular Characterization.
Neoplasms
MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3.
Neoplasms
microRNA-381-3p Confers Protection Against Ischemic Stroke Through Promoting Angiogenesis and Inhibiting Inflammation by Suppressing Cebpb and Map3k8.
Neoplasms
MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma.
Neoplasms
MicroRNA-98-5p regulates the proliferation and apoptosis of A549 cells by targeting MAP4K3.
Neoplasms
MicroRNA?9 suppresses human prostate cancer cell viability, invasion and migration via modulation of mitogen?activated protein kinase kinase kinase 3 expression.
Neoplasms
MiR-142-5p act as an oncogenic microRNA in colorectal cancer: Clinicopathological and functional insights.
Neoplasms
miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8.
Neoplasms
Missense mutations of the BRAF gene in human lung adenocarcinoma.
Neoplasms
Mitogen-activated kinase kinase kinase 1 inhibits hedgehog signaling and medulloblastoma growth through GLI1 phosphorylation.
Neoplasms
Mitogen-activated protein 3 kinase 6 mediates angiogenic and tumorigenic effects via vascular endothelial growth factor expression.
Neoplasms
Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Neoplasms
Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours.
Neoplasms
Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity.
Neoplasms
Mixed lineage kinase 3 modulates ?-catenin signaling in cancer cells.
Neoplasms
Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1.
Neoplasms
Mixed lineage kinase domain-like protein is a prognostic biomarker for cervical squamous cell cancer.
Neoplasms
Mixed Lineage Kinase MLK4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis.
Neoplasms
Mixed lineage kinase ZAK promotes epithelial-mesenchymal transition in cancer progression.
Neoplasms
Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein.
Neoplasms
MLK3 Is Associated With Poor Prognosis in Patients With Glioblastomas and Actin Cytoskeleton Remodeling in Glioblastoma Cells.
Neoplasms
MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation.
Neoplasms
MLK3 phosphorylation by ERK1/2 is required for oxidative stress-induced invasion of colorectal cancer cells.
Neoplasms
MLKL forms cation channels.
Neoplasms
MLKL is a potential prognostic marker in gastric cancer.
Neoplasms
Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis.
Neoplasms
Modelling oncogenic Ras/Raf signalling in the mouse.
Neoplasms
Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
Neoplasms
Molecular Basis of Inactive B-RAF(WT) and B-RAF(V600E) Ligand Inhibition, Selectivity and Conformational Stability: An in Silico Study.
Neoplasms
Molecular basis of inactive B-RAF(WT) and B-RAF(V600E) ligand inhibition, selectivity and conformational stability: an in silico study.
Neoplasms
Molecular characterization of neuroendocrine lung-tumors induced in hamsters by treatment with nitrosamines and hyperoxia.
Neoplasms
Molecular mechanisms governing microRNA-125a expression in human hepatocellular carcinoma cells.
Neoplasms
Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations.
Neoplasms
Molecular Study of Signaling-Pathway Genes in Experimental Rat Thyroid Carcinoma.
Neoplasms
Molecular targeting for treatment of advanced hepatocellular carcinoma.
Neoplasms
Moloney murine leukemia virus-induced tumors: recombinant proviruses in active chromatin regions.
Neoplasms
Mortalin (HSPA9) facilitates BRAF-mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability.
Neoplasms
Mouse model for pre-clinical study of human cancer immunotherapy.
Neoplasms
Mps1 is associated with the BRAFV600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.
Neoplasms
MST kinases monitor actin cytoskeletal integrity and signal via JNK stress-activated kinase to regulate p21Waf1/Cip1 stability.
Neoplasms
MTDH and MAP3K1 are direct targets of apoptosis-regulating miRNAs in colorectal carcinoma.
Neoplasms
Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
Neoplasms
Multiple polyps of esophagus, stomach, colon, and rectum accompanying rectal cancer in a patient with constitutional chromosomal inversion.
Neoplasms
Multiple primary malignant neoplasms: A case report and literature review.
Neoplasms
Mutant B-Raf Kinase inhibitors as anticancer agents.
Neoplasms
Mutant B-RAF mediates resistance to anoikis via Bad and Bim.
Neoplasms
Mutant p53 disrupts the stress MAPK activation circuit induced by ASK1-dependent stabilization of Daxx.
Neoplasms
Mutant SF3B1 promotes AKT- and NF-?B-driven mammary tumorigenesis.
Neoplasms
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Neoplasms
Mutation analysis of B-RAF gene in human gliomas.
Neoplasms
Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.
Neoplasms
Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas.
Neoplasms
Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.
Neoplasms
Mutational activation of the MAP3K8 protooncogene in lung cancer.
Neoplasms
Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.
Neoplasms
Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands.
Neoplasms
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.
Neoplasms
Mutual suppression of miR-125a and Lin28b in human hepatocellular carcinoma cells.
Neoplasms
MYC is a metastasis gene for non-small-cell lung cancer.
Neoplasms
Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.
Neoplasms
Natural molecule Munronoid I attenuates LPS-induced acute lung injury by promoting the K48-linked ubiquitination and degradation of TAK1.
Neoplasms
Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases.
Neoplasms
Necrosis and necroptosis in germ cell depletion from mammalian ovary.
Neoplasms
Negative regulation of mitochondrial VDAC channels by C-Raf kinase.
Neoplasms
Neuroprotective effects of Activin A on endoplasmic reticulum stress-mediated apoptotic and autophagic PC12 cell death.
Neoplasms
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer.
Neoplasms
NF-kappaB activation by the chemopreventive dithiolethione oltipraz is exerted through stimulation of MEKK3 signaling.
Neoplasms
NF?B-Associated Pathways in Progression of Chemoresistance to 5-Fluorouracil in an In Vitro Model of Colonic Carcinoma.
Neoplasms
NIK is a component of the EGF/heregulin receptor signaling complexes.
Neoplasms
No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Neoplasms
No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.
Neoplasms
Non-melanoma skin cancer in mouse and man.
Neoplasms
Novel biomarkers in malignant melanoma.
Neoplasms
Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.
Neoplasms
Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo.
Neoplasms
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.
Neoplasms
Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics.
Neoplasms
NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Neoplasms
Nuclear Localization Signal and p53 Binding Site in MAP/ERK Kinase Kinase 1 (MEKK1).
Neoplasms
Oncogenic B-Raf mutations: crystal clear at last.
Neoplasms
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.
Neoplasms
Oncogenic B-Raf(V600E) abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells.
Neoplasms
Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
Neoplasms
Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim.
Neoplasms
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
Neoplasms
Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Neoplasms
Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability.
Neoplasms
Optogenetic Control of Protein Kinase Activity in Mammalian Cells.
Neoplasms
Ovarian teratomas in mice lacking the protooncogene c-mos.
Neoplasms
Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis.
Neoplasms
Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.
Neoplasms
Overexpression of the Tpl-2/Cot oncogene in human breast cancer.
Neoplasms
Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-?B pathways in a model of Chronic Myeloid Leukemia.
Neoplasms
Overview of MDM2 and B-RAF Expression in Gastric Lesions.
Neoplasms
p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.
Neoplasms
p90 RSK2 mediates antianoikis signals by both transcription-dependent and -independent mechanisms.
Neoplasms
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
Neoplasms
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Neoplasms
Patterns of neoplasia in c-mos transgenic mice and their relevance to multiple endocrine neoplasia.
Neoplasms
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Neoplasms
PCB 153, a non-dioxin-like tumor promoter, selects for beta-catenin (Catnb)-mutated mouse liver tumors.
Neoplasms
Persistent hepatocyte apoptosis promotes tumorigenesis from diethylnitrosamine-transformed hepatocytes through increased oxidative stress, independent of compensatory liver regeneration.
Neoplasms
Perturbations of lens development in the transgenic mouse.
Neoplasms
Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors.
Neoplasms
Phase I Study of Liposome-Encapsulated c-raf Antisense Oligodeoxyribonucleotide Infusion in Combination with Radiation Therapy in Patients with Advanced Malignancies.
Neoplasms
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
Neoplasms
Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 syndrome.
Neoplasms
Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.
Neoplasms
Phosphoethanolamine induces caspase-independent cell death by reducing the expression of C-RAF and inhibits tumor growth in human melanoma model.
Neoplasms
Phosphoinositide-dependent kinase-1 inhibits TRAF6 ubiquitination by interrupting the formation of TAK1-TAB2 complex in TLR4 signaling.
Neoplasms
Phosphorylation of MEKK3 at threonine 294 promotes 14-3-3 association to inhibit nuclear factor kappaB activation.
Neoplasms
Phosphorylation of the C-Raf N-region promotes Raf dimerization.
Neoplasms
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
Neoplasms
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Neoplasms
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
Neoplasms
Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis.
Neoplasms
Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells.
Neoplasms
PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
Neoplasms
Polyelectrolyte complex micelles composed of c-raf antisense oligodeoxynucleotide-poly(ethylene glycol) conjugate and poly(ethylenimine): effect of systemic administration on tumor growth.
Neoplasms
Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation.
Neoplasms
Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1.
Neoplasms
PPAR?2 functions as a tumor suppressor in a translational mouse model of human prostate cancer.
Neoplasms
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Neoplasms
Presence of an allelic EcoRI restriction fragment of the c-mos locus in leukocyte and tumor cell DNAs of breast cancer patients.
Neoplasms
Presence of an EcoRI RFLP of the c-mos locus in normal and tumor tissue of esophageal cancer patients.
Neoplasms
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Neoplasms
Prevalence, Tumorigenic Role, and Biochemical Implications of Rare BRAF Alterations.
Neoplasms
Prognostic Values of EPDR1 Hypermethylation and Its Inhibitory Function on Tumor Invasion in Colorectal Cancer.
Neoplasms
Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
Neoplasms
Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.
Neoplasms
Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.
Neoplasms
Protein kinase D specifically mediates apoptosis signal-regulating kinase 1-JNK signaling induced by H2O2 but not tumor necrosis factor.
Neoplasms
Protein phosphatase with EF-hand domains 2 (PPEF2) is a potent negative regulator of apoptosis signal regulating kinase-1 (ASK1).
Neoplasms
Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration.
Neoplasms
Proteome analysis of chemically induced mouse liver tumors with different genotype.
Neoplasms
Proteomics analysis of immunoprecipitated proteins associated with the oncogenic kinase cot.
Neoplasms
Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx.
Neoplasms
Purification and kinetic characterization of recombinant human mitogen-activated protein kinase kinase kinase COT and the complexes with its cellular partner NF-kappa B1 p105.
Neoplasms
Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.
Neoplasms
Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.
Neoplasms
Quantitative proteomics suggest a potential link between early embryonic death and trisomy 16.
Neoplasms
Quinone reductase inhibitors block SAPK/JNK and NFkappaB pathways and potentiate apoptosis.
Neoplasms
Radiomics in Differentiated Thyroid Cancer and Nodules: Explorations, Application, and Limitations.
Neoplasms
RAF expression in human astrocytic tumors.
Neoplasms
Raf family kinases: old dogs have learned new tricks.
Neoplasms
Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3?.
Neoplasms
Raf kinases in signal transduction and interaction with translation machinery.
Neoplasms
Raf kinases: Oncogenesis and drug discovery.
Neoplasms
RAF protein-serine/threonine kinases: structure and regulation.
Neoplasms
Raf proteins and cancer: B-Raf is identified as a mutational target.
Neoplasms
Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.
Neoplasms
Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway.
Neoplasms
Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation.
Neoplasms
Rapid Somatic Mutation Testing in Colorectal Cancer by Use of a Fully Automated System and Single-Use Cartridge: A Comparison with Next-Generation Sequencing.
Neoplasms
Rare Ha-ras and c-mos alleles in patients with intracranial tumors.
Neoplasms
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
Neoplasms
Ras-mutant Cancer Cells Display B-Raf Binding to Ras That Activates Extracellular Signal-regulated Kinase and Is Inhibited by Protein Kinase A Phosphorylation.
Neoplasms
RAS/RAF/MEK Inhibitors in Oncology.
Neoplasms
RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
Neoplasms
Rat c-raf oncogene is located on chromosome 4 and may be activated by sequences from chromosome 13.
Neoplasms
Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8+ T cells.
Neoplasms
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma.
Neoplasms
Reactive oxygen species- and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction.
Neoplasms
Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.
Neoplasms
Rearrangement of the oncogene c-mos in mouse myeloma NSI and hybridomas.
Neoplasms
Recent Advances in the Research and Development of B-Raf Inhibitors.
Neoplasms
Recent advances of MEK inhibitors and their clinical progress.
Neoplasms
Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.
Neoplasms
Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death.
Neoplasms
Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis.
Neoplasms
Regulation and repurposing of nutrient sensing and autophagy in innate immunity.
Neoplasms
Regulation and role of raf-1/b-raf heterodimerization.
Neoplasms
Regulation of c-Raf Stability through the CTLH Complex.
Neoplasms
Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer.
Neoplasms
Regulation of Transforming Growth Factor ?-Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K(63) -Linked Autoubiquitination of Tumor Necrosis Factor Receptor-Associated Factor 6.
Neoplasms
Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas.
Neoplasms
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
Neoplasms
Restoration of miR17/20a in solid tumor cells enhances the natural killer cell antitumor activity by targeting Mekk2.
Neoplasms
Restoration of NF-kappaB activation by tumor necrosis factor alpha receptor complex-targeted MEKK3 in receptor-interacting protein-deficient cells.
Neoplasms
Revealing A-Raf functions through its interactome.
Neoplasms
RKIP downregulates B-Raf kinase activity in melanoma cancer cells.
Neoplasms
RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
Neoplasms
RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors.
Neoplasms
RNAi silencing of the MEKK3 gene promotes TRAIL-induced apoptosis in MCF-7 cells and suppresses the transcriptional activity of NF-?B.
Neoplasms
Role of apoptosis signal-regulating kinase in regulation of the c-Jun N-terminal kinase pathway and apoptosis in sympathetic neurons.
Neoplasms
Role of FIP200 in cardiac and liver development and its regulation of TNFalpha and TSC-mTOR signaling pathways.
Neoplasms
Role of Melanoma Inhibitor of Apoptosis (ML-IAP) Protein, a Member of the Baculoviral IAP Repeat (BIR) Domain Family, in the Regulation of C-RAF Kinase and Cell Migration.
Neoplasms
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Neoplasms
Role of receptor-interacting protein in tumor necrosis factor-alpha -dependent MEKK1 activation.
Neoplasms
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
Neoplasms
RRD-251 enhances All-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells.
Neoplasms
Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome.
Neoplasms
Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth.
Neoplasms
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Neoplasms
Selective Regulation of B-Raf Dependent K-Ras/Mitogen-Activated Protein by Natural Occurring Multi-kinase Inhibitors in Cancer Cells.
Neoplasms
Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo.
Neoplasms
Sequencing Analysis of BRAF Mutations in Human Cancers.
Neoplasms
Severe fever with thrombocytopenia syndrome phlebovirus non-structural protein activates TPL2 signalling pathway for viral immunopathogenesis.
Neoplasms
ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth.
Neoplasms
Signal Transduction Pathways as Therapeutic Targets. 25-28 January 2004, Luxembourg.
Neoplasms
Signaling pathways from membrane lipid rafts to JNK1 activation in reactive nitrogen species-induced non-apoptotic cell death.
Neoplasms
Silencing TAK1 alters gene expression signatures in bladder cancer cells.
Neoplasms
Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells.
Neoplasms
SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers.
Neoplasms
Sorafenib (BAY 43-9006, Nexavar((R))), a Dual-Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature.
Neoplasms
Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
Neoplasms
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Neoplasms
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Neoplasms
Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Neoplasms
Spitz nevus with a novel TFG-NTRK2 fusion: The first case report of NTRK2-rearranged Spitz/Reed nevus.
Neoplasms
Stabilization of C-RAF:KSR1 complex by DiRas3 reduces availability of C-RAF for dimerization with B-RAF.
Neoplasms
Stabilization of Physical RAF/14-3-3 Interaction by Cotylenin A as Treatment Strategy for RAS Mutant Cancers.
Neoplasms
State Institution "National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine" - research activities and scientific advance in 2014.
Neoplasms
Stimulation of the Na(+)-coupled glucose transporter SGLT1 by B-RAF.
Neoplasms
Structural basis for the interaction of TAK1 kinase with its activating protein TAB1.
Neoplasms
Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Neoplasms
Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis.
Neoplasms
Suppression of AP-1 activity by cycloprodigiosin hydrochloride.
Neoplasms
Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins.
Neoplasms
Suppression of B-Raf(V600E) cancers by MAPK hyper-activation.
Neoplasms
Suppression of Tak1 promotes prostate tumorigenesis.
Neoplasms
Synergistic Binding of the Phosphorylated S233- and S259-Binding Sites of C-RAF to One 14-3-3? Dimer.
Neoplasms
Syrian hamster embryo cell lines useful for detecting transforming genes in mouse tumours: detection of transforming genes in X-ray-related mouse tumours.
Neoplasms
Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer.
Neoplasms
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.
Neoplasms
TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation.
Neoplasms
TAK1 selective inhibition: state of the art and future opportunities.
Neoplasms
TAK1-dependent signaling requires functional interaction with TAB2/TAB3.
Neoplasms
TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-{kappa}B-independent survival pathways in tumor necrosis factor alpha signaling.
Neoplasms
Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.
Neoplasms
Targeted Therapy in Melanoma and Mechanisms of Resistance.
Neoplasms
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
Neoplasms
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Neoplasms
Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer.
Neoplasms
Targeting oxidative phosphorylation: why, when, and how.
Neoplasms
Targeting RTK Signaling Pathways in Cancer.
Neoplasms
Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
Neoplasms
Targeting the Raf kinases in human cancer: the Raf dimer dilemma.
Neoplasms
Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer.
Neoplasms
Targets of Raf in tumorigenesis.
Neoplasms
Technology evaluation: LErafAON, NeoPharm.
Neoplasms
TERT promoter mutation predicts radioiodine refractory in distant metastatic differentiated thyroid cancer.
Neoplasms
The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network.
Neoplasms
The Autophagy Machinery Controls Cell Death Switching between Apoptosis and Necroptosis.
Neoplasms
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.
Neoplasms
The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.
Neoplasms
The combination of TPL2 knockdown and TNF? causes synthetic lethality via caspase-8 activation in human carcinoma cell lines.
Neoplasms
The Crystal Structure of Cancer Osaka Thyroid Kinase Reveals an Unexpected Kinase Domain Fold.
Neoplasms
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.
Neoplasms
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Neoplasms
The Expression and Role of MEKK3 in Renal Clear Cell Carcinoma.
Neoplasms
The genesis of Zelboraf: targeting mutant B-Raf in melanoma.
Neoplasms
The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma-Association with Clinical Outcome and Tumor Phenotypes.
Neoplasms
The IL-1? signalling pathway and its role in regulating pro-inflammatory and pro-labour mediators in human primary myometrial cells.
Neoplasms
The inhibition of transforming growth factor beta-activated kinase 1 contributed to neuroprotection via inflammatory reaction in pilocarpine-induced rats with epilepsy.
Neoplasms
The landscape of cancer genes and mutational processes in breast cancer.
Neoplasms
The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer.
Neoplasms
The MAP3K7-mTOR Axis Promotes the Proliferation and Malignancy of Hepatocellular Carcinoma Cells.
Neoplasms
The MAPK Kinase Kinase 4 Deficiency in Intrahepatic Cholangiocarcinoma Leads to Invasive Growth and Epithelial-Mesenchymal Transition.
Neoplasms
The mechanism of activation of monomeric B-Raf V600E.
Neoplasms
The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors.
Neoplasms
The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.
Neoplasms
The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Neoplasms
The phosphorylation specificity of B-RAF WT, B-RAF D594V, B-RAF V600E and B-RAF K601E kinases: an in silico study.
Neoplasms
The potential role of necroptosis in clinical diseases (Review).
Neoplasms
The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism.
Neoplasms
The RAF proteins take centre stage.
Neoplasms
The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells.
Neoplasms
The Ras-association domain family (RASSF) members and their role in human tumourigenesis.
Neoplasms
The regulatory function of mixed lineage kinase 3 in tumor and host immunity.
Neoplasms
The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.
Neoplasms
The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts.
Neoplasms
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-?B/Snail/RKIP/PTEN Circuit.
Neoplasms
The role of gene fusions in melanocytic neoplasms.
Neoplasms
The role of tumor progression locus 2 protein kinase in glial inflammatory response.
Neoplasms
The roles of MAPKs in disease.
Neoplasms
The Tpl2 Kinase Regulates the COX-2/Prostaglandin E2 Axis in Adipocytes in Inflammatory Conditions.
Neoplasms
The tumor suppressor DiRas3 forms a complex with H-Ras and C-RAF proteins and regulates localization, dimerization, and kinase activity of C-RAF.
Neoplasms
The tumour suppressor DiRas3 interacts with C-RAF and downregulates MEK activity to restrict cell migration.
Neoplasms
The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice.
Neoplasms
Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL.
Neoplasms
TLR and TNF-R1 activation of the MKK3/MKK6-p38? axis in macrophages is mediated by TPL-2 kinase.
Neoplasms
TNF-induced necroptosis initiates early autophagy events via RIPK3-dependent AMPK activation, but inhibits late autophagy.
Neoplasms
Tpl-2 induces apoptosis by promoting the assembly of protein complexes that contain caspase-9, the adapter protein Tvl-1, and procaspase-3.
Neoplasms
Tpl-2 kinase downregulates the activity of p53 and enhances signaling pathways leading to activation of activator protein 1 induced by EGF.
Neoplasms
TPL-2 kinase induces phagosome acidification to promote macrophage killing of bacteria.
Neoplasms
TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations.
Neoplasms
TPL2 signalling: From Toll-like receptors-mediated ERK1/ERK2 activation to Cystic Fibrosis lung disease.
Neoplasms
TRAF2-MLK3 interaction is essential for TNF-alpha-induced MLK3 activation.
Neoplasms
Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-? production and endotoxin shock.
Neoplasms
trans-Fatty acids promote p53-dependent apoptosis triggered by cisplatin-induced DNA interstrand crosslinks via the Nox-RIP1-ASK1-MAPK pathway.
Neoplasms
Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma.
Neoplasms
Transformation by ras suppresses expression of the neurotrophic growth factor pleiotrophin.
Neoplasms
Transforming growth factor ?-activated kinase 1 signaling pathway critically regulates myocardial survival and remodeling.
Neoplasms
Transforming growth factor beta-activated kinase 1 (TAK1) kinase adaptor, TAK1-binding protein 2, plays dual roles in TAK1 signaling by recruiting both an activator and an inhibitor of TAK1 kinase in tumor necrosis factor signaling pathway.
Neoplasms
Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death.
Neoplasms
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
Neoplasms
Trisomy 8 in human hematologic neoplasia and the c-myc and c-mos oncogenes.
Neoplasms
Tuberous sclerosis-2 tumor suppressor modulates ERK and B-Raf activity in transformed renal epithelial cells.
Neoplasms
Tumor Cell-Derived Exosomal miR-770 Inhibits M2 Macrophage Polarization via Targeting MAP3K1 to Inhibit the Invasion of Non-small Cell Lung Cancer Cells.
Neoplasms
Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
Neoplasms
Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2).
Neoplasms
Tumor Necrosis Factor ?-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.
Neoplasms
Tumor necrosis factor alpha-induced desumoylation and cytoplasmic translocation of homeodomain-interacting protein kinase 1 are critical for apoptosis signal-regulating kinase 1-JNK/p38 activation.
Neoplasms
Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and SAPK while receptor interacting protein associates with a mitogen-activated protein kinase kinase kinase upstream of MKK6 and p38.
Neoplasms
Tumor necrosis factor-alpha and apoptosis signal-regulating kinase 1 control reactive oxygen species release, mitochondrial autophagy, and c-Jun N-terminal kinase/p38 phosphorylation during necrotizing enterocolitis.
Neoplasms
Tumor necrosis factor-related genes and colon and rectal cancer.
Neoplasms
Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production.
Neoplasms
Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation.
Neoplasms
Tumor progression locus 2 (Tpl2) deficiency does not protect against obesity-induced metabolic disease.
Neoplasms
Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration.
Neoplasms
Tumor progression locus 2/Cot is required for activation of extracellular regulated kinase in liver injury and toll-like receptor-induced TIMP-1 gene transcription in hepatic stellate cells in mice.
Neoplasms
Tumor progression locus-2 is a critical regulator of pancreatic and lung inflammation during acute pancreatitis.
Neoplasms
Two mechanistically and temporally distinct NF-kappaB activation pathways in IL-1 signaling.
Neoplasms
Two purified proteins from royal jelly with in vitro dual anti-hepatic damage potency: Major royal jelly protein 2 and its novel isoform X1.
Neoplasms
Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
Neoplasms
Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1).
Neoplasms
Understanding signaling cascades in melanoma.
Neoplasms
Understanding the Interplay between COX-2 and hTERT in Colorectal Cancer Using a Multi-Omics Analysis.
Neoplasms
Uniform response of c-raf expression to differentiation induction and inhibition of proliferation in a rat rhabdomyosarcoma cell line.
Neoplasms
Upregulation of Mobility in Pancreatic Cancer Cells by Secreted S100A11 Through Activation of Surrounding Fibroblasts.
Neoplasms
Upregulation of PSMB4 is Associated with the Necroptosis after Spinal Cord Injury.
Neoplasms
Uptake and tumor-suppressive pathways of exosome-associated GKN1 protein in gastric epithelial cells.
Neoplasms
Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice.
Neoplasms
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
Neoplasms
UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma.
Neoplasms
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.
Neoplasms
Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas.
Neoplasms
Virtual screening of B-Raf kinase inhibitors: A combination of pharmacophore modelling, molecular docking, 3D-QSAR model and binding free energy calculation studies.
Neoplasms
Vitamin C (Ascorbate) and Redox Topics in Cancer.
Neoplasms
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
Neoplasms
Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
Neoplasms
Xihuang pill promotes apoptosis of Treg cells in the tumor microenvironment in 4T1 mouse breast cancer by upregulating MEKK1/SEK1/JNK1/AP-1 pathway.
Neoplasms
[(11)C-carbonyl]CEP-32496: radiosynthesis, biodistribution and PET study of brain uptake in P-gp/BCRP knockout mice.
Neoplasms
[A Case of Serrated Polyposis Syndrome with Early Colon Cancer].
Neoplasms
[Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
Neoplasms
[Drug resistance, oncogenes, and anti-oncogenes in epithelial tumors]
Neoplasms
[Effects of flavone from leaves of Diospyros kaki on expression of apoptosis signal-regulating kinase 1 and rat vascular smooth muscle cells proliferation by tumor necrosis factor alpha in vitro]
Neoplasms
[Expression of oncogenes C-myc, C-raf and N-ras in advanced cancers of the upper respiratory and digestive tracts. Correlation with tumor clinical response to chemotherapy]
Neoplasms
[Functional Analysis of Apoptosis Signal-regulating Kinase Family in a Murine Model of Tumor Metastasis].
Neoplasms
[Genetic polymorphism and susceptibility to cancer]
Neoplasms
[Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies]
Neoplasms
[Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
Neoplasms
[Research progress of necroptosis on bone related diseases].
Neoplasms
[Serous genital carcinoma : Molecular pathogenesis and the role of tubal fimbria.]
Neoplasms
[Systemic treatment of distant metastatic malignant melanoma].
Neoplasms
[The RAS paradoxon of the EGFR-targeted therapy of colorectal cancer]
Neoplasms, Germ Cell and Embryonal
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Neoplasms, Germ Cell and Embryonal
Ovarian teratomas in mice lacking the protooncogene c-mos.
Neoplasms, Germ Cell and Embryonal
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Neoplasms, Neuroepithelial
A newly diagnosed case of polymorphous low-grade neuroepithelial tumor of the young.
Neoplasms, Squamous Cell
Mixed lineage kinase domain-like protein is a prognostic biomarker for cervical squamous cell cancer.
Nephritis
ASK1 inhibitor treatment suppresses p38/JNK signalling with reduced kidney inflammation and fibrosis in rat crescentic glomerulonephritis.
Nephritis
Proto-oncogene expression in human glomerular diseases.
Neural Tube Defects
Birth defects in pregestational diabetes: Defect range, glycemic threshold and pathogenesis.
Neural Tube Defects
Loss of mitogen-activated protein kinase kinase kinase 4 (MEKK4) results in enhanced apoptosis and defective neural tube development.
Neural Tube Defects
Maternal Hyperglycemia Activates an ASK1-FoxO3a-Caspase 8 Pathway That Leads to Embryonic Neural Tube Defects.
Neuralgia
Analgesic potential of intrathecal farnesyl thiosalicylic acid and GW 5074 in vincristine-induced neuropathic pain in rats.
Neuralgia
Inhibition of apoptosis signal-regulating kinase by paeoniflorin attenuates neuroinflammation and ameliorates neuropathic pain.
Neuralgia
Upregulation of miR-183 represses neuropathic pain through inhibiton of MAP3K4 in CCI rat models.
Neurilemmoma
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
Neuroblastoma
95-kilodalton B-Raf serine/threonine kinase: identification of the protein and its major autophosphorylation site.
Neuroblastoma
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Neuroblastoma
Computational algorithms for in silico profiling of activating mutations in cancer.
Neuroblastoma
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Neuroblastoma
Detection of c-mos proto-oncogene expression in human cells.
Neuroblastoma
Histiocytic neoplasms in the era of personalized genomic medicine.
Neuroblastoma
Human TAO kinase 1 induces apoptosis in SH-SY5Y cells.
Neuroblastoma
Interferon-? counter-regulates its own pro-apoptotic action by activating p38 MAPK signalling in human SH-SY5Y neuroblastoma cells.
Neuroblastoma
Intraductal tubulopapillary neoplasm accompanied by invasive carcinoma of the pancreas: A case report and review of the literature.
Neuroblastoma
Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma.
Neuroblastoma
Participation of type II protein kinase A in the retinoic acid-induced growth inhibition of SH-SY5Y human neuroblastoma cells.
Neuroblastoma
Phosphorylation of endogenous proteins by adenosine 3':5'-monophosphate-dependent protein kinase in mouse neuroblastoma cells.
Neuroblastoma
[Ap1-like cis-elements in 5'-regulatory region of human apolipoprotein A-I gene]
Neurodegenerative Diseases
A new class of supramolecular ligands stabilizes 14-3-3 protein-protein interactions by up to two orders of magnitude.
Neurodegenerative Diseases
An axonal stress response pathway: degenerative and regenerative signaling by DLK.
Neurodegenerative Diseases
Development of an HTS-compatible assay for the discovery of ASK1 signalosome inhibitors using alphascreen technology.
Neurodegenerative Diseases
DLK Activation Synergizes with Mitochondrial Dysfunction to Downregulate Axon Survival Factors and Promote SARM1-Dependent Axon Degeneration.
Neurodegenerative Diseases
Identification of 3H-Naphtho[1,2,3-de]quinoline-2,7-diones as Inhibitors of Apoptosis Signal-Regulating Kinase 1 (ASK1).
Neurodegenerative Diseases
Identification of apoptosis signal-regulating kinase 1 (ASK1) inhibitors among the derivatives of benzothiazol-2-yl-3-hydroxy-5-phenyl-1,5-dihydro-pyrrol-2-one.
Neurodegenerative Diseases
Identification of novel ASK1 inhibitors using virtual screening.
Neurodegenerative Diseases
Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
Neurodegenerative Diseases
Protein phosphatase with EF-hand domains 2 (PPEF2) is a potent negative regulator of apoptosis signal regulating kinase-1 (ASK1).
Neurodegenerative Diseases
The regulatory function of mixed lineage kinase 3 in tumor and host immunity.
Neurofibromatoses
Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
Neurofibromatoses
MEKK2 mediates aberrant ERK activation in neurofibromatosis type I.
Neurofibromatosis 1
Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
Neurofibromatosis 1
MEKK2 mediates aberrant ERK activation in neurofibromatosis type I.
Neurofibrosarcoma
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Neuroinflammatory Diseases
Apoptosis signal regulating kinase 1 deletion mitigates ?-synuclein pre-formed fibril propagation in mice.
Neuroinflammatory Diseases
Apoptosis signal-regulating kinase 1 modulates the phenotype of ?-synuclein transgenic mice.
Neuroinflammatory Diseases
Inhibiting RIP1 Improves Chronic Stress-Induced Cognitive Impairments in D-Galactose-Induced Aging Mice.
Neuroinflammatory Diseases
Inhibition of apoptosis signal-regulating kinase by paeoniflorin attenuates neuroinflammation and ameliorates neuropathic pain.
Nevi and Melanomas
BRAF mutational epidemiology in dysplastic nevi: Does different solar UV radiation exposure matter?
Nevi and Melanomas
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Nevi and Melanomas
Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
Nevus
Activation of B-raf in non-malignant nevi predicts a novel tumor suppressor gene in melanoma (MAP kinase phosphatase).
Nevus
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.
Nevus
Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
Nevus
BRAF mutational epidemiology in dysplastic nevi: Does different solar UV radiation exposure matter?
Nevus
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Nevus
Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
Nevus
Human nevi: no longer precursors of melanomas?
Nevus
IGFBP7 is not required for B-RAF-induced melanocyte senescence.
Nevus
Oncogene-Induced Senescence Does Not Require the p16(INK4a) or p14ARF Melanoma Tumor Suppressors.
Nevus
Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
Nevus
Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
Nevus, Epithelioid and Spindle Cell
Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
Nevus, Epithelioid and Spindle Cell
Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
Nevus, Pigmented
B-RAF and melanocytic neoplasia.
Nevus, Pigmented
Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
Nevus, Pigmented
Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.
Nevus, Pigmented
Malignant melanoma--a genetic overview.
Nevus, Pigmented
Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.
Nevus, Pigmented
Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
Nevus, Pigmented
Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Non-alcoholic Fatty Liver Disease
Decrease in fat de novo synthesis and chemokine ligand expression in non-alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain-like pseudokinase.
Non-alcoholic Fatty Liver Disease
Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1).
Non-alcoholic Fatty Liver Disease
Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
FBXW5 mediates the ubiquitination of ASK1 and exacerbates nonalcoholic steatohepatitis.
Non-alcoholic Fatty Liver Disease
Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6-Linked Polyubiquitination of Apoptosis Signal-Regulating Kinase 1.
Non-alcoholic Fatty Liver Disease
Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Melatonin safeguards against fatty liver by antagonizing TRAFs-mediated ASK1 deubiquitination and stabilization in a ?-arrestin-1 dependent manner.
Non-alcoholic Fatty Liver Disease
Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes.
Non-alcoholic Fatty Liver Disease
Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
Non-alcoholic Fatty Liver Disease
Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
Non-alcoholic Fatty Liver Disease
The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial.
Non-alcoholic Fatty Liver Disease
The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis.
Non-alcoholic Fatty Liver Disease
The ménage à trois of autophagy, lipid droplets and liver disease.
Non-alcoholic Fatty Liver Disease
Tumor Necrosis Factor ?-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.
Noonan Syndrome
Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling.
Noonan Syndrome
PHENOTYPIC CONSEQUENCES AND THE MALIGNANCY RISK IN FAMILIAL NOONAN SYNDROME DUE TO A RARE P.S427G RAF1 MUTATION.
Obesity
MAP3K8 (TPL2/COT) affects obesity-induced adipose tissue inflammation without systemic effects in humans and in mice.
Obesity
The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance.
Oncogene Addiction
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Opisthorchiasis
[Molecular genetic approaches in parasitology (in case of opisthorchiasis)]
Optic Nerve Glioma
BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.
Osteoarthritis
CX3CL1 promotes MMP-3 production via the CX3CR1, c-Raf, MEK, ERK, and NF-?B signaling pathway in osteoarthritis synovial fibroblasts.
Osteoarthritis
CXCL1 contributes to IL-6 expression in osteoarthritis and rheumatoid arthritis synovial fibroblasts by CXCR2, c-Raf, MAPK, and AP-1 pathway.
Osteoarthritis
Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.
Osteoarthritis
Stress-Induced Activation of Apoptosis Signal-Regulating Kinase 1 Promotes Osteoarthritis.
Osteosarcoma
Expression of protooncogenes in murine osteosarcomas.
Osteosarcoma
Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma.
Osteosarcoma
Oncogenic activation of murine mos protein kinase by DNA rearrangement of its N-terminal coding region.
Otitis Media
Jun N-terminal protein kinase enhances middle ear mucosal proliferation during bacterial otitis media.
Ototoxicity
Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure.
Ovarian Cysts
Functional analysis of sperm from c-mos(-/-) mice.
Ovarian Neoplasms
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.
Ovarian Neoplasms
B-RAF mutations are a rare event in pituitary adenomas.
Ovarian Neoplasms
Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer.
Ovarian Neoplasms
Estrogen inhibits paclitaxel-induced apoptosis via the phosphorylation of apoptosis signal-regulating kinase 1 in human ovarian cancer cell lines.
Ovarian Neoplasms
Integrated analysis of germline and somatic variants in ovarian cancer.
Ovarian Neoplasms
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.
Ovarian Neoplasms
Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients.
Ovarian Neoplasms
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Ovarian Neoplasms
MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas.
Ovarian Neoplasms
MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells.
Ovarian Neoplasms
MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
Ovarian Neoplasms
Mixed lineage kinase 3 is required for matrix metalloproteinase expression and invasion in ovarian cancer cells.
Ovarian Neoplasms
Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.
Ovarian Neoplasms
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Ovarian Neoplasms
Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.
Ovarian Neoplasms
Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells.
Pancreatic Neoplasms
A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
Pancreatic Neoplasms
Anti-proliferative effects of unmodified antisense oligodeoxynucleotides targeted against c-raf mRNA: use of poly (lysine/serine) copolymers or cationic lipopolyamines.
Pancreatic Neoplasms
Apoptosis signal-regulating kinase 1 exhibits oncogenic activity in pancreatic cancer.
Pancreatic Neoplasms
Association of Breast Cancer Susceptibility Variants with Risk of Pancreatic Cancer.
Pancreatic Neoplasms
Associations of novel variants in PIK3C3, INSR and MAP3K4 of the ATM pathway genes with pancreatic cancer risk.
Pancreatic Neoplasms
Combined inhibition of PAK7, MAP3K7 and CK2alpha kinases inhibits the growth of MiaPaCa2 pancreatic cancer cell xenografts.
Pancreatic Neoplasms
Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.
Pancreatic Neoplasms
Development of an enzyme-linked immunosorbent assay (ELISA) for the specific detection of MEKK1 expression in cells.
Pancreatic Neoplasms
Dominant negative MEKK1 inhibits survival of pancreatic cancer cells.
Pancreatic Neoplasms
Drosophila happyhour modulates JNK-dependent apoptosis.
Pancreatic Neoplasms
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
Pancreatic Neoplasms
EB1 phosphorylation mediates the functions of ASK1 in pancreatic cancer development.
Pancreatic Neoplasms
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
Pancreatic Neoplasms
Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: Involvement of protein kinase C-? activation.
Pancreatic Neoplasms
Inhibition of mutant Kras(G12D)-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Pancreatic Neoplasms
Investigation of Anti-Tumor Effects of an MLK1 Inhibitor in Prostate and Pancreatic Cancers.
Pancreatic Neoplasms
KRAS-related proteins in pancreatic cancer.
Pancreatic Neoplasms
MAP4K3 modulates cell death via the post-transcriptional regulation of BH3-only proteins.
Pancreatic Neoplasms
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity.
Pancreatic Neoplasms
Mixed Lineage Kinase 3 phosphorylates prolyl-isomerase PIN1 and potentiates GLI1 signaling in pancreatic cancer development.
Pancreatic Neoplasms
Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5.
Pancreatic Neoplasms
Phosphorylation of the C-Raf N-region promotes Raf dimerization.
Pancreatic Neoplasms
RNA interference may be more potent than antisense RNA in human cancer cell lines.
Pancreatic Neoplasms
Selective activation of tumor-suppressive MAPKP signaling pathway by triptonide effectively inhibits pancreatic cancer cell tumorigenicity and tumor growth.
Pancreatic Neoplasms
Survival regulation in pancreatic cancer cells by c-Jun.
Pancreatic Neoplasms
[Mechanism underlying pancreatic cancer cell resistance to mTOR inhibitor RAD001 via c-Raf/ERK1/2 activation].
Pancreatitis
Inhibition of RIPK1-dependent regulated acinar cell necrosis provides protection against acute pancreatitis via the RIPK1/NF-?B/AQP8 pathway.
Pancreatitis
Tumor progression locus-2 is a critical regulator of pancreatic and lung inflammation during acute pancreatitis.
Pancreatitis, Chronic
Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG12D/Pdx-1-Cre Mice.
Panuveitis
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib.
Papillomavirus Infections
Human papillomavirus and gene mutations in head and neck squamous carcinomas.
Parkinson Disease
A Caenorhabditis elegans p38 MAP kinase pathway mutant protects from dopamine, methamphetamine, and MDMA toxicity.
Parkinson Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Parkinson Disease
c-Jun N-Terminal Kinase Signaling Inhibitors Under Development.
Parkinson Disease
Discovery, Synthesis, and Characterization of an Orally Bioavailable, Brain Penetrant Inhibitor of Mixed Lineage Kinase 3.
Parkinson Disease
Genetic analysis of LRRK2 functional domains in Brazilian patients with Parkinson's disease.
Parkinson Disease
MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson's disease.
Parkinson Disease
Mixed lineage kinase 2 and hippocalcin are localized in Lewy bodies of Parkinson's disease.
Parkinson Disease
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
Parkinson Disease
MPTP activates ASK1-p38 MAPK signaling pathway through TNF-dependent Trx1 oxidation in parkinsonism mouse model.
Parkinson Disease
Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson's disease, as an anti-cancer stem cell drug.
Parkinson Disease
The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss.
Perinatal Death
Neural-specific ablation of the scaffold protein JSAP1 in mice causes neonatal death.
Periodontitis
Loss of periodontal ligament fibroblasts by RIPK3-MLKL-mediated necroptosis in the progress of chronic periodontitis.
Peritoneal Neoplasms
Therapeutic implications of B-RAF mutations in colorectal cancer.
Pheochromocytoma
Identification of a negative regulatory element that inhibits c-mos transcription in somatic cells.
Pheochromocytoma
Oncogene and growth factor expression in MEN 2 and related tumors.
Pheochromocytoma
Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 syndrome.
Pheochromocytoma
Ras controls coupling of growth factor receptors and protein kinase C in the membrane to Raf-1 and B-Raf protein serine kinases in the cytosol.
Pheochromocytoma
The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic.
Phytoplasma Disease
Genome-wide identification of MAPKKK genes and their responses to phytoplasma infection in Chinese jujube (Ziziphus jujuba Mill.).
Pituitary Neoplasms
A mutation and expression analysis of the oncogene BRAF in pituitary adenomas.
Pituitary Neoplasms
Activation of Raf/MEK/ERK and PI3K/Akt/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
Pituitary Neoplasms
B-RAF mutations are a rare event in pituitary adenomas.
Plant Diseases
MEKK1 is required for flg22-induced MPK4 activation in Arabidopsis plants.
Plasmacytoma
Activation of the c-mos oncogene in a mouse plasmacytoma by insertion of an endogenous intracisternal A-particle genome.
Plasmacytoma
AKT induces transcriptional activity of PU.1 through phosphorylation-mediated modifications within its transactivation domain.
Plasmacytoma
Functions of the mos oncogene family and associated gene products.
Plasmacytoma
Rearrangement of the oncogene c-mos in mouse myeloma NSI and hybridomas.
Plasmacytoma
Resolution and general properties of different types of ribosomal protein kinases in mouse plasmocytoma.
Plasmacytoma
Structure and activity of the translocated c-myc in mouse plasmacytoma XRPC-24.
Pneumonia
Hierarchy of clinical manifestations in SAVI N153S and V154M mouse models.
Pneumonia
MAP3K8 Regulates Cox-2-Mediated Prostaglandin E2 Production in the Lung and Suppresses Pulmonary Inflammation and Fibrosis.
Pneumonia
Tumor progression locus 2 reduces severe allergic airway inflammation by inhibiting Ccl24 production in dendritic cells.
Pneumonia
Tumor progression locus-2 is a critical regulator of pancreatic and lung inflammation during acute pancreatitis.
Polycystic Kidney Diseases
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
Polycystic Kidney Diseases
MAP/ERK kinase kinase 1 (Mekk1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.
Polycystic Kidney Diseases
Targeting B-Raf as a treatment strategy for polycystic kidney disease.
Polycystic Kidney Diseases
Therapies to slow polycystic kidney disease.
Polycystic Kidney, Autosomal Dominant
Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.
Polycystic Kidney, Autosomal Dominant
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
Polycystic Kidney, Autosomal Dominant
Ouabain activates the Na,K-ATPase signalosome to induce autosomal dominant polycystic kidney disease cell proliferation.
Polycystic Kidney, Autosomal Dominant
Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease.
Polycystic Kidney, Autosomal Dominant
Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
Polycystic Kidney, Autosomal Dominant
Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
Porcine Reproductive and Respiratory Syndrome
Chitin receptor-mediated activation of MAP kinases and ROS production in rice and Arabidopsis.
Porcine Reproductive and Respiratory Syndrome
Expression and function of mixed lineage kinases in dendritic cells.
Porcine Reproductive and Respiratory Syndrome
Receptor-Like Cytoplasmic Kinases Directly Link Diverse Pattern Recognition Receptors to the Activation of Mitogen-Activated Protein Kinase Cascades in Arabidopsis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The EcoRI RFLP of c-mos in patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia, compared to geriatric and non-geriatric controls.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-?B.
Prediabetic State
Inhibition of MafA transcriptional activity and human insulin gene transcription by interleukin-1beta and mitogen-activated protein kinase kinase kinase in pancreatic islet beta cells.
Premature Birth
ASK1 promotes uterine inflammation leading to pathological preterm birth.
Prolactinoma
PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.
Prostatic Neoplasms
AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion.
Prostatic Neoplasms
AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2.
Prostatic Neoplasms
Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function.
Prostatic Neoplasms
Antisense approaches in prostate cancer.
Prostatic Neoplasms
Aryl hydrocarbon receptor enhances the expression of miR-150-5p to suppress in prostate cancer progression by regulating MAP3K12.
Prostatic Neoplasms
B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer.
Prostatic Neoplasms
Coordinate Loss of MAP3K7 and CHD1 Promotes Aggressive Prostate Cancer.
Prostatic Neoplasms
Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers.
Prostatic Neoplasms
Distinct Genomic Alterations in Prostate Tumors Derived from African American Men.
Prostatic Neoplasms
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
Prostatic Neoplasms
Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder, prostate, kidney cancers.
Prostatic Neoplasms
Investigation of Anti-Tumor Effects of an MLK1 Inhibitor in Prostate and Pancreatic Cancers.
Prostatic Neoplasms
Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous Recombination.
Prostatic Neoplasms
MAP3K7 and CHD1 Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells.
Prostatic Neoplasms
MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1.
Prostatic Neoplasms
MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression.
Prostatic Neoplasms
miRNA-627 inhibits cell proliferation and cell migration, promotes cell apoptosis in prostate cancer cells through upregulating MAP3K1, PTPRK and SRA1.
Prostatic Neoplasms
Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer.
Prostatic Neoplasms
Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Prostatic Neoplasms
Mixed lineage kinase 3 connects reactive oxygen species to c-Jun NH2-terminal kinase-induced mitochondrial apoptosis in genipin-treated PC3 human prostate cancer cells.
Prostatic Neoplasms
Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells.
Prostatic Neoplasms
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer.
Prostatic Neoplasms
Parallel-Reaction-Monitoring-Based Proteome-Wide Profiling of Differential Kinase Protein Expression during Prostate Cancer Metastasis in Vitro.
Prostatic Neoplasms
Suppression of miR-4735-3p in androgen receptor-expressing prostate cancer cells increases cell death during chemotherapy.
Prostatic Neoplasms
The Autophagy Machinery Controls Cell Death Switching between Apoptosis and Necroptosis.
Prostatic Neoplasms
ZNF507 affects TGF-? signaling via TGFBR1 and MAP3K8 activation in the progression of prostate cancer to an aggressive state.
Protein Deficiency
Early-onset colorectal cancer: A distinct entity with unique genetic features.
Proteinuria
Proto-oncogene expression in human glomerular diseases.
Psoriasis
Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis.
Pulmonary Arterial Hypertension
Apoptosis signal-regulating kinase 1 inhibition in in vivo and in vitro models of pulmonary hypertension.
Pulmonary Arterial Hypertension
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pulmonary Disease, Chronic Obstructive
Apoptosis signal-regulating kinase 1 inhibition attenuates human airway smooth muscle growth and migration in chronic obstructive pulmonary disease.
Pulmonary Fibrosis
MAP3K8 Regulates Cox-2-Mediated Prostaglandin E2 Production in the Lung and Suppresses Pulmonary Inflammation and Fibrosis.
receptor protein-tyrosine kinase deficiency
Endothelin-1, but not Ang II, activates MAP kinases through c-Src independent Ras-Raf dependent pathways in vascular smooth muscle cells.
Rectal Neoplasms
Comparative mutational analysis of distal colon cancer with rectal cancer.
Renal Insufficiency, Chronic
Targeting apoptosis signal-regulating kinase 1 in acute and chronic kidney disease.
Reperfusion Injury
Brain-targeting delivery for RNAi neuroprotection against cerebral ischemia reperfusion injury.
Reperfusion Injury
Increased expression of IRE1alpha and stress-related signal transduction proteins in ischemia-reperfusion injured retina.
Reperfusion Injury
Inhibition of apoptosis signal-regulating kinase 1 reduces myocardial ischemia-reperfusion injury in the mouse.
Respiratory Distress Syndrome
Genetic Variation in MAP3K1 Associates with Ventilator-free Days in Acute Respiratory Distress Syndrome.
Retinal Degeneration
Targeting Oxidative Stress for Treatment of Glaucoma and Optic Neuritis.
Retinitis
Antisense oligonucleotides for cancer therapy-an overview.
Retinitis Pigmentosa
CDK5 and MEKK1 mediate pro-apoptotic signalling following endoplasmic reticulum stress in an autosomal dominant retinitis pigmentosa model.
Retinoblastoma
Alteration of the c-fms gene in a blood sample from a Thorotrast individual.
Retinoblastoma
Direct binding of apoptosis signal-regulating kinase 1 to retinoblastoma protein: novel links between apoptotic signaling and cell cycle machinery.
Retinoblastoma
Rat karyotyping by fluorescence in situ hybridization (FISH): localization of oncogene c-raf to 4q42, retinoblastoma antioncogene to 15q12, and mitochondrial D-loop-like sequences to the Y chromosome.
Retinoblastoma
RRD-251 enhances All-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells.
Rhabdomyosarcoma
Uniform response of c-raf expression to differentiation induction and inhibition of proliferation in a rat rhabdomyosarcoma cell line.
Rhabdomyosarcoma
Up-regulation of hERG K? channels by B-RAF.
Rickets
Raf Kinases Are Essential for Phosphate Induction of ERK1/2 Phosphorylation in Hypertrophic Chondrocytes and Normal Endochondral Bone Development.
Sarcoma
Abnormally banded region in a poorly differentiated sarcoma is not correlated with amplification of c-MYC or c-MOS protooncogenes.
Sarcoma
Activation of the transforming potential of a normal cell sequence: a molecular model for oncogenesis.
Sarcoma
Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome.
Sarcoma
Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation: A case report and literature review.
Sarcoma
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Sarcoma
Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer.
Sarcoma
Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes.
Sarcoma
Association of BMI and major molecular pathological markers of colorectal cancer in men and women.
Sarcoma
Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase.
Sarcoma
Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature.
Sarcoma
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Sarcoma
Clinicopathological observation of primary lung enteric adenocarcinoma and its response to chemotherapy: A case report and review of the literature.
Sarcoma
Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
Sarcoma
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Sarcoma
Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.
Sarcoma
Defects in lens fiber differentiation are linked to c-mos overexpression in transgenic mice.
Sarcoma
Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy.
Sarcoma
EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer.
Sarcoma
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.
Sarcoma
Expression of c-mos proto-oncogene in undifferentiated teratocarcinoma cells.
Sarcoma
Expression of c-mos proto-oncogene transcripts in mouse tissues.
Sarcoma
Expression of hepatocyte growth factor and c-Met is characteristic of ?-fetoprotein-producing colorectal adenocarcinoma: A report of three cases.
Sarcoma
Expression of proto-oncogenes and cytoskeletal actin gene in foreign body-induced murine sarcomas.
Sarcoma
Histiocytic neoplasms in the era of personalized genomic medicine.
Sarcoma
Human papillomavirus and gene mutations in head and neck squamous carcinomas.
Sarcoma
Human proto-oncogene c-mos maps to 8q11.
Sarcoma
Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population.
Sarcoma
Intraductal tubulopapillary neoplasm accompanied by invasive carcinoma of the pancreas: A case report and review of the literature.
Sarcoma
KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population.
Sarcoma
Long-fragment DNA as a potential marker for stool-based detection of colorectal cancer.
Sarcoma
MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Sarcoma
Molecular alterations in non-small cell lung carcinomas of the young.
Sarcoma
Multiple primary malignant neoplasms: A case report and literature review.
Sarcoma
Mutational Profile of Papillary Thyroid Carcinoma in an Endemic Goiter Region of North India.
Sarcoma
Nucleotide sequence and biochemical activities of the Moloney murine sarcoma virus strain HT-1 mos gene.
Sarcoma
Nucleotide sequence of the transforming gene of m1 murine sarcoma virus.
Sarcoma
Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.
Sarcoma
Pancoast-Tobias Syndrome: A Unique Presentation of Lung Cancer.
Sarcoma
Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Sarcoma
Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.
Sarcoma
Production and characterization of a monoclonal antibody to the v-mos oncogene protein.
Sarcoma
Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
Sarcoma
Rates of evolution of the retroviral oncogene of Moloney murine sarcoma virus and of its cellular homologues.
Sarcoma
Squamous Cell Differentiation in Metastatic Papillary Thyroid Carcinoma: Metaplastic Reversion or Progression?
Sarcoma
Structural analysis of normal and transforming mil(raf) proteins: effect of 5'-truncation on phosphorylation in vivo or in vitro.
Sarcoma
Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.
Sarcoma
Targeting BRAF and RAS in Colorectal Cancer.
Sarcoma
TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases.
Sarcoma
The cyclin B2 component of MPF is a substrate for the c-mos(xe) proto-oncogene product.
Sarcoma
Viral src gene products are related to the catalytic chain of mammalian cAMP-dependent protein kinase.
Sarcoma, Avian
Cytosolic malic dehydrogenase activity is associated with a putative substrate for the transforming gene product of Rous sarcoma virus.
Sarcoma, Avian
Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus.
Sarcoma, Avian
Rat c-raf oncogene activation by a rearrangement that produces a fused protein.
Sarcoma, Ewing
Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas.
Schistosomiasis mansoni
TPL-2 Regulates Macrophage Lipid Metabolism and M2 Differentiation to Control TH2-Mediated Immunopathology.
Scoliosis
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Seizures
Endocrine abnormalities in cardiofaciocutaneous syndrome: a case of precocious puberty, hyperprolactinemia and diabetes insipidus.
Seminoma
Differential expression of protooncogenes in human germ cell tumors of the testis.
Sepsis
Apoptosis signal-regulating kinase 1 (ASK1) inhibition reduces endothelial cytokine production without improving permeability after toll-like receptor 4 (TLR4) challenge.
Sepsis
[Role and mechanisms of MLKL-NLRP3-mediated necroinflammation in mice with sepsis-induced acute lung injury].
Shock, Septic
Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-? production and endotoxin shock.
Silicosis
[Effect of N-acetyl-seryl-aspartyl-lysyl-proline on regulation of expression of ras-raf-ERK1/2 signal transduction pathway in lung of rats with silicosis].
Skin Neoplasms
A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma.
Skin Neoplasms
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma.
Small Cell Lung Carcinoma
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2.
Small Cell Lung Carcinoma
Loss of heterozygosity at the c-raf locus in small cell lung carcinoma.
sphingosine kinase deficiency
SPHK1 deficiency protects mice from acetaminophen-induced ER stress and mitochondrial permeability transition.
Spinal Cord Injuries
Depolarization-Dependent C-Raf Signaling Promotes Hyperexcitability and Reduces Opioid Sensitivity of Isolated Nociceptors after Spinal Cord Injury.
Spinal Cord Injuries
Up-regulation of Ras/Raf/ERK1/2 signaling in the spinal cord impairs neural cell migration, neurogenesis, synapse formation, and dendritic spine development.
Spinal Dysraphism
Loss of mitogen-activated protein kinase kinase kinase 4 (MEKK4) results in enhanced apoptosis and defective neural tube development.
Squamous Cell Carcinoma of Head and Neck
A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway.
Squamous Cell Carcinoma of Head and Neck
Apoptosis signal-regulating kinase 1 is involved in WISP-1-promoted cell motility in human oral squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Downregulation of long non-coding RNA B-Raf proto-oncogene-activated non-coding RNA reverses cisplatin resistance in laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Expression of polysialic acid in primary laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Lack of B-RAF mutations in head and neck squamous cell carcinoma.
Starvation
A zinc-finger protein, Rst2p, regulates transcription of the fission yeast ste11(+) gene, which encodes a pivotal transcription factor for sexual development.
Starvation
Candida glabrata Ste11 is involved in adaptation to hypertonic stress, maintenance of wild-type levels of filamentation and plays a role in virulence.
Starvation
Constitutive activation of the fission yeast pheromone-responsive pathway induces ectopic meiosis and reveals ste11 as a mitogen-activated protein kinase target.
Starvation
Ecl1, a regulator of the chronological lifespan of Schizosaccharomyces pombe, is induced upon nitrogen starvation.
Starvation
Gene ste20 controls amiloride sensitivity and fertility in Schizosaccharomyces pombe.
Starvation
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Starvation
Phosphorylation of the MEKK Ste11p by the PAK-like kinase Ste20p is required for MAP kinase signaling in vivo.
Starvation
Phosphorylation of the Transcription Factor Atf1 at Multiple Sites by the MAP Kinase Sty1 Controls Homologous Recombination and Transcription.
Starvation
Regulation and role of an RNA-binding protein Msa2 in controlling the sexual differentiation of fission yeast.
Starvation
Regulation of calcineurin gene expression in Schizosaccharomyces pombe. Dependence on the ste11 transcription factor.
Starvation
Saccharomyces cerevisiae Ste50 binds the MAPKKK Ste11 through a head-to-tail SAM domain interaction.
Starvation
Schizosaccharomyces pombe pac2+ controls the onset of sexual development via a pathway independent of the cAMP cascade.
Starvation
Schizosaccharomyces pombe ste11+ encodes a transcription factor with an HMG motif that is a critical regulator of sexual development.
Starvation
Schizosaccharomyces pombe Ste7p is required for both promotion and withholding of the entry to meiosis.
Starvation
The RGS domain-containing fission yeast protein, Rgs1p, regulates pheromone signalling and is required for mating.
Stomach Neoplasms
A MAP3k1 SNP predicts survival of gastric cancer in a Chinese population.
Stomach Neoplasms
Apoptosis signal-regulating kinase 1 and cyclin D1 compose a positive feedback loop contributing to tumor growth in gastric cancer.
Stomach Neoplasms
Geldanamycin induces apoptosis in human gastric carcinomas by affecting multiple oncogenic kinases that have synergic effects with TNF-related apoptosis-inducing ligand.
Stomach Neoplasms
Genetic predisposition to gastric cancer.
Stomach Neoplasms
Germline mutations in MAP3K6 are associated with familial gastric cancer.
Stomach Neoplasms
Inhibition of gastric tumor growth by a novel Hsp90 inhibitor.
Stomach Neoplasms
Long non-coding RNA CCDC144NL-AS1 sponges miR-143-3p and regulates MAP3K7 by acting as a competing endogenous RNA in gastric cancer.
Stomach Neoplasms
MAP3K1 rs889312 genotypes influence survival outcomes of Chinese gastric cancer patients who received adjuvant chemotherapy based on platinum and fluorouracil regimes.
Stomach Neoplasms
Overview of MDM2 and B-RAF Expression in Gastric Lesions.
Stomach Neoplasms
Prognostic value of mixed lineage kinase domain-like protein expression in the survival of patients with gastric caner.
Stomach Neoplasms
[Effect of B-RAF-specific RNA interference on gastric cancer BGC823 cell line]
Stroke
Apoptosis signal-regulating kinase 1 (ASK1) is linked to neural stem cell differentiation after ischemic brain injury.
Stroke
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.
Stroke
MAP3K6 Mutations in a Neurovascular Disease Causing Stroke, Cognitive Impairment, and Tremor.
Stroke
The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase.
Tauopathies
A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Telangiectasia, Hereditary Hemorrhagic
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Teratocarcinoma
Changes of c-mos expression in response to 2-O-tetradecanoylphorbol-13-acetate in undifferentiated teratocarcinoma cells.
Teratocarcinoma
Expression of c-mos proto-oncogene in undifferentiated teratocarcinoma cells.
Teratocarcinoma
Suppression of c-mos expression in teratocarcinoma cells with a new type of inducer of differentiation, 3,5-di-tert-butylchalcone 4'-carboxylic acid.
Teratoma
Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas.
Teratoma
Ovarian teratomas in mice lacking the protooncogene c-mos.
Thrombocytopenia
Apoptosis signal-regulating kinase 1 regulates immune-mediated thrombocytopenia, thrombosis, and systemic shock.
Thrombocytopenia
In vivo gene amplification in non-cancerous cells: cholinesterase genes and oncogenes amplify in thrombocytopenia associated with lupus erythematosus.
Thrombosis
Apoptosis signal-regulating kinase 1 regulates immune-mediated thrombocytopenia, thrombosis, and systemic shock.
Thrombosis
Platelet MEKK3 regulates arterial thrombosis and myocardial infarct expansion in mice.
Thymoma
Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation.
Thyroid Cancer, Papillary
A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker.
Thyroid Cancer, Papillary
Aberrant Expression of COT Is Related to Recurrence of Papillary Thyroid Cancer.
Thyroid Cancer, Papillary
Association analysis and the clinical significance of BRAF gene mutations and ultrasound features in papillary thyroid carcinoma.
Thyroid Cancer, Papillary
Association between BRAF(V600E) mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma.
Thyroid Cancer, Papillary
B-Raf mutation and papillary thyroid carcinoma patients.
Thyroid Cancer, Papillary
B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas.
Thyroid Cancer, Papillary
B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules.
Thyroid Cancer, Papillary
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Thyroid Cancer, Papillary
Cytogenetic status and oxidative stress parameters in patients with thyroid diseases.
Thyroid Cancer, Papillary
High prevalence of B-RAF mutation in papillary carcinoma of the thyroid in north-east Italy.
Thyroid Cancer, Papillary
MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies.
Thyroid Cancer, Papillary
Molecular Profiling of Follicular Variant of Papillary Thyroid Cancer.
Thyroid Cancer, Papillary
Morphological features predictive for BRAF(V600E) mutation in papillary thyroid microcarcinomas.
Thyroid Cancer, Papillary
Mutation Profile of Well-Differentiated Thyroid Cancer in Asians.
Thyroid Cancer, Papillary
Mutations of the TERT promoter are associated with aggressiveness and recurrence/distant metastasis of papillary thyroid carcinoma.
Thyroid Cancer, Papillary
No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Thyroid Cancer, Papillary
Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma.
Thyroid Cancer, Papillary
Personalization of targeted therapy in advanced thyroid cancer.
Thyroid Cancer, Papillary
Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy.
Thyroid Cancer, Papillary
Radiomics Study of Thyroid Ultrasound for Predicting BRAF Mutation in Papillary Thyroid Carcinoma: Preliminary Results.
Thyroid Cancer, Papillary
Recent advances of MEK inhibitors and their clinical progress.
Thyroid Cancer, Papillary
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Thyroid Cancer, Papillary
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Thyroid Cancer, Papillary
The diagnostic pathology of the nuclear envelope in human cancers.
Thyroid Cancer, Papillary
THE RELATIONSHIP OF BRAF
Thyroid Diseases
Cytogenetic status and oxidative stress parameters in patients with thyroid diseases.
Thyroid Neoplasms
Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Thyroid Neoplasms
Aberrant Expression of COT Is Related to Recurrence of Papillary Thyroid Cancer.
Thyroid Neoplasms
B-Raf Inhibition in the Clinic: Present and Future.
Thyroid Neoplasms
B-Raf mutation and papillary thyroid carcinoma patients.
Thyroid Neoplasms
B-Raf mutation: a key player in molecular biology of cancer.
Thyroid Neoplasms
B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas.
Thyroid Neoplasms
Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells.
Thyroid Neoplasms
Cytogenetic status and oxidative stress parameters in patients with thyroid diseases.
Thyroid Neoplasms
Downregulation of survivin and aurora a by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy.
Thyroid Neoplasms
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Thyroid Neoplasms
FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.
Thyroid Neoplasms
Genome-Wide Association Studies of Autoimmune Thyroid Diseases, Thyroid Function, and Thyroid Cancer.
Thyroid Neoplasms
Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
Thyroid Neoplasms
Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas.
Thyroid Neoplasms
Molecular Study of Signaling-Pathway Genes in Experimental Rat Thyroid Carcinoma.
Thyroid Neoplasms
Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.
Thyroid Neoplasms
Mutation Profile of Well-Differentiated Thyroid Cancer in Asians.
Thyroid Neoplasms
Novel molecular targeted therapies for refractory thyroid cancer.
Thyroid Neoplasms
Pax-8-PPAR-? fusion protein in thyroid carcinoma.
Thyroid Neoplasms
Personalization of targeted therapy in advanced thyroid cancer.
Thyroid Neoplasms
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Thyroid Neoplasms
Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 syndrome.
Thyroid Neoplasms
RAF protein-serine/threonine kinases: structure and regulation.
Thyroid Neoplasms
Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
Thyroid Neoplasms
Recent Advances in the Research and Development of B-Raf Inhibitors.
Thyroid Neoplasms
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Thyroid Neoplasms
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
Thyroid Neoplasms
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.
Thyroid Neoplasms
THE RELATIONSHIP OF BRAF
Thyroid Neoplasms
[Effects of serine/threonine-protein kinase B-Raf-activated long-chain non-coding RNA on apoptosis and autophagy in thyroid carcinoma cells].
Thyroid Nodule
B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules.
Thyroiditis
Expression analysis of B-Raf oncogene in V600E-negative benign and malignant tumors of the thyroid gland: correlation with late disease onset.
Thyroiditis
Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto's thyroiditis.
transaldolase deficiency
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Tremor
MAP3K6 Mutations in a Neurovascular Disease Causing Stroke, Cognitive Impairment, and Tremor.
Triple Negative Breast Neoplasms
MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells.
Trophoblastic Neoplasms
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Trophoblastic Tumor, Placental Site
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Tuberculosis
Post translational modifications in tuberculosis: ubiquitination paradox.
Tuberculosis
TLR and TNF-R1 activation of the MKK3/MKK6-p38? axis in macrophages is mediated by TPL-2 kinase.
Tuberous Sclerosis
Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization.
Tuberous Sclerosis
Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma.
Urinary Bladder Neoplasms
CCDC34 is up-regulated in bladder cancer and regulates bladder cancer cell proliferation, apoptosis and migration.
Urinary Bladder Neoplasms
Implication of RAF and RKIP Genes in Urinary Bladder Cancer.
Uterine Cervical Neoplasms
Bag-1L is a stress-withstand molecule prevents the downregulation of Mcl-1 and c-Raf under control of heat shock proteins in cisplatin treated HeLa cervix cancer cells.
Uterine Cervical Neoplasms
Low Necroptosis Process Predicts Poor Treatment Outcome of Human Papillomavirus Positive Cervical Cancers by Decreasing Tumor-Associated Macrophages M1 Polarization.
Uterine Cervical Neoplasms
MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis.
Uterine Cervical Neoplasms
MLK3 silence induces cervical cancer cell apoptosis via the Notch-1/autophagy network.
Uterine Cervicitis
MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis.
Vaccinia
Differential Inhibitor Sensitivity between Human Kinases VRK1 and VRK2.
Vascular Diseases
Laser-scanning velocimetry: a confocal microscopy method for quantitative measurement of cardiovascular performance in zebrafish embryos and larvae.
Ventricular Dysfunction, Left
Inhibition of apoptosis signal-regulating kinase 1 ameliorates left ventricular dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome.
Vesicular Stomatitis
MAP3K7 and CHD1 Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells.
Virus Diseases
MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation.
Virus Diseases
RIPK3-driven cell death during virus infections.
Virus Diseases
The Dietary Restriction-Like Gene drl-1, Which Encodes a Putative Serine/Threonine Kinase, Is Essential for Orsay Virus Infection in Caenorhabditis elegans.
Virus Diseases
Tumor-derived exosomes antagonize innate antiviral immunity.
Whooping Cough
Calpain-mediated regulation of the distinct signaling pathways and cell migration in human neutrophils.
Whooping Cough
Development of a homogeneous MAP kinase reporter gene screen for the identification of agonists and antagonists at the CXCR1 chemokine receptor.
Whooping Cough
Hypertrophic agonists stimulate the activities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes.
Whooping Cough
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Whooping Cough
sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation.
Whooping Cough
The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice.
Wilms Tumor
K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.
Wiskott-Aldrich Syndrome
Gene expression pattern in human brain endothelial cells in response to Neisseria meningitidis.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2.7.11.25 mitogen-activated protein kinase kinase kinase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
